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Chapter 1
General Introduction
8Introduction
Pertussis, also called whooping cough, is an acute, highly contagious and serious infection 
of the human upper respiratory tract [1,2]. Whooping cough is caused by the Gram-negative 
bacterium Bordetella pertussis and less frequently by Bordetella parapertussis. Pertussis-like 
symptoms can also be caused by Bordetella bronchiseptica and Bordetella holmesii infections, 
however, between these four Bordetella species, B. pertussis generaflly causes the most 
severe symptoms [2,3]. The typical symptoms of the disease are the paroxysmal coughs, 
often followed by vomiting and whooping, which is due to a forced inhalation through restricted 
airways. Despite vaccination, pertussis has resurged, in particular in adolescents and adults.
The genus Bordetella
The genus Bordetella belongs to the class of β-proteobacteria and to the family of the 
Alcaligenaceae [4,5]. Alcaligenaceae are generally found in water and soil. However, some 
members are pathogens for humans and animals. The Bordetellae are small (0.2-0.7 µm), 
gram-negative coccobacilli and mainly obligate aerobes. At present, the genus Bordetella 
consists of nine different species: B. bronchiseptica, B. pertussis, B. parapertussis, B. holmesii, 
B. hinzii, B. avium, B. petrii, B. ansorpii and B. trematum (Table 1) [4]. 
Table 1. The nine species comprising the genus Bordetella.
Species Host range/source Genome size (bp) Disease
1. B. pertussis Human 4,086,186 Pertussis
2. B. parapertussis Human, sheep 4,773,551 Pertussis, pneumonia
3. B. bronchiseptica Mammals 5,338,400 Respiratory disease 
4. B. holmesii Human ND Septicemia, respiratory disease
5. B. avium Birds 3,732,255 Rhinotracheitis
6. B. trematum Human ND
Opportunistic infections, 
wound infections, otitis 
media
7. B. hinzii Poultry ND Opportunistic infections
8. B. petrii Environment, human ND Opportunistic infections
9. B. ansorpii Human ND Opportunistic infections
Abbreviation: ND, not determined.
Whooping cough infections in humans are mainly caused by the three closely related “classical” 
Bordetellae: B. pertussis, B. parapertussis and B. bronchiseptica [4]. Two distinct B. parapertussis 
lineages have been found, designated as B. parapertussis
hu
 and B. parapertussis
ov
, which 
infect humans and sheep, respectively [6,7]. B. holmesii, which is phylogenetically distinct from 
the classical Bordetellae [8], is also able to infect humans and can also cause pertussis-like 
symptoms [9]. Based on previous work done by Musser et al. [10], van der Zee et al. [6] and 
Diavatopoulos et al. [8], it was concluded that B. pertussis and B. parapertussis evolved from 
91two distinct B. bronchiseptica lineages, indicating that adaptation to humans occurred as two 
independent events.
Bordetella pertussis
B. pertussis, the focus of this thesis, was first isolated in 1906 by Bordet en Gengou [11]. As has 
been observed for a number of human pathogens [12], B. pertussis is extremely monomorphic 
[13] and limited genetic diversity has been found in B. pertussis populations so far based 
on 16S rDNA sequences [14], pulsed-field gel electrophoresis (PFGE) [15,16], multiple-locus 
variable-number tandem repeat analysis (MLVA) [17] and single nucleotide polymorphisms 
(SNPs) [18,19]. The extreme monomorphism of B. pertussis may suggest a recent origin of this 
species or a recent population bottleneck. Both possibilities result in a loss of genetic diversity 
due to the establishment of a new niche by a single strain or a small number of strains (i.e. the 
founder effect) [20]. 
B. pertussis contains a high number of insertion sequence elements (ISEs), comprising 6.8% of 
the complete genome. 238 copies of IS481, 6 copies of IS1002 and 17 copies of IS1663 have 
been found in the Tohama I strain [21]. A high density of ISEs has been observed in several 
other human pathogens [22-24]. This may be due to a small population size in which intra-
species competition is less intense facilitating deleterious mutations [21]. ISEs facilitate the 
processes of genome reduction and chromosomal rearrangements in B. pertussis by serving 
as targets for homologous recombination [21,25-27]. 
A comparison of the genome sizes of B. pertussis and B. bronchiseptica (respectively, 
5,338,400 bases and 4,086,186 bases, Table 1) suggests that B. pertussis has lost about 
23% of its genome since its divergence from a B. bronchiseptica-like ancestor [21]. Several 
studies have provided evidence that gene loss is still ongoing [26,28-30] and indeed, in an 
extensive study comprising 171 strains, King et al. estimated that B. pertussis has lost 1.5% 
of its genome in the last 60 years [28]. In addition to gene loss by deletion, the functional 
genome of B. pertussis is also reduced by the formation of pseudogenes. Pseudogenes may 
arise by insertion of ISEs or by small mutations leading to frame shifts [21]. It is estimated that 
9.4% of the B. pertussis Tohama I genome is comprised of pseudogenes. Inactivated genes 
predominantly code for proteins involved in transport, small-molecule metabolism, regulation 
and synthesis of surface structures [21].
While gene loss has played a prominent role in the evolution of B. pertussis, there is little 
evidence for gene acquisition. However, several observations suggest that B. pertussis is able 
to exchange DNA horizontally. The transfer of a pathogenicity island from B. pertussis to B. 
holmesii is an example of horizontal gene transfer [8], as is the transfer of IS1002 between B. 
pertussis and B. parapertussis [6]. Mixed infections of B. pertussis and B. parapertussis have 
been described in humans [31,32] so there is opportunity for DNA exchange. The reduction in the 
genome of B. pertussis may have been caused by niche restriction. I.e. while B. bronchiseptica 
is able to survive outside its host, B. pertussis is not [33,34], therefore many of the lost or 
inactivated B. pertussis genes may have been required to survive in the environment. Thus B. 
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pertussis has evolved into an obligate human pathogen. 
Despite gene loss and a monomorphic genome, B. pertussis is a highly successful pathogen. 
Its success may be attributed to a large number of virulence genes, many of which are focused 
on immune suppression [35]. Further, B. pertussis harbors many repeat regions which may 
generate diversity by means of slipped stand mispairing [36-38]. These regions may affect 
expression or the structure of gene products. 
The disease
There has been much speculation about the origin of whooping cough. The first written 
description of whooping cough in Europe has been found in 1540 [39]. And the first written 
reference of a whooping cough epidemic dates from 1640 when Guillome Baillou described 
an epidemic in Paris which occurred in 1578 [40]. In the 16th and 17th century, descriptions of 
epidemics in Europe occurred more frequently [39], suggesting a wider geographical distribution. 
The absence of references to pertussis-like symptoms in the ancient (European) literature 
and the lack of genetic diversity in B. pertussis populations have been taken as evidence 
that the association of B. pertussis with humans is of recent origin. But the identification of a 
B. bronchiseptica lineage associated with humans suggests other hypotheses [5]. Thus, the 
association of B. pertussis with humans could be ancient and the monomorphic nature of B. 
pertussis could be due to a recent worldwide spread of a limited number of B. pertussis clones, 
possibly linked to human migration. Alternatively, whooping cough may have been chronicled 
only recently due to the recent acquisition by B. pertussis of the ability to cause more severe, 
pertussis-like symptoms [13].
Whooping cough is highly infectious and transmission between humans occurs via respiratory 
droplets or by direct contact. After an incubation period of one to two weeks, whooping cough 
begins with the catarrhal phase, characterized by low-grade fever, rhinorrhea and progressive 
cough, which lasts about ten days. This phase is usually similar to a common cold and the 
patient is highly infectious. During the first two to three weeks, bacteria can be recovered 
in large numbers from the nasopharynx and during a severe infection, also from the lungs. 
The subsequent paroxysmal phase, lasting two to four weeks, is characterized by severe and 
spasmodic cough episodes. The following convalescent phase, lasting one to three weeks, is 
characterized by a continuous decline of the cough before the patient returns to normal [1]. 
Mucus production is profuse and is responsible for the restriction of the airways, especially 
in newborns. Serious complications, sometimes fatal, are bronchopneumonia and acute 
encephalopathy. The latter is caused primarily by a deficiency of oxygen and may result in 
lifelong brain damage or even death. Additionally, intractable pulmonary hypertension, leading 
to cardiac failure and shock, is also recognized as a frequent problem in infants with fatal 
pertussis [41,42].
Treatment with antibiotics such as erythromycin is only effective when started within two to 
three weeks after the beginning of the first symptoms [43]. After three weeks, most of the 
bacteria are cleared from the nasopharynx and the lungs and it has been proposed that the 
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1long lasting symptoms are caused by the secreted toxins or tissue damage. Whooping cough 
is most severe for young, un- or incompletely vaccinated infants. 75-90% of infants younger 
than six months with pertussis are hospitalized and more than 90% of deaths due to pertussis 
are found in this group [44]. Although whooping cough used to be viewed as a childhood 
disease, nowadays, it is most common in adults and adolescents. Seroprevalence studies 
have shown an infection frequency of more than 9% of the population above 9 years in 2006-
2007 [45]. As adults infected with B. pertussis often have atypical or mild symptoms, they 
are often not diagnosed as pertussis patients resulting in underreporting [46-48]. The high 
circulation rate of pertussis among adolescents and adults is a threat to infants too young to 
be (fully) vaccinated. Indeed, several studies have shown that adults are the main source of 
infection for infants [45,49-51].
Persistence and resurgence of whooping cough
Pertussis has re-emerged in countries with highly vaccinated populations such as Australia 
[52], the USA [53], Norway [54], Poland [55] and the Netherlands [13]. Pertussis became 
a notifiable disease in the Netherlands in 1976 and since then, two epidemics have been 
observed. The first epidemic occurred from 1983-1987 and its causes are discussed in chapter 
3. The second epidemic started in 1996 and is still ongoing. In 1996, pertussis notifications 
increased ten-fold relative to the three previous years (Fig. 1). Regular epidemic peaks have 
been observed since 1996 every two to three years.
Figure 1. Pertussis notifications in the Netherlands from 1976 – 2010 and changes in vaccination pro-
gram. Source: Dutch National Institute for Public health and the Environment (RIVM). The following 
changes in vaccine and vaccination schedule have been implemented: decrease in vaccine dose from 
16 international opacity units/human dose (IOU/HD) to 10 IOU/HD in the period 1975 to 1984, accelera-
tion of vaccination schedule from 3, 4, 5 and 12 months to 2, 3, 4 and 11 months in 1999, introduction 
of an ACV booster at 4 years in 2001 and the replacement of WCV by ACV in 2005. Abbreviations: IOU/
HD, international opacity units/human dose; ACV, acellular vaccine; WCV, whole cell vaccine. 
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Several causes have been proposed for the increase in pertussis observed in the Netherlands 
and elsewhere; increased awareness, improved diagnostics, suboptimal vaccines, waning 
vaccine-induced immunity and pathogen adaptation. As yet there is no consensus about the 
true cause and the main cause for the re-emergence of pertussis may vary between different 
countries. Large shifts have been observed in the B. pertussis population in the Netherlands 
and in other countries. As these shifts have occurred after the introduction of vaccination, 
it seems likely that they were vaccine-driven [56-72]. Significantly, a relative high degree of 
polymorphism was observed in virulence factors shown to contribute to protective immunity. 
These virulence factors are included in the currently used acellular vaccines (ACVs). It was 
found that, throughout the years, antigenic divergence between vaccine strains and circulating 
strains has occurred. This phenomenon is consistent with the hypothesis that the shifts in 
B. pertussis populations are (at least partly) vaccine-driven. Although the variations in the 
virulence factors involve only a few amino acids, vaccination and challenge experiments with 
mice have shown that they affect vaccine efficacy [55,73-76] as discussed below. It has been 
proposed that the mismatches are mainly important in hosts with waning immunity and allow 
B. pertussis to re-infect earlier after vaccination [13]. To summarize, it seems likely that a 
combination of waning immunity and pathogen adaptation may be the most important reason 
for the re-emergence of pertussis in the Netherlands. 
Pertussis vaccines
Vaccination against pertussis with a whole cell pertussis vaccine (WCV) was introduced in 
the Netherlands in 1953. Initially, infants were vaccinated at the age of 3, 4, 5 and 12 months, 
with a booster at 4 years. The introduction of vaccination resulted in a dramatic decrease 
of pertussis notifications in the Netherlands in the following years [13]. In the 1990s many 
countries switched from a WCV to ACVs consisting of purified B. pertussis antigens. The 
immune response induced by the two types of vaccines is different. WCVs induce a broad 
immune response, with relatively low titers against individual antigens, while ACVs induce an 
immune response against only a few antigens, but with higher titers [77]. Moreover, WCVs are 
associated with more side effects compared to ACVs and the production of WCVs is difficult to 
standardize and various methods to kill and detoxify B. pertussis bacteria have been used in 
different countries [78]. The production and composition of ACVs is more easily standardized 
compared to WCVs, resulting in a more consistent product. The number and concentration 
of antigens can vary between manufacturers. But all ACVs are comprised of one to five of 
the following antigens; fimbriae (Fim2 and/or Fim3), pertussis toxin (Ptx), pertactin (Prn) and 
filamentous hemagglutinin (FHA), in various combinations and concentrations (Table 2) [78]. 
13
1Table 2. Composition of acellular vaccines.
B. pertussis antigens (µg/dose)
Manufacturer Trademark Ptx FHA Prn Fim2/3
Pediatric dose
SSIa Certiva 40 - - -
SPb Tripedia 23.4 23.4 - -
GSKc Infanrix/Pediatrix 25 25 8 -
SP Pediacel/Quadracel/Pentacel 20 20 3 5
Takeda Chemical
Industries Ltd, 
Tokyo
Takeda 3.2 34.4 1.6
0.8 
(Fim2)
Adult dose
GSK Boostrix 8 8 2.5 -
SP Adacel/Repevax 2.5 2.5 5 3
a Statens Serum Institute, Copenhagen, Denmark
b Sanofi Pasteur, Lyon, France
c Glaxo Smith Kline, London, United Kingdom 
In the last 60 years, changes have been implemented in both vaccines and vaccination 
schedules in the Netherlands (Fig. 1). In 1975, the dose of the WCV was decreased from 
16 IOU/HD to 10 IOU/HD in order to decrease side effects of the vaccine such as crying, 
mood changes, mild fever, and soreness at the injection site [79]. The dose was increased 
back to 16 IOU/HD in 1984 due to the increase in notifications after 1981 (See chapter 3). 
In 1999, the vaccination schedule was changed from 3, 4, 5 and 11 months to 2, 3, 4 and 11 
months. This accelerated schedule was implemented to reduce the period in which babies 
are not vaccinated from three to two months. In 2001, an acellular preschool booster was 
introduced for 4 year old children to reduce the disease burden in the age category 5-9 years. 
This booster indeed strongly decreased the disease burden in the targeted age category [44]. 
In 2001, the highest incidence was observed in the age category 4-5 years but in 2004, the first 
epidemic year after introduction of the ACV booster, the incidence in this age group declined. 
The highest incidence in 2004 was found in the age category 7-8 years. Further, in 2008, 2009 
and 2010, the incidence in these two groups was low while a higher incidence was found in 
the 10-12 year olds (Fig. 2). Additionally, the incidence in infants from 0-5 months showed a 
decline suggesting a reduced transmission from young infants and siblings [44]. 
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Figure 2. Age specific incidence of pertussis notifications per 100,000 in the Netherlands for the years 
2001, 2004, 2008, 2009 and 2010. 
Finally, in 2005, the WCV, still used in the primary series, was replaced by an ACV. Surveillance 
of side effects revealed that the ACV was associated with fewer side effects than the WCV [80]. 
Although the changes had a significant effect on the targeted age categories, they did not have 
a significant effect on the total circulation of B. pertussis in the Netherlands (Fig. 1). Thus the 
high circulation of B. pertussis remains a threat for infants too young to be (fully) vaccinated.
B. pertussis virulence factors
Regulation of virulence factors
So far investigated, expression of all virulence factors, except for tracheal cytotoxin (TCT), is 
regulated by the bvgASR (Bordetella virulence genes) locus. BvgASR comprises the genes 
bvgA, bvgS and bvgR [81]. The bvgA and bvgS genes are members of a two-component 
regulatory system which is environmentally responsive. Expression of bvgAS can be activated 
in vitro by growth at 350C, while bvgAS is repressed by growth at 250C or growth in the presence 
of 40 mM MgSO4 or 10 mM nicotinic acid [82]. The gene encoding BvgR mediates repression 
and is located immediately downstream of the bvgAS locus. Expression of bvgR is activated 
by BvgA. Environmental stimuli like temperature cause the inner membrane sensor histidine 
kinase BvgS to undergo autophosphorylation. Subsequently, BvgS transfers its phosphate 
group to BvgA. This results in activation of the transcription of a number of vir-activated genes, 
including adhesins and toxins, by binding of BvgA to their promoter regions [81]. Simultaneously, 
an additional class of genes, called vir-repressed genes is repressed by BvgR [81]. Different 
phases in the bacterium can be distinguished: Bvg+, Bvg- and Bvgi. In the Bvg+, or virulent 
phase, virulence genes are expressed, while a number of mainly outer membrane proteins are 
repressed [83]. The Bvg+ phase is necessary for colonization of the mouse respiratory tract. In 
15
1the Bvg-, or avirulent phase, virulence genes are repressed [82]. The Bvgi phase is similar to 
the Bvg+ phase, except that some virulence genes are maximally or exclusively expressed in 
this phase [83]. The virulence genes that are included in the currently used ACVs are described 
in more detail because of their important role in this thesis; Fimbriae (Fim), pertactin (Prn), 
pertussis toxin (Ptx) and filamentous hemagglutinin (FHA). An additional virulence factor, the 
tracheal colonization factor A (TcfA), not included in ACVs, is discussed in chapter 2.
Fimbriae
Fimbriae are filamentous proteins that extend from the outer membrane [38]. B. pertussis 
fimbriae consist of one of the major fimbrial subunits (Fim2 of Fim3) and a minor subunit, called 
FimD. Fim2 (22.5 kDa) and Fim3 (22 kDa) are encoded by the unlinked chromosomal loci fim2 
and fim3, respectively [21]. A third unlinked locus, fimX, is expressed only at very low levels 
[84,85]. Fimbriae are involved in attachment to host epithelial cells and modulation of the host 
immune response [86-90]. 
Expression of fimbriae is not only positively regulated by the bvgAS locus but the fim genes are 
also subject to phase variation caused by slip-strand mispairing [38]. Strains can switch randomly 
between fimbrial serotypes, Fim2 and Fim3, by insertions and deletions in a homopolymeric 
C-track. This C-track is located between the -10 and -35 elements of the fimbrial promoter 
region. These small insertions and deletions may affect transcription by varying the distance 
between the binding site for BvgA and the RNA polymerase [38,91]. Phase variation results in 
strains which carry either Fim2 or Fim3, both fimbriae or no fimbriae.
Field trials provided evidence that antibodies against fimbriae were associated with protective 
immunity [92-94]. Further, a relationship has been found between the fimbrial serotype present 
in the whole cell vaccine (WCV) and the predominant serotype isolated from pertussis patients 
[95,96], consistent with a role of fimbriae in protection. Mouse models have also provided 
evidence that fimbriae confer protection [97].
Single nucleotide polymorphisms (SNPs) have been observed in both fim2 and fim3. Two fim2 
alleles, fim2-1 and fim2-2, and four fim3 alleles, fim3-1 to fim3-4, have been found so far. The 
difference between fim2-1 and fim2-2 is one SNP which results in an amino acid substitution 
[62]. The SNP differences of fim3-2 and fim3-3 relative to fim3-1 result in one and two amino 
acid substitutions, respectively, while fim3-4 contains a silent mutation relative to fim3-1 (Fig. 
3) [98]. The non-silent mutation in fim2-3 and fim3-3 was found to be located in a surface 
epitope that has been mapped by serum antibodies from infected or vaccinated subjects [98]. 
Figure 3. Protein variants for Fim2 (left) and Fim3 (right) found in B. pertussis populations. Dots indicate 
identical amino acids and the silent mutation in fim3-4 is shaded [13]. 
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The two Dutch vaccine strains used for the WCV contain fim2-1, fim2-2 and fim3-1; the strain 
used by GSK for the production of the ACV contains the alleles fim2-1 and fim3-1, while the 
strain used by SP contains fim2-2 and fim3-1 (Table 3) [62,72,99-101].
In the 1990s, fim3-1 was temporally replaced by fim3-2 in the Netherlands, but fim3-1 is currently 
the predominating type again. Little variation in fim2 has been found in the Netherlands where 
fim2-2 was only found in a few strains in the 1950s (chapter 7). However, fim-2-1 has been 
replaced by fim2-2 in other vaccinated populations [60,102]. 
Table 3. Alleles present in vaccine strains and circulating strains.
alleles
Vaccine prn ptxA fim2 fim3
WCV
134 prn1 ptxA2 fim2-1 fim3-1
509 prn7 ptxA4 fim2-2 fim3-1
ACV
Tohama Ia prn1 ptxA2 fim2-1 fim3-1
10536b prn7 ptxA4 fim2-2 fim3-1
Dominating alleles in the Netherlands from 
2007-2011 (frequency)
prn2
(100%)
ptxA1
(100%)
fim2-1
(100%)
fim3-1
(100%)
a Three-component ACV (GSK)
b Five-component ACV (SP)
Pertactin
Pertactin (Prn) or P.69 is a 68-70 kDa surface-associated protein. Prn belongs to the family 
of autotransporters, which direct their own transport through the outer membrane [103]. Prn 
contains the amino acid triplet arginine-glycine-aspartic acid (Arg-Gly-Asp or RGD) which 
functions as a cell-binding site in a number of mammalian proteins like vitronectin, vibronectin 
and fibrinogen. This RGD motif is assumed to be involved in adherence to host cells [104]. 
Field trials provided evidence that antibodies against Prn were associated with protective 
immunity [92,93].
Polymorphism in Prn is mainly caused by insertions or deletions of repeats in two regions, region 
1 (containing GGxxP repeats) and region 2 (containing PQP repeats) (Fig. 4) [62,72,100]. Both 
regions have been identified as B-cell epitopes, are immunodominant and induce protective 
antibodies in the mouse model [73,105]. Prn is one of the most variable proteins found in B. 
pertussis. Thirteen different prn alleles have been described so far while the alleles prn1, prn2 
and prn3 are the predominant alleles found in most countries (Fig. 4) (chapter 7) [13]. 
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Figure 4. The 13 Prn variants found in B. pertussis populations. Prn variants are shown on the left and 
dots and dashes indicate identical and absent amino acids respectively. Silent mutations are shaded 
and numbering is relative to the start of the protein. The two regions (region 1 and 2) with five and three 
amino acid repeats have been blocked. Small differences are observed between the five amino acid 
repeats and the three subtypes have been given different colors. The RGD motif, involved in adherence, 
is underlined [13] (this figure is available in color in the appendix). 
Strains used for the Dutch WCV and ACVs contain prn1 and/or prn7 (Table 3) [62,72,99-101]. 
Strains carrying non-vaccine type alleles prn2 and prn3 were first observed in the late 1970s in 
the Netherlands and replaced strains with the vaccine type alleles prn1 or prn7. Further, prn2 
strains increased in frequency in the 1980s while prn3 strains were not detected anymore. In 
the last five years, prn2 strains comprised 100% of the Dutch B. pertussis population (Table 
3). Previous work showed that variation in region 1 affected the efficacy of a WCV in a mouse 
model [73]. The reasons why particular non-vaccine type prn alleles predominate are not well 
understood and are investigated in chapter 4 of this thesis. 
Pertussis toxin
Pertussis toxin (Ptx) is an A-B exotoxin with a total mass of 117 kDa and composed of five 
subunits which are designated as PtxA-PtxE or S1-S5 [106]. Ptx has many biological activities 
including suppression of host immune responses [107,108]. Ptx also causes leukocytosis, high 
levels of which are associated with increased mortality in infants due to pulmonary hypertension 
(defined as an increase in blood pressure in the lung vasculature) which can result in death 
due to the lack of oxygen or hart failure [41]. 
Evidence for an important role for Ptx in protective immunity came from a double blind efficacy 
trial trail which showed that a vaccine containing Ptx only had an efficacy of 77% [109]. 
Consistent with this observation, serological correlates for protection for Ptx antibodies were 
found in several studies [92,93].
PtxA is the most immunogenic subunit and harbors the catalytic, toxic activity [110]. Moreover, 
PtxA is the most polymorphic subunit and eight ptxA alleles have been identified so far (Fig. 5).
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Figure 5. The eight PtxA variants found in B. pertussis populations. Polymorphisms in PtxA known to 
affect T-cell and B-cell epitopes are indicated [13,110,111]. See legend to Fig. 4 for further details. 
Strains used for the WCV and ACVs contain ptxA1, ptxA2 and ptxA4 (Table 3) [62,72,99-101]. 
The strains used for the Dutch WCV contain the alleles ptxA2 and ptxA4. Strains with these 
alleles predominated in the prevaccination period but were gradually replaced by the ptxA1 
strains (Table 3) [62,72]. Very little variation has been found in the other subunits; variation 
was found in ptxC where one silent mutation discriminates between two ptxC alleles ptxC1 and 
ptxC2 [62]. A non-silent mutation has been found in ptxB [19,112] but one allele has only been 
detected in the Tohama I strain used for the production of some vaccines.
Although the variation in Ptx involves only five amino acids (Fig. 5), several observations 
support the contention that variation in PtxA is immunologically relevant and may serve to 
evade host immunity. Two studies identified a T-cell epitope in PtxA at amino acid position 68, 
and a B-cell epitope at amino acid position 196, respectively (Fig. 5) [110,111]. Epitope mapping 
has only identified one conformational epitope recognized by protective antibodies [113]. 
Substitution of one or two amino acids constituting this epitope resulted in the abolishment 
of binding of protective monoclonal antibodies, but not of non-protective antibodies. Similarly, 
replacement of single amino acids abolished a T-cell epitope [110,114]. However, significant 
amino acid changes in the pertussis toxin sequence can occur without drastically altering the 
ability of antibodies to recognize and neutralize the toxin molecule suggesting that high titers 
can overcome antigenic variation [115]. 
Filamentous hemagglutinin
Filamentous hemagglutinin (FHA) is a large (220-kDa), hairpin-shaped molecule, present in 
both a secreted and a surface-associated form [35]. Just as Prn, FHA contains the RGD motif 
which is assumed to be involved in attachment to host cells [2,116]. Indeed, an in vivo study 
using B. bronchiseptica FHA mutants showed that FHA is absolutely required, but not sufficient, 
for tracheal colonization in healthy animals [117].  
FHA is highly immunogenic and data regarding the role of FHA in protection against B. pertussis 
infections in humans can be gleaned from pertussis vaccine studies. Vaccinees who received 
FHA containing pertussis vaccines mounted an antibody response to this protein [77,118] and, 
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1in general, acellular vaccines which contain FHA as well as Ptx had slightly greater efficacy 
than monocomponent Ptx vaccines [119-121]. However, one WCV which did not induce an 
anti-FHA response in humans was nevertheless highly efficacious [122-124] and two studies 
in which serologic correlates of immunity were determined, it was found that FHA made no 
contribution to protection. The latter suggest that, in the presence of antibodies to multiple 
antigens (pertactin, pertussis toxin and fimbriae), the additional presence of antibodies to FHA 
does not contribute further to protection [92,93].
Only two allelic variants have been described for fhaB, fhaB1 and fhaB2, which differ by a 
single, non-silent, SNP (Fig. 6). The two strains used for the production of the Dutch WCV 
contain fhaB1 and fhaB2. However, most strains isolated after 1965 were found to harbor 
fhaB1 [62]. 
Figure 6. The two FHA variants found in the B. pertussis populations. See legend to Fig. 4 for further 
details [62]. 
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Aims and outline of this thesis
The aim of this thesis was to study the evolution of the Dutch B. pertussis population in order 
to gain insight into the different strategies this pathogen has used to resurge and persist in the 
face of intensive vaccination. These insights can be used for short term (e.g. by changing the 
vaccination schedule) and long term (e.g. by changing the vaccine) interventions. Chapter 2 
describes the analysis of strains that do not express the tracheal colonization factor A (TcfA). 
Examination of epidemiologically unrelated strains showed two different mechanisms to 
inactivate the TcfA gene; recombination between repeats followed by the deletion of the whole 
gene and (reversible) mutations in a homopolymeric G-track resulting in the truncation of 
TcfA. Gene loss has played an important role in the evolution of B. pertussis and the tentative 
adaptive values of these changes are discussed. In chapter 3, we re-investigated the causes 
of the whooping cough epidemic that occurred in the Netherlands from 1983 – 1987. At the 
time the vaccine dose was decreased to reduce side effects. Interestingly, the large increase 
in notifications occurring after this change in the vaccination program was suggested to be a 
surveillance artifact caused by the introduction of improved diagnostics. By combining strain 
typing with notification and hospitalization data, we were able to provide evidence that the 
increase in notification reflected a true epidemic. Chapter 4 focused on the question why 
particular Prn variants predominate in vaccinated populations. In contrast to other groups, we 
were able to show that Prn enhances the colonization of the mouse respiratory tract. Further, 
we showed that variation in region 1 of Prn affected colonization. Prn1 was associated with 
the most efficient colonization, possibly explaining why it predominated before the introduction 
of vaccination. Prn2 and Prn3 strains were less efficient colonizers of naïve mice and we 
speculate that their emergence was only possible after change of the competitive balance 
between the variants due to the introduction of vaccines harboring Prn1. We conclude that the 
inclusion of Prn2 in current vaccines may improve their efficacy. In chapter 5, the development 
of a new useful typing method to study B. pertussis populations is described. This typing 
method was based on SNPs. SNP typing was compared with other, current, typing methods, 
and was found to be superior for establishing phylogenic relationships and in identifying 
successful clones. In chapter 6, the cause for the second and current epidemic was studied. 
A strong association was observed between the increase in pertussis notifications in 1996 
and the emergence of strains carrying a novel allele for the pertussis toxin promoter, ptxP3. It 
was shown that the mutation resulting in ptxp3 was associated with increased Ptx production. 
Epidemiological data on morbidity and mortality suggested that the ptxp3 strains are more 
virulent than the ptxP1 strains they replaced. This work suggests that pertussis vaccines may 
be improved by increasing the persistence of Ptx antibodies. The role of small mutations in the 
resurgence of pertussis is still contentious and in chapter 7 we sought to investigate the effect 
of these mutations on strain fitness. Phylogenetic analysis showed that the Dutch B. pertussis 
population evolved by the successive accumulation of the small mutations in virulence-
associated genes. Further, the mutations were associated with clonal expansions, suggesting 
that they significantly affected strain fitness. Genomic analysis revealed a number of additional 
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1mutations which may have contributed to clonal expansions. Our results suggest that the B. 
pertussis gene repertoire is already well adapted to its current niche and required only fine 
tuning to persist in the face of vaccination. Further, this work shows that small mutations, even 
single SNPs, can drive large changes in the populations of bacterial pathogens within a time 
span of six to 19 years. Finally, in chapter 8, the results and findings of the preceding chapters 
are summarized and discussed and future perspectives are presented. 
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Abstract
Bordetella pertussis, the causative agent of whooping cough, has remained endemic and is re-
surging in some countries despite vaccination. B. pertussis produces a wide range of virulence 
factors which are assumed to play an important role in infection and transmission, including 
tracheal colonization factor (TcfA). Here we show that clinical isolates belonging to distinct 
lineages may loose their ability to produce TcfA. Irreversible and reversible loss occurred, re-
spectively, by recombination between repeats leading to deletion of the tcfA gene and by mu-
tations in a polymorphic G-track. These phenomena may reflect adaptation to distinct niches. 
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Introduction
Bordetella pertussis and Bordetella parapertussis are the causative agents of whooping cough 
or pertussis, a highly contagious disease of the human upper respiratory tract [1]. B. per-
tussis is generally isolated from whooping cough cases with higher frequencies (70%-95%) 
compared to B. parapertussis. The closely related species Bordetella bronchiseptica infects a 
broad range of mammalian species, including humans [2]. Since the 1950s, effective vaccines 
against pertussis are available and their introduction has led to a dramatic decrease in pertus-
sis world-wide. However, despite more than 50 years of vaccination whooping cough remains 
an endemic disease in many countries with outbreaks occurring every 3 to 5 years. Globally 
c. 48.5 million cases of pertussis are notified with as many as 295,000 deaths, mainly among 
children [3]. B. pertussis produces a large number of virulence factors including tracheal colo-
nization factor A (TcfA). TcfA is a member of the autotransporter family, which is able to direct 
its own transport across the outer membrane of the bacterium [4]. During routine surveillance, 
we observed several B. pertussis strains isolated from children in which the tcfA gene was not 
detected by PCR. Here we characterize these and other tcfA mutants and show that they arise 
by two different mechanisms. Expression of tcfA was assessed with antibodies raised against 
peptides. Further, we show that the tcfA mutations are found in epidemiologically unrelated iso-
lates, suggesting that inactivation of the tcfA gene occurred independently in different strains.
Materials and methods
Bacterial strains and culture conditions
Characteristics of B. pertussis isolates used in this study are listed in Table 1.The strains were 
grown on Bordet Gengou (Becton, Dickinson and Company, Franklin Lakes, NJ) agar supple-
mented with 15% sheep blood and incubated for 3 – 5 days at 350C. All strains were isolated 
from pertussis patients. The age of the Belgian patients was 1 month for B2774, B3099 and 
B3100, 3 months for B2772, B2775 and B3098 and 5 years for B2773. Based on the age of the 
patients, we presume that three patients were unvaccinated, three patients were incompletely 
vaccinated and one patient was fully vaccinated. No patient information was available from the 
Dutch and American strains.
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Table 1. Characteristics of B. pertussis strains used in this study.
Strain Country of origin Year of isolation MLVA type ST
B2772 Belgium 1998 36 1
B2773 Belgium 2000 29 2
B2774 Belgium 2001 27 1
B2775 Belgium 2002 16 1
B3098 Belgium 2002 70 3
B3099 Belgium 2005 16 1
B3100 Belgium 2006 27 4
B1191 USA 1993 27 5
B3008 the Netherlands 1980 92 6
B2934 the Netherlands 1984 130 6
B0613 the Netherlands 1995 ND ND
B1831 the Netherlands 1999 ND ND
B1834 the Netherlands 1999 ND ND
Abbreviations: MLVA, multiple-locus variable-number tandem repeat analysis; ST, sequence type obtained by 
MLST; ND, not determined.
PCR and sequencing
Chromosomal DNA was isolated using the Wizard Genomic DNA Purification Kit (Promega, 
Madison, WI), following the instructions for Gram negative bacteria. To sequence tcfA, the 
gene was amplified by PCR. Primers used for PCR and sequencing are listed in Table 2. PCR 
was performed by adding 1 µl DNA to 19 µl of a PCR mix consisting of 50% HotstarTaq Mas-
termix (Qiagen, Westburg), 1M betain (Sigma Aldrich), 10 pmol of PCR primer tcfA-F, 10 pmol 
of primer tcfA-R and 3 µl H2O. Thermal cycling was as follows: 15 min at 950C, 30 cycli of 30 
sec at 950C, 30 sec at 550C, 1 min at 720C. A final extension was performed for 10 min at 720C. 
The PCR products were purified using ExoSap-IT (USB, Cleveland), according to the manu-
facturer’s instructions, and sequenced with the same forward and reversed primers used for 
amplification. Sequence reactions were performed with an ABI Prism Big Dye terminator reac-
tion kit and the reactions were analyzed with a model 3700 ABI DNA Sequencer (Perkin-Elmer 
Applied Biosystems). A DNA region containing tcfA and 1,500 bases upstream and down-
stream sequences was amplified as follows. Chromosomal DNA 2 µl was added to 18 µl of a 
PCR mix consisted of 50% HotstarTaq Mastermix (Qiagen, Westburg), 5 % dimethyl sulfoxide 
(ICN), 10 pmol of PCR primer tcfA-all F, 10 pmol of primer tcfA-all R and 5 µl H2O. Thermal 
cycling was as follows: 15 min at 950C, 30 cycli of 10 sec at 950C, 1 min at 580C, 5 min at 720C. 
A final extension was performed for 10 min at 720C. The PCR products were purified using 
the QIAquick PCR Purification Kit (Qiagen, Westburg) according to the manufacturer’s instruc-
tions. After sequencing with tcfA-all sp1 F – sp 2R, tcfA sequences were compared with the 
tcfA sequence of the B. pertussis Tohama I strain, GenBank Accession number NC_002929. 
Primers used for sequencing are listed in Table 2.
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Table 2. Primers and tcfA probes used in this study.
Target Primer name Sequence (5’ - 3’)
tcfA
tcfA-F CTTTCTCCTCCCTCGGCATGG
tcfA-R AGCGCCGTCCGGATTCAAG
Regions flanking 
tcfA
tcfA-all F AACGAGGACCTCGGCAAGTG
tcfA-all R TCACCGAATACATCATGGCG
tcfA-all sp1 F GATGACGACAGCGTGCACG
tcfA-all sp2 F CCACGCGTTCAAGGTGGAC
tcfA-all sp1 R CGCTACCGCCTACCGCTAC
tcfA-all sp2 R CATGCGCAGGACCTTGCTC
ptxA
ptxA-F CCCCCTGCCATGGTGTGATC
ptxA-R AGAGCGTCTTGCGGTCGATC
ptxC
ptxC-F CTTCCGGAGGTTTCGACGTTTC
ptxC-R TCTTTCAAGGGATTCATTCGC
pertactin
prn-F GCCAATGTCACGGTCCAA
prn-R GCAAGGTGATCGACAGGG
fim2
fim2-F GCGCCGGGCCCTGCATGCAC
fim2-R GGGGGGTTGGCGATTTCCAGTTTCTC
fim3
fim3-F GACCTGATATTCTGATGCCG
fim3-R CGCAAGGCTTGCCGGTTTTTTTTGG
adk
adk-F AGCCGCCTTTCTCACCCAACACT
adk-R TGGGCCCAGGACGAGTAGT
tyrB
tyrB-F CGAGACCTACGCTTATTACGAT
tyrB-R TGCCGGCCAGTTCATTTT
tcfA tcfA-probe CTTTCTCCTCCCTCGGCATGG
Southern blot hybridization
Chromosomal DNA was purified using the Wizard Genomic DNA Purification Kit (Promega, 
Madison, WI) and was digested with the restriction enzyme ClaI (Roche Diagnostics). As tcfA- 
positive strain, B0613 was used. Southern blotting and hybridization with a biotine-labeled 
oligonucleotide probe was performed as described before [5]. The tcfA probe used for hybrid-
ization is listed in Table 2
Peptide synthesis and immunization
Polyclonal rabbit anti–TcfA sera were raised at the Eurogentec facility (Eurogentec, Seraing, 
Belgium). New Zealand white rabbits (n = 2) were immunized with a mixture of two 16–mer 
synthetic tcfA peptides (CSLEDFKRSLQESAPS and CERGDDAGPKPPEGEG) coupled to 
KLH.   
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS – page) and West-
ern blotting
Bacterial cells were collected and separated on SDS – PAGE as described [6]. Samples were 
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mixed with loading buffer and boiled for 5 minutes before loading onto 4 – 20% Tris - Glycine 
polyacrylamide gels (Pierce, Rockford, IL).
Proteins were transferred to PVDF membranes (Amersham Biosciences, Buckinghamshire, 
UK), air-dried and blocked with 5% (w/v) Protifar (Nutricia, Zoetermeer, the Netherlands) and 
0,05% (w/v) Tween20 (Merck, USA) in 0,08 M TRIS HCL/1,5 M NaCl buffer pH = 7,3 – 7,5 and 
subsequently incubated for 1 h with polyclonal rabbit anti-TcfA sera. Membranes were washed 
three times for 10 min with Tris/NaCl buffer containing 0,05% (w/v) Tween20 and incubated 
for 30 minutes with goat anti-rabbit IgG conjugated to horseradish peroxidase [7] (Pierce, 
Rockford, IL). Membranes were washed three times for 10 min with Tris/NaCl buffer containing 
0,05% Tween20 (w/v) and as substrate, SuperSignal West Femto Maximum Sensitivity Sub-
strate (Pierce, Rockford, IL) was used. Signals were detected using the LAS – 3000 Imaging 
System (Fujifilm, USA). 
Multiple-locus variable-number tandem repeat analysis (MLVA)
For MLVA, the number of tandem repeats in 6 loci (VNTR1, VNTR3a, VNTR3b, VNTR4, VNTR5 
and VNTR6) was determined [8]. MLVA profiles were clustered as described previously [8]. 
 
Multiple-locus sequence typing (MLST)
MLST was performed using 6 genes known to be polymorphic in B. pertussis [2,7]. Four genes 
(ptxA, prn, fim2 and fim3) code for surface proteins, while two genes (adk and tyrB) code for 
house keeping genes. Primers used are indicated in Table 2. For prn, the two regions harbor-
ing repeats were sequenced as previous research has indicated that variation is essentially 
limited to these regions [7].
Results
The tcfA gene is absent from epidemiologically unrelated Belgian B. pertussis clinical 
isolates
To detect shifts in the bacterial population, clinical isolates in Belgium and the Netherlands 
are characterized with respect to a number of genes coding for surface proteins, including 
tcfA [7,9]. In the period 1998-2002, four Belgian clinical isolates were observed in which tcfA 
was not detected with PCR. The primers used for PCR were positioned inside the tcfA gene 
suggesting imperfect fit of the primers or absence of one or both primer binding sites. To in-
vestigate these possibilities, a PCR was performed with primers located outside the tcfA gene 
(primers tcfA-all F and tcfA-all R, Fig. 1, Table 2). With these primers, PCR fragments of 3 kb 
and 5 kb were found in the Belgian strains and the Tohama I strain, respectively (not shown). 
The latter strain is known to contain an intact tcfA gene [7]. These results indicated the pres-
ence of a 2- kb deletion in the region harboring tcfA in Belgian isolates. As the tcfA gene com-
prises 1,944 bases, this suggests that the complete gene was deleted. 
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BapB  CHP HPtetRtcfAb B
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tcfA-all F tcfA-all RtcfA-F tcfA-R
GGGGGGGGG
Figure 1. Overview of the B. pertussis chromosomal region harboring tcfA. The deletion found in some 
strains is indicated and corresponds to position 1,264,096 to 1,266,422 in Tohama I [12]. The positions 
of the polymorphic G-track and the primers used for amplification are indicated. Abbreviation: HP, hypo-
thetical protein.
To confirm the absence of the tcfA gene, a southern blot was performed using an oligonucle-
otide derived from the 5’-end of the tcfA gene (tcfA-probe) (Table 2). When chromosomal DNA 
was digested with Cla1, the probe revealed a 5 kbp band in B0613, which contains tcfA2. 
However, no hybridizing bands were detected in the Belgian strains (B2272, B2773, B2774 
and B2775) (Fig. 2). 
Figure 2. Detection of tcfA in B. pertussis strains. Chromosomal DNA was digested with ClaI and hybrid-
ized to a tcfA-specific probe. The numbers on the left refer to base pair sizes of marker DNA fragments 
(MF).
To identify the boundaries of the deletion, the 3 kb PCR fragment derived from the isolates was 
sequenced. All four strains revealed the same sequence. Comparison with the Tohama I strain 
revealed a deletion encompassing 2,326 bases. The deletion was located between two direct 
repeats of 539 bases, suggesting it was the result of homologous recombination (Fig. 1). To 
confirm the absence of the tcfA product, Western blotting was performed with rabbit anti-TcfA 
sera. A 60 kDa protein was detected in strains with an intact tcfA gene (B1831 and B1834), but 
not in the four Belgian strains in which the gene was deleted (Fig. 3).
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Figure 3. Detection of TcfA with specific antibodies. Western blotting was performed with polyclonal 
rabbit anti-TcfA antibodies. B2775 and B3099 are representatives of strains missing the complete tcfA 
gene (ΔtcfA) or carrying a frame-shift mutation (tcfA5). The numbers on the left refer to molecular mass 
of protein markers.
tcfA Mutant strains are not confined to Belgium
In our strain collection ten additional isolates were found which harbored mutations in the tcfA 
gene, seven from Belgium, two from the Netherlands and one from the US [7 and this work]. 
One Dutch strain (B3008, isolated in 1980) contained the same deletion as the four Belgian 
strains. The three Belgian strains (B3098, B3099 and B3100, isolated in 2002, 2005 and 2006) 
and the strain from the USA (B1191, isolated in 1993) contained an insertion (tcfA5) and sec-
ond Dutch strain (B2934, isolated in 1984) contained a deletion of a G (tcfA9) in a polymeric 
G-track located in tcfA, resulting in a frame-shift and premature termination of translation (Fig. 
1) [7]. The absence of TcfA in strains containing mutations in tcfA was confirmed by western 
blotting (Fig. 3).
tcfA mutations are observed in distinct B. pertussis lineages
To determine if tcfA mutants arise in particular lineages the MLVA and MLST types of the ten 
strains were determined. Seven different MLVA types were found. Two Belgian strains, isolated 
in 2001 and 2006, were MLVA type 27 and two Belgian strains, isolated in 2002 and 2005, were 
MLVA type 16 (Tables 1 and 3). A minimum spanning tree revealed that the tcfA mutations 
occurred in different B.pertussis lineages (Fig. 4). The two Dutch strains with MLVA types 92 
and 130, were closely related according to the MLVA analysis, differing in one locus, although 
they were isolated in different years. Six Belgian strains were found to differ in one or two loci 
and one Belgian strain, with MLVA type 70, was found to differ in at least 3 loci and was most 
closely related to the two Dutch strains with MLVA type 130 and 92. 
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Table 3. VNTR analysis of B. pertussis isolates used in this study.
Strain VNTR1 VNTR3A VNTR3B VNTR4 VNTR5 VNTR6 MLVA type
B2772 8 7 8 7 6 7 36
B2773 8 7 0 7 6 9 29
B2774 8 7 0 7 6 7 27
B2775 8 6 0 7 6 7 16
B3098 7 6 0 7 6 8 70
B3099 8 6 0 7 6 7 16
B3100 8 7 0 7 6 7 27
B1191 8 7 0 7 6 7 27
B3008 7 6 0 7 6 9 92
B2934 7 6 0 6 6 9 130
Abbreviation: MLVA, multiple-locus variable-number tandem repeat analysis.
Figure 4. Minimum spanning tree based on MLVA of Dutch isolates. MLVA types are indicated in the 
circles, the size of which is related to the number of isolates within that particular MLVA type. MLVA 
types harboring tcfA mutants are indicated by thick set numbers. Thick set and stippled lines indicate 
differences of one and more than one locus, respectively. The country of isolation is indicated. A total 
of 213 Dutch isolates were included for this analysis [8]. Abbreviations: B, Belgium; N, the Netherlands; 
U, USA.
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MLST was performed using six genes known to be polymorphic in B.pertussis (Table 1) [7]. 
Six Sequence Types (STs) could be distinguished. The seven Belgian strains were comprised 
of four distinct sequence types, ST1 (four strains), ST2 (one strain), ST3 (one strain) and ST4 
(one strain). The two Dutch strains revealed the same ST (ST6), while the strain from the US 
belonged to ST 5 (Tables 1 and 4) Thus both the MLVA and MLST results suggest that the tcfA 
mutations occurred in distinct lineages.  
Table 4. MLST analysis of B. pertussis isolates used in this study.
Strain adk tyrB ptxA ptxC prn fim2 fim3 ST
B2772 adk1 tyrB3 ptxA1 ptxC2 prn2 fim2-1 fim3B 1
B2773 adk1 tyrB3 ptxA1 ptxC1 prn1 fim2-1 fim3A* 2
B2774 adk1 tyrB3 ptxA1 ptxC2 prn2 fim2-1 fim3B 1
B2775 adk1 tyrB3 ptxA1 ptxC2 prn2 fim2-1 fim3B 1
B3098 adk1 tyrB3 ptxA1 ptxC1 prn1 fim2-2 fim3A 3
B3099 adk1 tyrB3 ptxA1 ptxC2 prn2 fim2-1 fim3B 1
B3100 adk1 tyrB3 ptxA1 ptxC2 prn2 fim2-1 fim3A 4
B1191 adk1 tyrB3 ptxA1 ptxC1 prn2 fim2-1 fim3A 5
B3008 adk1 tyrB3 ptxA1 ptxC1 prn1 fim2-1 fim3A 6
B2934 adk1 tyrB3 ptxA1 ptxC1 prn1 fim2-1 fim3A 6
Abbreviations: MLST, multiple-locus sequence typing; ST, sequence type obtained by MLST.
*Contains a silent mutation
Discussion 
In this study, 10 epidemiologically unrelated B. pertussis tcfA mutants were characterized. Two 
classes of tcfA mutants were observed. In the first class, the tcfA gene was deleted, whereas 
the second class contained frame shifts in the tcfA gene. Five strains, four isolated in Belgium 
and one in the Netherlands, contained an identical deletion of 2,326 bases which removed 
the whole tcfA gene. The deletion was located between two direct repeats of 539 bases. The 
two repeats comprise the 5’-ends of bapB and tcfA, respectively, and code for a conserved 
C-terminal region, called the β–barrel required for transport across the bacterial cell wall (Fig. 
1) [4]. Thus the proximity of bapB and tcfA facilitates recombination between the conserved 5’-
ends of these genes resulting in deletion of tcfA. Five strains, isolated in Belgium, the US and 
the Netherlands, belonged to the second class of mutants and harbored a single base insertion 
and deletion, respectively, in a homopolymeric G-track resulting in a translational frame shift. 
Regions with reiterated bases are know to be hotspots for small insertions or deletions due to 
transient misalignment during replication [10]. Such regions are found in the promoter region 
of B.pertussis fimbrial genes and also in several structural genes [11,12] and allow phase 
variation, i.e. the reversible, random, switching between expression and non-expression of 
genes. The B.pertussis tcfA mutants have been found in Belgium, the Netherlands, the United 
States [7, this work] and in the UK [13] and in different years. Furthermore, they were present 
in distinct B.pertussis lineages. Finally, two mechanisms of tcfA inactivation were observed. 
41
2
This indicates that inactivation of tcfA has occurred independently in different strains. As yet we 
do not know if the tcfA mutants are transmissible and able to persist in the human population. 
tcfA mutants are less well able to colonize mice, suggesting that tcfA is important for strain 
fitness, at least in the mouse model [14,15]. However, tcfA is not expressed by B. parapertus-
sis and B. bronchiseptica [15], suggesting that its loss may be compensated by other genes. 
The evolution of B.pertussis has been accompanied by substantial gene loss and 9.4% of its 
genes are pseudogenes [12]. It is conceivable that the inactivation or loss of tcfA reflects the 
ongoing reduction of the B.pertussis genome. Alternatively, temporary loss of tcfA expression 
may confer an advantage during particular stages in the transmission cycle of B.pertussis. The 
loss of tcfA expression may be related to immunological pressure. E.g. in all three countries 
where the TcfA mutants were observed whole cell vaccines, which contain tcfA, have been 
used for more than 40 years. Compared to other B.pertussis surface proteins, TcfA is highly 
polymorphic [7]  suggesting that an immune response targeting TcfA has a significant effect on 
bacterial fitness. Under such conditions (temporary) loss of tcfA may be beneficial. Previous 
studies have suggested an important role for other B.pertussis surface antigens in adaptation 
to vaccination with whole cell vaccines [16]. In the last decade, whole cell pertussis vaccines 
have been replaced by acellular vaccines which induce high antibody levels against a limited 
number B.pertussis proteins and this may result in new adaptations. Clearly it is important to 
continue to monitor changes in the B.pertussis population.
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Abstract
Despite more than 50 years of vaccination, whooping cough is still an endemic disease in the 
Netherlands with regular epidemic outbreaks. In the last 20 years, two periods of increased 
notifications were observed. The causes of the increased notifications in the first period, from 
1983 – 1987, are contentious. At the time it was suggested to be a surveillance artifact, caused 
by changes in diagnostic procedures and increased awareness. An alternative explanation, 
a reduction in the vaccine dose, was downplayed at the time. The aim of this study was to 
reinvestigate the causes of the increased notifications by identifying changes in the Bordetella 
pertussis population. B. pertussis strains, isolated from 1965 to 1992, were characterized by 
means of fimbrial serotyping, multiple-locus sequence typing of virulence genes (MLST) and 
multiple-locus variable-number tandem repeat analysis (MLVA). Shifts in fimbrial serotypes 
and MLVA types were associated with changes in vaccine dose and increased number of 
notifications. One to three years after lowering of the vaccine dose, the predominant fimbrial 
serotype changed from Fim3 to Fim2, and the reverse trend was observed when the vaccine 
dose was increased. Significantly, changes in fimbrial serotypes were evident at least seven 
years before the increase in notifications. Our results provide evidence that the change in 
vaccine dose affected host immunity and, consequently, contributed to an increase in pertussis 
morbidity. Further, we show that MLVA and fimbrial serotyping of strains can be used as early 
warning for pertussis epidemics.
45
3
Introduction
Whooping cough or pertussis, caused by the Gram–negative bacteria Bordetella pertussis and 
Bordetella parapertussis, is a disease of the human upper respiratory tract and most severe 
for young, unvaccinated infants [1]. Despite more than 50 years of vaccination, pertussis is still 
one of the most prevalent vaccine–preventable diseases worldwide. Significantly, pertussis 
has resurged in many vaccinated populations in the 1980s and 1990s [2]. Several causes 
have been proposed for the resurgence of pertussis. It has been suggested that the increase 
is, at least in part, due to more awareness and improved diagnosis [3]. Other factors which 
may have contributed to the resurgence of pertussis include waning immunity and pathogen 
adaptation [4]. 
A whole cell pertussis vaccine, produced by the Netherlands Vaccine Institute, was introduced 
in the Netherlands in 1953. In 2005, the whole cell vaccine was replaced by an acellular 
vaccine. Vaccine coverage has been consistently high (>95%) throughout this period. Two 
periods of increased notifications were observed in the last 20 years in the Netherlands. The 
second, most recent, period started in 1996, and notifications have remained high since then 
[5-7]. Previously, we showed that the increase in notifications in 1996 and subsequent years 
cannot be explained by improved surveillance alone and that, in addition to waning vaccine-
derived immunity, pathogen adaptation has played an important role [6,8,9]. The first period, 
encompassed the years 1983-1987 when a 14-fold increase in pertussis notifications was 
observed from 200 to 2,709 (Fig. 1). In 1988 notifications decreased to 112. Hospitalizations 
showed a similar trend (Fig. 1). At the time, the causes of the increased notifications were 
contentious and it was suggested that growing awareness of the disease and the introduction 
of more sensitive diagnostic procedures, based on antibody titers against pertussis antigens, 
contributed to an increase of notified patients (Fig. 1) [10,11]. Another suggested cause was 
import of the disease from Germany and England, where increased incidences of pertussis 
were observed [12,13]. A fourth possible cause discussed, was the reduction of the vaccine 
dose from 16 International Opacity Units (IOU) to 10 IOU in 1975 – 1984. This lowering of the 
vaccine dose was implemented to reduce the side effects of the whole cell vaccine [10,14] and 
was thought to have affected the level of immunity and to have resulted in a more susceptible 
population. However, at the time the effect of the lowering of the vaccine dose was downplayed 
and increased awareness and improved diagnosis were seen as the main causes for the 
increased notifications [10]. 
In this study, we aimed to elucidate the causes of the increased notifications in the period 
1983-1987 by studying changes in the B. pertussis population at that time. To this purpose, we 
determined temporal trends in fimbrial serotypes and in the frequencies of three alleles coding 
for virulence factors of B. pertussis. Further, strains were typed by means of multiple-locus 
variable-number tandem repeat analysis (MLVA). 
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Figure 1. Changes in vaccine dose, diagnostic criteria, notifications and hospitalizations in the Nether-
lands in the period 1975 to 1992. Data on notifications and hospitalizations were not available before 
1976. The vaccine dose was lowered from 16 to 10 IOU in 1975-1984. Abbreviations: 1-pt and 2-pt, one 
point serology based on a titer in a single serum sample and two point serology based on an increase in 
titers in paired samples, respectively. IgA and IgG antibodies were determined against a crude cell wall 
extract and pertussis toxin, respectively.
Materials and methods
Isolates
A total of 252 Dutch B. pertussis clinical isolates, selected from the period 1965 to 1992, were 
characterized in this study (a table with strain information is available online from http://www.
sciencedirect.com/science/article/pii/S0264410X09001753). We attempted to obtain at least 
20 strains per year, however only 32 isolates were available for the period 1965 to 1978 and no 
isolates were available for the years 1971, 1973 to 1975 and 1979. For most strains both the 
date and place of isolation were available, allowing us to determine that the strains were not 
epidemiologically related. Strains were grown on Bordet Gengou (BG) agar supplemented with 
15% sheep blood (BD, Franklin Lakes, NJ, USA) and incubated for 3 days at 350C. Bacterial 
cells were lysed in Tris EDTA buffer (Sigma-Aldrich, Zwijndrecht, NL) at 950C for 5 minutes, 
centrifuged briefly and used in PCR. 
 
0
500
1000
1500
2000
2500
3000
19
75
19
76
19
77
19
78
19
79
19
80
19
81
19
82
19
83
19
84
19
85
19
86
19
87
19
88
19
89
19
90
19
91
19
92
no
tif
ic
at
io
ns
0
50
100
150
200
250
300
350
400
450
500
ho
sp
ita
liz
at
io
ns
notifications
hospitalizations
Clinical symptoms, culture 
Clinical 
symptoms, 
culture,  
1-pt IgA 
Clinical 
symptoms, 
culture, 1-pt 
IgA, IgG 
Clinical 
symptoms, 
culture, 2-pt IgA, 
IgG 
Diagnostic 
criteria: 
Vaccine dose 
years 
47
3
Multiple-locus variable-number tandem repeat analysis
For MLVA, the variable number of tandem repeats in 6 loci (VNTR1, VNTR3A, VNTR3B, 
VNTR4, VNTR5 and VNTR6) was determined. MLVA profiles were clustered as described 
before [15,16]
Multiple-locus sequence typing of genes encoding surface proteins 
Polymorphisms in the genes for tracheal colonization factor A (tcfA), pertussis toxin subunit A 
(ptxA) and pertactin (prn) were determined as described before [8,17].
Serotyping
A bacterial suspension was mixed on glass slide with a physiological salt solution that contained 
monoclonal antibodies against Fim2 or Fim3 (NIBSC, South Mimms, UK). Agglutination was 
macroscopically determined after 1 minute. To determine if autoagglutination occurred, bacterial 
suspensions were mixed with a physiological salt solution without monoclonal antibodies 
[18,19]. 
Notification data
Since 1976, pertussis notification is obligatory by law in the Netherlands. Notifications for 
the period 1976 until 1992 were studied. Before 1976, diagnosis of pertussis was based 
on culture and/or clinical symptoms. To increase the sensitivity of pertussis diagnosis, high 
levels of IgA antibodies against a crude cell wall preparation of B. pertussis were added as 
diagnostic criterion in 1981 [6,20]. The pertussis serodiagnosis was further improved in 1984 
by determining IgG titers against pertussis toxin. Finally, in 1988, more stringent criteria were 
introduced and pertussis serodiagnosis was based on two-point serology, i.e. a significant 
increase in IgA and/or IgG titers in paired sera [6]. The changes in diagnostic criteria have 
been indicated in Fig. 1.
Data analysis 
The prevalence of different strains of B. pertussis was determined for the period of study and 
genetic relationship between strains was tested with a minimum spanning tree (MST) based on 
MLVA [15,16]. Changes in the B. pertussis population were set against changes in vaccination 
dose and trends in notifications. For convenience we distinguished three periods. Period I 
encompasses the years 1965 to 1974, during which the high vaccine dose was used. No data 
on notifications were available from this period, as pertussis became a notifiable disease in 
1976. Period II defines the periods in which the vaccine dose was lowered (1975 to 1984) and 
pertussis notifications increased (1983 to 1987). Finally, period III (1988 to 1992) refers to the 
period where the vaccine dose was increased. Further, to increase the number of data points, 
the years 1965-1966, 1967-1972, 1976-1978 and 1991-1992 were pooled.
Differences in proportions of MLVA types, allel frequencies and serotypes between the three 
periods were assessed by means of Fisher’s exact test. For all tests, a P-value of < 0.05 was 
considered statistically significant. Tests were performed using the Statistical Analysis System 
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version 9.1.3.
Results
Changes in MLVA
Of the 61 different MLVA types found, 55 - which occurred in low frequencies (frequency less 
than 4% of all isolates) - were pooled and included in the calculations of frequencies, but were 
not discussed further. Although MLVA27  represented only 2.8% of all isolates, it was included 
because it became the predominant type in more recent years [16].
The distribution of the MLVA types over three periods (see Materials and methods) was 
compared and was found to be significantly different (P < 0.0001). Three MLVA types (MLVA92, 
MLVA130 and MLVA132) predominated period II (Fig. 2A). MLVA130 was essentially confined 
to period II as it was found only in the years 1980 to 1988 in frequencies of 20% to 71%. 
MLVA92 and MLVA132 were also detected in the same period but in lower frequencies. MLVA92 
was detected between 1980 and 1989 (frequencies 3% - 27%) and MLVA132 was detected 
between 1978 and 1988 (frequencies 5% - 17%).
Two MLVA types were mainly found outside period II (Fig. 2B). MLVA29 predominated before 
(frequencies 33% - 100%) and after period II (frequencies 29% – 33%) while, in general, it was 
present in lower frequencies within this period (frequencies 5% - 47%). MLVA27 was found 
for the first time in 1984 (frequency 5%) and gradually increased in frequency to 11% in 1990. 
Between 1993 and 2004, it was the predominant type in the Netherlands [16].
Changes in allele frequencies 
We investigated changes in the frequencies of the alleles for three virulence genes, tcfA, ptxA, 
and prn, known to be polymorphic in B. pertussis [8,17]. The two vaccine strains contained 
the alleles tcfA2, ptxA2, ptxA4, prn1 and prn7 [8,17]. The distribution of tcfA, ptxA and prn 
alleles over the three periods was significantly different (P < 0.0001, P = 0.0018 and P < 
0.0001, respectively). Six tcfA alleles (tcfA2, tcfA3, tcfA4, tcfA7, tcfA8 and tcfA9) were found. 
In two strains the tcfA gene was deleted. As reported previously, such deletions probably occur 
by recombination between repeated regions [15]. The tcfA2 allele predominated in all three 
periods (frequencies 71%-100%, Fig. S1). Three ptxA alleles were identified, ptxA1, ptxA2 and 
ptxA4. With the exception of 1976-1978, when ptxA2 was found in a frequency of 50%, ptxA1 
predominated in all three periods (frequencies 42%-100%, Fig. S2). Three prn alleles were 
found, prn1, prn2 and prn3. In periods I and II, prn1 predominated with frequencies of 83% 
-100% while the non-vaccine type alleles prn2 and prn3 appeared first in 1977 and in 1981 
respectively (Fig. S3). A gradual decrease in prn1 frequency and concomitant increase in prn2 
and prn3 frequencies was observed from 1989–1992. The replacement of prn1 by the two non-
vaccine type alleles continued in subsequent years and currently prn2 is found in more than 
90% of the strains [8,16]. 
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Figure 2. Notifications and frequencies of MLVA types in the period 1965 to 1992. Some years were 
pooled to increase the number of analyzed strains to at least six. Panel A shows the MLVA types pre-
dominating in period II, encompassing the low vaccine dose period (1975 – 1984) and the period with 
increased notifications (1983 – 1987), while panel B shows the predominant MLVA types found before 
and after period II. The number of strains analyzed in the different periods has been indicated.  The dis-
tribution of the MLVA types over the three periods was significantly different (P < 0. 0001).
Changes in serotypes
The two strains used to produce the WCV express both Fim2 and Fim3. The distribution of the 
three B. pertussis serotypes (Fim2, Fim3 and Fim2,3) over the three periods was significantly 
different (P < 0.0001). Fim2 strains predominated in period II (frequencies 40% to 100%) (Fig. 
3). In the periods I and III, Fim2 strains were found in low frequencies (0% to 20%) and in these 
periods Fim3 strains dominated (frequencies 52% to 100%). Between 1984 and 1991/1992, 
a gradual increase in the frequency of Fim3 strains was observed from 5% to 85%. Fim2,3 
strains were generally detected in low frequencies (3%-17%), except in 1983 and 1984, when 
Fim2,3 strains comprised 50% and 40% of the sampled population, respectively. 
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Figure 3. Notifications and frequencies of fimbrial serotypes in the period 1965 to 1992. The distribution 
of the fimbrial serotypes over the three periods was significantly different (P <0. 0001). See legend to 
Fig. 2 for further details.
Genetic relationship based on a minimum spanning tree
We investigated the genetic relationship between the strains with a minimum spanning tree 
(MST) based on MLVA. The MST revealed that MLVA types characteristic for period II (i.e. 
MLVA92, MLVA130 and MLVA132) were closely related and distinct from the MLVA type 
predominating in period I and III (i.e. MLVA29) (Fig. 4). Further, there was an association 
between these predominant MLVA types and serotypes. MLVA92, MLVA130 and MLVA132 
were predominantly of the Fim2 type (85%). In contrast, MLVA29 mainly expressed Fim3 
(69%).
 
Figure 4. Minimum spanning tree based on MLVA of 252 Dutch B. pertussis clinical isolates. MLVA types 
are indicated in the circles, the size of which is related to the number of isolates with that particular MLVA 
type. The colored segments indicate the frequencies of serotypes: Fim2 (green), Fim3 (red), Fim2,3 
(blue) and not detectable or autoagglutinable (yellow). Thick set, thin set and dotted lines indicate dif-
ferences of one locus, two loci and more than two loci respectively (this figure is available in color in the 
appendix).
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Discussion
Despite the successful vaccination against pertussis since the 1950s, a sudden increase in 
pertussis notifications was observed in the Netherlands from 1983 to 1987. At that time, it 
was suggested that the increase in notified patients was mainly a surveillance artifact caused 
by increased awareness and the introduction of more sensitive diagnostic procedures [10]. 
Indeed, the increase in notifications coincided with the introduction of more sensitive diagnostic 
methods based on serology [21]. Significantly, when more stringent criteria, based on two 
point serology, were introduced, notifications decreased.  Based on these observation, it was 
concluded that the lowering of the vaccine dose played no, or only a minor role in the increased 
notifications [10]. On the other hand, simultaneously to the increase in the notifications, 
the incidence of hospitalizations for pertussis also increased. As hospitalizations are less 
sensitive for surveillance artifacts, since clinical symptoms are often evident and diagnosis 
is less dependent on laboratory confirmation [6], the combined increase of notifications and 
hospitalizations suggested a true increase in the incidence of pertussis at that time. 
The aim of this study was to reinvestigate the causes for the increased notifications. In previous 
studies we have shown that the introduction of vaccination in the Netherlands has significantly 
affected the B. pertussis population [4,22]. Therefore we reasoned that, if lowering of the 
vaccine dose in 1975-1984 had affected host immunity, this may be reflected in changes in 
the B. pertussis population. Indeed, our data showed significant changes in the B. pertussis 
population from 1983-1987, following the lowering of the vaccine dose.
The frequencies of three MLVA types (MLVA92, MLVA130 and MLVA132) were higher in period 
II compared to the periods I and III. A MST indicated that MLVA types characteristic for period II 
were related and distinct from those isolated in period I and III. Most (85%) of the three MLVA 
types expressed Fim2 and consequently, period II was also characterized by a predominance 
of Fim2 strains. The decrease in vaccine dose coincided with a replacement of Fim3 strains by 
Fim2 and, transiently, Fim2,3 strains. A reversed trend was observed when the vaccine dose 
was increased again, when Fim2 strains were replaced by Fim3 strains.
The results obtained with MLVA and serotyping suggested that a change in population immunity 
had affected the competitive balance between B. pertussis strains. This is consistent with 
previous studies in which it was shown that the prevalent fimbrial serotypes changed from 
Fim2,3 and Fim2 to a predominance of Fim3 after the introduction of vaccination [22-24] This 
phenomenon has been attributed to the lower content or immunogenicity of Fim3 in vaccines 
and to the higher level of cross-reacting antibodies induced by Fim3 compared to Fim2 [18,25]. 
Further, Fim2 and Fim3 strain frequencies have been shown to reflect vaccine uptake, whereby 
a lower vaccine uptake resulted in a replacement of Fim3 by Fim2 [26]. The latter suggests 
that a lower vaccine-derived population immunity results in an increase in Fim2 strains, which 
is consistent with our work described here. 
We observed a gradual replacement of prn1 by prn2 and prn3. The vaccine strains contained 
prn1 and prn7 and the emergence of novel prn alleles may have affected vaccine efficacy [27]. 
However, the largest changes in prn alleles were observed after period II, and it is therefore 
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unlikely that they contributed significantly to the increased notifications. Although significant, 
the differences observed in tcfA and ptxA in the three periods analyzed were small and the 
tcfA2 and ptxA1 alleles remained predominant. Thus these markers were less useful to assess 
changes in the B.pertussis population.
The increase in Fim2 was first evident in the years 1976-1977, i.e. one to three years after the 
lowering of the vaccine dose and at least seven years before an increase in notifications was 
observed. Four years after the increase in vaccine dose, a large decrease in Fim2 serotypes 
was observed with a concomitant increase in Fim3. A smaller effect was already apparent 
one year after the dose increase. Therefore, fimbrial serotyping can be very useful to monitor 
population immunity and can be used as an early warning system for epidemics. The same 
holds true for MLVA, as changes in MLVA types also preceded the increase in notifications.  
In conclusion, we have shown that significant changes occurred in the B. pertussis population 
after lowering of the vaccine dose. We propose that these changes were driven by a decrease 
in host immunity and, that the increase in notifications at least in part reflects a true epidemic. 
Our work shows that strain surveillance can serve as an early warning system for future 
pertussis epidemics.
53
3
References
1. Mattoo S, Cherry JD (2005) Molecular 
pathogenesis, epidemiology, and clinical 
manifestations of respiratory infections due 
to Bordetella pertussis and other Bordetella 
subspecies. Clin Microbiol Rev 18: 326-382.
2. Mooi FR, Q H, N G (2007) Phylogeny, 
Evolution and Epidemiology of Bordetellae. 
Bordetella  Molecular Microbiology 1: 17-45.
3. Cherry JD (2005) The epidemiology of 
pertussis: a comparison of the epidemiology 
of the disease pertussis with the epidemiology 
of Bordetella pertussis infection. Pediatrics 
115: 1422-1427.
4. Mooi FR, van Loo IH, King AJ (2001) Adaptation 
of Bordetella pertussis to vaccination: a cause 
for its reemergence? Emerg Infect Dis 7: 526-
528.
5. de Melker HE, Conyn-van Spaendonck MA, 
Rumke HC, van Wijngaarden JK, Mooi FR, 
et al. (1997) Pertussis in The Netherlands: an 
outbreak despite high levels of immunization 
with whole-cell vaccine. Emerg Infect Dis 3: 
175-178.
6. de Melker HE, Schellekens JF, Neppelenbroek 
SE, Mooi FR, Rumke HC, et al. (2000) 
Reemergence of pertussis in the highly 
vaccinated population of the Netherlands: 
observations on surveillance data. Emerg 
Infect Dis 6: 348-357.
7. de Greeff SC, Mooi FR, Schellekens JF, de 
Melker HE (2008) Impact of acellular pertussis 
preschool booster vaccination on disease 
burden of pertussis in The Netherlands. 
Pediatr Infect Dis J 27: 218-223.
8. Mooi FR, van Oirschot H, Heuvelman K, 
van der Heide HG, Gaastra W, et al. (1998) 
Polymorphism in the Bordetella pertussis 
virulence factors P.69/pertactin and pertussis 
toxin in The Netherlands: temporal trends and 
evidence for vaccine-driven evolution. Infect 
Immun 66: 670-675.
9. van Boven M, Mooi FR, Schellekens JF, de 
Melker HE, Kretzschmar M (2005) Pathogen 
adaptation under imperfect vaccination: 
implications for pertussis. Proc Biol Sci 272: 
1617-1624.
10. van de Water HP (1988) [Registration of 
whooping cough in The Netherlands 1976-
1986 and the need for a uniform definition of 
disease]. Ned Tijdschr Geneeskd 132: 821-
828.
11. Bijkerk H (1984) [Is whooping cough really on 
the increase?]. Ned Tijdschr Geneeskd 128: 
1421-1422.
12. Bos SE (1984) [Whooping cough]. Ned 
Tijdschr Geneeskd 128: 1409-1411.
13. Nagel J, de Graaf S, Schijf-Evers D (1984) 
[Serodiagnosis of whooping cough]. Ned 
Tijdschr Geneeskd 128: 1427-1429.
14. Aronson DC, Pilon JW, van der Blij JF (1984) 
[Pertussis vaccine; a hitch somewhere?]. Ned 
Tijdschr Geneeskd 128: 1412-1415.
15. van Gent M, Pierard D, Lauwers S, van 
der Heide HG, King AJ, et al. (2007) 
Characterization of Bordetella pertussis 
clinical isolates that do not express the 
tracheal colonization factor. FEMS Immunol 
Med Microbiol 51: 149-154.
16. Schouls LM, van der Heide HG, Vauterin L, 
Vauterin P, Mooi FR (2004) Multiple-locus 
variable-number tandem repeat analysis of 
Dutch Bordetella pertussis strains reveals 
rapid genetic changes with clonal expansion 
during the late 1990s. J Bacteriol 186: 5496-
5505.
17. van Loo IH, Heuvelman KJ, King AJ, Mooi 
FR (2002) Multilocus sequence typing of 
Bordetella pertussis based on surface protein 
genes. J Clin Microbiol 40: 1994-2001.
18. Preston NW (1985) Essential immunogens in 
human pertussis: the role of fimbriae. Dev Biol 
Stand 61: 137-141.
19. Mooi FR, Hallander H, Wirsing von Konig 
CH, Hoet B, Guiso N (2000) Epidemiological 
typing of Bordetella pertussis isolates: 
recommendations for a standard methodology. 
Eur J Clin Microbiol Infect Dis 19: 174-181.
20. Nagel J, Poot-Scholtens EJ (1983) Serum IgA 
54
antibody to Bordetella pertussis as an indicator 
of infection. J Med Microbiol 16: 417-426.
21. van de Water HP, van de Laar MJ, Leentvaar-
Kuijpers A (1988) [When is it whooping cough? 
Relation between laboratory diagnosis findings 
and symptoms]. Ned Tijdschr Geneeskd 132: 
828-833.
22. Van Loo IH, Mooi FR (2002) Changes in the 
Dutch Bordetella pertussis population in the 
first 20 years after the introduction of whole-
cell vaccines. Microbiology 148: 2011-2018.
23. Preston NW (1976) Prevalent serotypes 
of Bordetella pertussis in non-vaccinated 
communities. J Hyg (Lond) 77: 85-91.
24. Borisova O, Kombarova SY, Zakharova 
NS, van Gent M, Aleshkin VA, et al. (2007) 
Antigenic divergence between Bordetella 
pertussis clinical isolates from Moscow, 
Russia, and vaccine strains. Clin Vaccine 
Immunol 14: 234-238.
25. Robinson A, Gorringe AR, Funnell SG, 
Fernandez M (1989) Serospecific protection 
of mice against intranasal infection with 
Bordetella pertussis. Vaccine 7: 321-324.
26. Miller E, Vurdien JE, White JM (1992) The 
epidemiology of pertussis in England and 
Wales. Commun Dis Rep CDR Rev 2: R152-
154.
27. King AJ, Berbers G, van Oirschot HF, 
Hoogerhout P, Knipping K, et al. (2001) Role 
of the polymorphic region 1 of the Bordetella 
pertussis protein pertactin in immunity. 
Microbiology 147: 2885-2895.
55
3
Figure S1. Notifications and frequencies of tcfA2, tcfA3, tcfA4, tcfA7, tcfA8, tcfA9 and ∆tcfA alleles in the 
period 1965 to 1992. The distribution of the tcfA alleles over the three periods was significantly different 
(P<0.0001). See legend to Fig. 2 for further details (this figure is available in color in the appendix).
Figure S2. Notifcations and frequencies of ptxA1, ptxA2 and ptxA4 alleles in the period 1965 to 1992. 
The distribution of the ptx alleles over the three periods was significantly different (P=0.0018). See leg-
end to Fig. 2 for further details (this figure is available in color in the appendix).
Figure S3. Notifications and frequencies of prn1, prn2 and prn3 alleles in the period 1965 to 1992. The 
distribution of the prn alleles over the three periods was significantly different (P<0.0001). See legend to 
Fig. 2 for further details (this figure is available in color in the appendix). 
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Abstract 
The virulence factor pertactin (Prn) is a component of pertussis vaccines and one of the 
most polymorphic Bordetella pertussis antigens. After the introduction of vaccination shifts 
in predominant Prn types were observed and strains with the Prn vaccine type (Prn1) were 
replaced by strains carrying non-vaccine types (Prn2 and Prn3), suggesting vaccine-driven 
selection. The aim of this study was to elucidate the shifts observed in Prn variants. We show 
that, although Prn2 and Prn3 circulated in similar frequencies in the 1970s and 1980s, in the 
1990s Prn2 strains expanded and Prn3 strains disappeared, suggesting that in vaccinated 
populations Prn2 strains are fitter than Prn3 strains. We established a role for Prn in the mouse 
model by showing that a Prn-knock out (Prn-ko) mutation reduced colonization in trachea and 
lungs. Restoration of the mutation resulted in a significant increase in colonization compared 
to the knock out mutant. The ability of clinical isolates with different Prn variants to colonize the 
mouse lung was compared. Although these isolates were also polymorphic at other loci, only 
variation in the promoter for pertussis toxin (ptxP) and Prn were found to contribute significantly 
to differences in colonization. Analysis of a subset of strains with the same ptxP allele revealed 
that the ability to colonize mice decreased in the order Prn1>Prn2 and Prn3. Our results are 
consistent with the predominance of Prn1 strains in unvaccinated populations. Our results 
show that ability to colonize mice is practically the same for Prn2 and Prn3. Therefore other 
factors may have contributed to the predominance of Prn2 in vaccinated populations. The 
mouse model may be useful to assess and predict changes in the B. pertussis population due 
to vaccination.
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Introduction 
Bordetella pertussis causes whooping cough or pertussis, a respiratory disease that is most 
severe in infants. Before childhood vaccination was introduced in the 1950s, pertussis was a 
major cause of infant mortality worldwide. Whole cell vaccines against pertussis were introduced 
in the 1940s to 1960s and these were replaced by more defined and less reactogenic acellular 
vaccines (ACVs) in the 1990s [1,2]. All ACVs contain pertussis toxin (Ptx). In addition, they 
may contain filamentous hemagglutinin (FHA), pertactin (Prn) and serotype 2 and 3 fimbriae. 
Widespread vaccination of children significantly reduced morbidity and mortality. However, 
in the 1990s a resurgence of pertussis was observed in countries with highly vaccinated 
populations and pertussis has become the most prevalent vaccine preventable disease 
in developed countries [2,3]. Although morbidity is highest in newly born, pertussis is now 
recognized as a frequent infection of adults [4,5].
The re-emergence of pertussis has been attributed to waning vaccine-induced immunity 
and pathogen adaptation [3,6]. Pathogen adaptation is supported by several observations. 
Antigenic divergence has occurred between vaccine strains and clinical isolates with respect 
to several vaccine components; Ptx, Prn, and fimbriae [3,6-8]. Further variation in Ptx and Prn 
has been shown to affect vaccine efficacy in a mouse model [9-13]. In addition to antigenic 
variation, increased Ptx production has been associated with the resurgence of pertussis [14]. 
Strains with a novel allele for the Ptx promoter (ptxP3) emerged in the 1990s, replacing the 
resident ptxP1 strains. A role of vaccination in driving shifts in B. pertussis populations is also 
supported by recent genomic data [15,16].
Prn, the focus of this study, is one of the most polymorphic B. pertussis proteins known and 
13 prn alleles have been identified so far [3,6]. Variation in Prn is mainly limited to two regions, 
designated R1 and R2, which are comprised of Gly-Gly-X-X-Pro and Pro-Gln-Pro repeats, 
respectively. The R1 region is located proximal to a RGD motif implicated in receptor binding 
[17] (Fig. 1A). Studies in a number of countries have revealed similar temporal trends in the 
frequency of Prn variants [8,10,18-28]. In the last fifty years three Prn variants have been found 
to predominate: Prn1, Prn2 and to a lesser extent Prn3. In the prevaccination era, essentially all 
analyzed strains produced Prn1. However in the 1980s, 20 to 30 years after the introduction of 
whole cell vaccination, Prn strains were replaced by Prn2 and Prn3 strains. As most vaccines 
contain Prn1 it was suggested that the emergence of Prn2 and Prn3 was vaccine-driven [8]. 
Consistent with this assumption, it was found that a whole cell vaccine containing Prn1 was 
less effective against Prn2 strains compared to Prn1 strains in a mouse model [13]. Prn2 
strains now predominate in most vaccinated populations. Njamkepo et al. [29] have analyzed 
strains from a region in Senegal where vaccination was introduced only recently (and where 
the coverage was still low). They found that, in contrast to strains isolated in the same period 
in France (where vaccination was introduced in the 1950s and where vaccination coverage is 
high), all Senegalese strains carried the prn1 allele, characteristic for prevaccination strains. 
This observation is consistent with the theory of vaccine-driven shifts. Other arguments for 
the role of vaccination in shifts of Prn variants have recently been reviewed [3]. In the 1990s, 
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whole cell vaccines were replaced by acellular vaccines. Sporadically, in the acellular vaccine 
period, strains have been isolated which do not produce Prn [30]. However, recently in France 
a significant percentage (5.6%) of the strains isolated from hospitalized children did not 
produce pertactin [31]. It was found that the Prn gene was inactivated by deletion or insertion 
of IS481 [31]. Spread of such Prn-knock out strains may reduce vaccine efficacy, in particular 
of acellular vaccines which induce a less broad immunity than whole cell vaccines. Evaluation 
of this threat is hampered by our lack of understanding of the role Prn plays in the ecology of 
B. pertussis. Here we compare the ability of a Prn-knock out strain with a wild type strain to 
colonize the mouse lungs and trachea. We also assess the effect of variation in R1 of Prn on 
colonization in this model.
Figure 1. Variation in pertactin (A) and temporal trends in the frequency of pertactin alleles (B). The 
number in the pertactin sequences indicates the amino acid position relative to the N-terminus. The 
RGD motif implicated in binding to host receptors has been underlined. Repeat motifs are blocked. Dots 
and dashes indicate sequence identity with Prn1 and gaps, respectively. No strains were available from 
the period 1960-1964 to determine allele frequencies. Vaccination against pertussis was introduced in 
1953.
Materials and methods 
Bacterial strains 
B. pertussis strains were isolated from Dutch patients in the period 1949 to 1996. Strains were 
grown on Bordet-Gengou agar (Difco Catalogue no. 0048-17-5) supplemented with 1% (v/v) 
glycerol and 15% (v/v) sheep blood at 35°C for 3 days. Strains were made streptomycin resistant 
to allow recovery on selective plates from mouse lungs and trachea  (a table with strain information 
is available online from http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.
pone.0018014#s5). Tohama I derivatives were used to construct Prn mutants (Table 1) [32].
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Table 1. Characteristics of strains used in this study1.
Tohama I derivatives
Strain designation Genotype Remarks Reference
B0213 ptxP1, ptxA2, tcfA2, 
prn1, Fim2
Strep resistant Tohama I derivative [48]
B1686 ptxP1, ptxA2, tcfA2, 
prn::kan, Fim2
Prn-knock out derived from B0213 This work
B2576 ptxP1, ptxA2, tcfA2, 
prn1, Fim2
Back mutant derived from B1686 This work
Vaccine strains
Strain designation Genotype Remarks Reference
strain 134 ptxP1, ptxA2, tcfA2, 
prn1, Fim2,3
Used for the Dutch whole-cell 
vaccine
[3]
strain 509 ptxP1, ptxA4, tcfA2, 
prn7, Fim2,3
Used for the Dutch whole-cell 
vaccine
[3]
1Alleles for ptxP, ptxA, tcfA and prn are shown in addition to the fimbrial (Fim) serotype produced. 
Construction of Prn-knock out mutants
To construct a Prn-knock out mutant (Prn-ko), a fragment of prn (469 bases in size) was amplified 
using primers PrnXba1F (GCTCTAGAGCCTGGCATCCAATGAACATGT) and PrnEcoR1R 
(GGAATTCCTGTTCGCCGGCCACATAG), and cloned into pSS1129 [33], resulting in pSR2.1. 
Subsequently, a kanamycin resistance gene cassette was cloned into the RsrII site located in 
the 469 base prn fragment of pSR2.1, resulting in pSR2-1.1. The latter plasmid was used to 
introduce the kan gene into prn1 of the Tohama I derivative B0213 by allelic exchange [34]. 
Correct insertion was checked by sequencing and one strain, B1686, was selected for further 
studies. Expression of Prn in the knock out mutant was restored by allelic exchange using 
pSR2.1. Back mutants were identified by PCR and DNA sequencing. One clone, B2576, was 
selected for studies in the mouse model. Expression of Prn by B0213 and its derivatives was 
assessed by immunoblotting. 
Strain typing
Genotyping was focused on the following genes essentially as described in [35,36]: prn, ptxP, 
ptxA and tcfA, coding for, respectively, Prn, the Ptx promoter, the Ptx S1 subunit, and the 
tracheal colonization factor. Typing of prn alleles is done by sequencing of the repeat regions 
1 and 2, and does not distinguish between prn1 and prn7 which are identical in region 1 and 2 
but differ in a non-silent SNP outside these regions. Whole genome sequencing has revealed 
that prn7 is associated with strains which only circulated in the 1950s and 1960s and we 
assumed here that all strains harbored prn1. Serotyping, which distinguishes between strains 
producing type 2 or type 3 fimbriae (Fim2 or Fim3) was carried out using the slide agglutination 
technique [37].
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Mouse infection model
All animal experiments were conducted according to relevant national and international 
guidelines. Strains were grown on Bordet-Gengou plates at 35oC for 24 hrs. After harvesting, 
the bacterial concentration was adjusted to 5 x 109 bacteria/ml. The bacterial suspensions were 
flash-frozen in ethanol/dry ice in small aliquots in Verwey medium [38] with 15% glycerol and 
stored at –80oC. The viability of the frozen cell suspensions was determined prior to infection. 
For infection, eight BALB/c mice (Harlan, OlHsd) 4-5 weeks old, were lightly anaesthetised 
with isoflurane and 40 µl of the inoculum, containing 2*107 CFUs bacteria, was placed on 
the nostrils and allowed to be inhaled. Three days after infection, mice were sacrificed by 
intraperitoneal injection of NembutalR (Sanofi/Algrin). To recover B. pertussis, trachea and 
lungs were removed. The trachea was vortexed in 500 µl Verwey medium with 5 glass pearls 
for 30 sec at RT. Lungs were homogenised in 900 µl Verwey medium for 10 sec at 20,000 rpm 
with a homogenizer (Pro Scientific, Pro200) at RT. Appropriate dilutions were plated on Bordet-
Gengou plates supplemented with streptomycin, and the number of CFUs was determined. All 
animal experiments were approved by the Institute’s Animal Ethics Committee. 
Statistical analysis 
CFU counts recovered from mice were log-transformed and zero counts were considered 
missing values. The data were analysed by Proc GLM in SAS 9.1 (SAS Institute Inc., Cary, 
NC, USA). The significance among means was tested by the Student-Newman-Keuls test 
at alpha = 0.01 or 0.05. Strengths of effects of variation in fimbrial serotype, Prn, the Ptx 
promoter (ptxP), the Ptx S1 subunit (PtxA) and TcfA on colonization were assessed by ANOVA, 
followed by a Tukey post-test (Tukey Honest Significant Differences) (Table 2).  Based on this 
information, the effect of variation in Prn was assessed in a subset of strains which harbored 
the same ptxP allele, ptxP1. 
Table 2. Analysis of variance of the effect of B. pertussis polymorphisms on colonization of the mouse 
lung.
Df Sum Sq mean Sq F value Pr (>F)
Fim 2 2.35 1.17 1.2271 0.290
prn 2 9.68 4.48 5.0557 0.007
ptxP 2 7.24 3.62 3.7804 0.024
ptxA 2 1.29 0.65 0.6760 0.510
tcfA 1 2.75 2.75 2.8768 0.091
St: prn 1 1.06 1.06 1.1089 0.293
St: ptxP 1 0.85 0.85 0.8875 0.347
St: ptxA 1 2.26 2.26 2.3620 0.125
Residuals 407 389.69 0.96
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Results
Temporal trends in prn alleles in the Netherlands
In a previous work, we analyzed the frequencies of Prn variants in the Netherlands between 
1949 and 1996 [8]. Here we extended this analysis to 2009 and included more strains. Pertussis 
vaccination in the Netherlands was introduced in 1953. The strain composition of the whole 
cell vaccine was changed a few times, but remained the same from the early 1960s on, when 
it was comprised of two strains producing Prn1 and Prn7. Prn1 and Prn7 are identical, except 
for a single amino acid substitution outside the two repeat regions [3]. In the period 1949-1975, 
Prn1 strains predominated, representing 97% of the isolates (N=64) (Fig. 1B). In this period 
only two other Prn variants were observed, each in a single strain, Prn2 in 1950 and Prn10 in 
1954. In the period 1976-1985, Prn2 and Prn3 strains emerged. Initially, frequencies of both 
Prn2 and Prn3 strains increased with similar rates. However, in the mid 1990s Prn3 strains 
decreased in frequency, while Prn2 strains continued to expand. Since 2003, only Prn2 strains 
have been detected in the Netherlands (N=203). These data suggest that Prn1 strains are 
more fit in unvaccinated populations, while the non-vaccine types, Prn2 and Prn3, strains are 
more fit in vaccinated populations. However, of the two non-vaccine types, Prn2 seemed to 
confer the greatest increase in fitness in vaccinated populations.
The effect of inactivation of the prn gene on colonization of the mouse respiratory tract
In a next step we aimed to determine the effect of variation in Prn on colonization of the 
mouse respiratory tract. However, it was not clear whether Prn played any role in this animal 
model. To investigate this, mice were infected with the Tohama I strain or a derivative in which 
the Prn gene was inactivated by insertion of a kanamycin resistant gene cassette (Prn-ko 
strain). Subsequently, colonization was assessed three days after infection (Fig. 2). The Prn-
ko mutation reduced colonization in trachea and lungs 6- and 4-fold, respectively (P < 0.01). 
When the wild type phenotype was restored by back mutating the knock out strain, colonization 
of trachea and lungs was restored (Fig. 2). Although the back mutant showed slightly lower 
colonization levels compared to the wild type strain in trachea and lungs, the difference was 
not statistically significant. In contrast, the back mutation significantly increased colonization 
compared to the knock out mutant in trachea and lungs (P < 0.01).
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Figure 2. Role of Prn in colonization of the mouse respiratory tract. Mice were infected intranasally with 
the Tohama I strain (wt), a mutant derivative in which the Prn was inactivated (ko), or a back-mutant 
in which the Prn gene was restored. Three days post-infection, CFUs were determined in trachea and 
lungs. The experiment was performed twice, and pooled data from both experiments are shown. Error 
bars and asterisks indicate 95% confidence intervals and significant differences (P < 0.01), respectively.
The effect of natural variation in Prn on colonization of the mouse lung
To investigate the effect of natural variation in Prn on colonization, mice were infected with clinical 
isolates producing one of the three predominant Prn variants, Prn1, Prn2 or Prn3. Colonization 
of lungs was assessed three days post infection. A comparison of the colonizing ability of Prn 
variants was complicated by the fact that, in addition to Prn, the strains showed variation in a 
number of other surface proteins such as PtxA, TcfA and fimbriae. Further, strains also differed 
with respect to the pertussis toxin promoter, ptxP. Three ptxP alleles (ptxP1, ptxP2 and ptxP3) 
were present in this collection of strains. We have shown that ptxP3 strains produce more Ptx 
than ptxP1 [14] and Ptx has been shown to affect the colonization of naïve mice [39]. Thus any 
effect observed in mice could be due to one or more of these polymorphic loci. Multivariate 
analysis revealed that only variation in Prn and ptxP significantly affected colonization of the 
mouse (P=0.007 and 0.024, respectively). Based on this information, the effect of variation 
in Prn was assessed in a subset of strains which harbored the same ptxP allele, ptxP1. Only 
ptxP1 strains were used in these experiments because the changes observed in Prn types 
occurred in a period when most strains carried the ptxP1 allele. It was found that the ability of 
the strains to colonize the mouse lung decreased in the order Prn1>Prn2>Prn3 (Fig. 3). Only 
the difference between Prn1 and Prn2 was significant, however. 
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Figure 3. Effect of variation in Prn on colonization of the mouse lung. Mice were infected with clinical iso-
lates producing Prn1 (N=15), Prn2 (N=5) or Prn3 (N=8). Three days after infection, the number of CFUs 
in the lung was determined. Error bars and asterisks indicate 95% confidence intervals and significant 
differences (P < 0.05), respectively.
Discussion 
The role Prn plays in the ecology of B. pertussis is still under investigation. Prn is non-covalently 
attached to the outer membrane and may play a role in adherence to monocytes and other 
host cells [17,40]. Further, Prn may affect the host immune response as it has been shown that 
it can augment the suppressive effect of FHA on LPS-induced IL-12 production in vitro [41]. 
The role of Prn in colonization of the mouse respiratory tract has been studied with B. pertussis 
and the closely related species Bordetella bronchiseptica. Nicholson and coworkers [42], used 
a swine isolate of B. bronchiseptica to study the contribution of FHA and Prn to respiratory 
disease in swine. They found that colonization of the FHA-knock out (FHA-ko) mutant was 
lower than that of the wild type in the nasal cavity, trachea and lungs. Further, the FHA-ko 
mutant caused limited to no disease. In contrast, the Prn-ko mutant caused similar disease 
severity relative to the wild type, however, colonization of the Prn mutant was reduced relative 
to the wild type during early and late infection. Inatsuka and coworkers studied the role of Prn 
in both rats and mice [43]. They observed that, while a Prn-ko B. bronchiseptica strain did not 
differ from a wild type strain in its ability to establish respiratory infection in rats, it was cleared 
much faster than wild type bacteria from the mouse lung. These authors went on to show that 
Prn allows B. bronchiseptica to resist neutrophil-mediated clearance. Studies with B. pertussis 
gave less clear results with respect to the role of Prn. Roberts and coworkers [44] concluded 
that a Prn mutant was able to colonize and grow in the lungs and trachea of mice as well as 
the parent strain, BBC26, although it reached slightly lower levels in both organs. In contrast, 
in two other studies no effect of a Prn mutation on colonization of the mouse lung was found 
[45,46]. Overall, these results suggested that the role of Prn in colonization of the mouse was 
subtle.
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In this study, inactivation of the Prn gene significantly reduced colonization of both the trachea 
and lungs of mice (Fig. 2). Back mutation restored the colonization ability. When clinical 
isolates were tested for their ability to colonize the mouse lung, significant differences were 
found. The clinical isolates differ at several other loci making it difficult to assign phenotypes 
to particular polymorphisms. Multivariate analysis indicated that only variation in ptxP and Prn 
contributed significantly to the differences in colonization. Ptx enhances colonization of the 
mouse respiratory tract, presumably by suppressing host innate immunity [39]. Thus the effect 
of ptxP on colonization is probably due to different levels of Ptx produced in vivo, consistent 
with in vitro data [14]. When strains were compared which carried an identical ptxP allele 
(ptxP1), it was observed that the ability to colonize mice decreased in the order Prn1>Prn2 
and Prn3 (Fig. 3). This may be due to differential binding of Prn variants to host receptors, as 
the variable region is located close to the RGD sequence implicated in attachment (Fig. 1A) 
[17,47].
The effect of variation in Prn on colonization of mice lungs shows interesting parallels with 
epidemiological data. In the prevaccination era, essentially all strains analyzed produced Prn1. 
Prn2 and Prn3 emerged in the 1980s, 20 to 30 years after the introduction of vaccination and 
although the frequency of the two variants was initially similar, Prn2 is now by far the most 
predominant type. Coexistence of Prn1, Prn2 and Prn3 strains in vaccinated populations has 
also been observed in Finland, Sweden and the UK [28,48-50]. Invariably, Prn2 strains rose to 
predominance. These data suggest that Prn1 strains are more fit in unvaccinated populations, 
while the non-vaccine types, Prn2 and Prn3, strain are more fit in vaccinated populations. 
However, of the two non-vaccine types, Prn2 seemed to confer the greatest increase in fitness 
in vaccinated populations.
Taking together, based on our results and those on vaccinated mice previously published [9-13] 
we propose that of the three Prn variants, Prn1 binds most efficiently to the host cells, explaining 
its predominance in unvaccinated populations. Vaccination with Prn1-containing vaccines 
may have shifted the competitive balance between Prn variants allowing non-vaccine types 
Prn2 and Prn3 to emerge. Regarding Prn2 strains, it is not so clear that they colonized more 
efficiently than Prn3 strains; however, other factors may have contributed to the predominance 
of Prn2 strains in vaccinated populations. E.g. it is conceivable that antibodies induced by 
Prn1 bind less well to Prn2 compared to Prn3. Indeed the Dutch WCV was shown to be less 
efficacious in the mouse model against Prn2 strains compared to Prn3 strains, although the 
difference was not statistically significant [13]. In addition to Prn1, Prn2 and Prn3, 10 other 
Prn types have been found in low frequencies in a number of countries [3]. We speculate that 
the frequency of these variants is the compound effect of receptor fit and cross immunity with 
vaccine-induced Prn antibodies. 
The effect of the Prn-ko mutation in the mouse model was relatively small, and one should be 
careful in extrapolating these results to human populations. Continued strain surveillance in 
human populations is required to address the question whether Prn-ko mutants which have 
emerged in France [31] are less fit in human populations and will have a limited ability to spread 
or cause disease compared to wild type strains. The B. pertussis genome contains many silent 
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genes with unknown function [32] and it is conceivable that compensatory mutations may 
occur in Prn-ko mutants by gene reactivation or by other mechanisms.
In addition to variation in Prn, variation in ptxP was found to significantly affect colonization 
of the mouse respiratory tract. The long term effect of vaccination on pathogen populations 
generally cannot be evaluated in the relatively short period in which clinical trials take place. 
Our results suggest that the mouse model can be used to explain and predict changes in the 
B. pertussis population due to vaccination.
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Abstract
To monitor changes in Bordetella pertussis populations, mainly two typing methods are used; 
pulsed-field gel electrophoresis (PFGE) and multiple-locus variable-number tandem repeat 
analysis (MLVA). In this study, a single nucleotide polymorphism (SNP) typing method, based 
on 87 SNPs, was developed and compared with PFGE and MLVA. The discriminatory indices of 
SNP typing, PFGE and MLVA were found to be 0.85, 0.95 and 0.83, respectively. Phylogenetic 
analysis, using SNP typing as Gold Standard, revealed false homoplasies in the PFGE and 
MLVA trees. Further, in contrast to the SNP-based tree, the PFGE- and MLVA-based trees did 
not reveal a positive correlation between root-to-tip distance and the isolation year of strains. 
Thus PFGE and MLVA do not allow an estimation of the relative age of the selected strains. 
In conclusion, SNP typing was found to be phylogenetically more informative than PFGE and 
more discriminative than MLVA. Further, in contrast to PFGE, it is readily standardized allowing 
interlaboratory comparisons. We applied SNP typing to study strains with a novel allele for the 
pertussis toxin promoter, ptxP3, which have a worldwide distribution and which have replaced 
the resident ptxP1 strains in the last 20 years. Previously, we showed that ptxP3 strains 
showed increased pertussis toxin expression and that their emergence was associated with 
increased notification in the Netherlands. SNP typing showed that the ptxP3 strains isolated 
in the Americas, Asia, Australia and Europe formed a monophyletic branch which recently 
diverged from ptxP1 strains. Two predominant ptxP3 SNP types were identified which spread 
worldwide. The widespread use of SNP typing will enhance our understanding of the evolution 
and global epidemiology of B. pertussis.
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Introduction
Whooping cough or pertussis, caused by the Gram-negative bacterium Bordetella pertussis, 
is an infection of the human respiratory tract and most severe for young, unvaccinated, infants 
[1,2]. Vaccination against whooping cough, introduced in most countries in the 1950s and 
1960s, has been highly successful in controlling the disease [2]. However, whooping cough 
resurged in the 1980s and in many developed countries it has become the most prevalent 
vaccine preventable disease [1-3]. Several causes for the increase in whooping cough have 
been proposed, most prominently waning immunity and pathogen adaptation [2,4-6]. Initially, 
pathogen adaptation involved antigenic divergence between clinical isolates and vaccines 
strains [7-15]. More recently strains emerged with increased pertussis toxin (Ptx) production 
which harbored a novel allele for the Ptx promoter, ptxP3 [16]. In the Netherlands, ptxP3 strains 
have largely replaced the resident strains which carry the ptxP1 allele and the emergence of 
ptxP3 strains was closely associated with the increase in notifications [16]. The ptxP3 strains 
have been found in several European countries, Japan and the Americas, suggesting a 
worldwide distribution [16].
Reliable methods to type bacterial pathogens are important tools in infectious disease control. 
Strain typing can be used to identify successful clones, to establish genetic relationships, 
to study pathogen evolution and may serve as an early warning system for epidemics [17]. 
Mainly three typing methods have been used to study B. pertussis populations, multiple-locus 
antigen sequence typing (MAST), pulsed-field gel electrophoresis (PFGE) [18] and multiple-
locus variable-number tandem repeat analysis (MLVA) [17]. MAST has been very useful to 
reveal antigenic divergence between circulating strains and vaccine strains [2,4]. However, the 
discriminative power of MAST is limited and it is not suitable to establish genetic relationships 
as it targets genes subjected to immune selection. PFGE is used most widely for typing of B. 
pertussis strains and has a high resolving power [19]. However, it is laborious and because it 
is difficult to standardize, interlaboratory comparisons of PFGE patterns are problematic. MLVA 
results in digital profiles allowing accurate interlaboratory comparisons [13,17,20,21] [www.
mlva.net]. Further, compared to PFGE it is much less laborious. Unfortunately, the resolving 
power of MLVA is lower compared to PFGE. Another issue concerning PFGE and MLVA, 
addressed in this work, is their ability to reveal genetic relationships between strains. Typing 
of B. pertussis strains based on single nucleotide polymorphisms (SNPs) has not been widely 
used due to the monomorphic nature of B. pertussis [22]. However, recently the genomes 
of several B. pertussis strains have been sequenced, identifying hundreds of novel SNPs 
and potentially providing the tools for SNP typing [23-25]. Based on the genome of seven B. 
pertussis strains, we selected 87 SNPs to type strains from Europe and Africa. The results 
were compared to those of PFGE and MLVA typing. Further, we used SNP typing to extend our 
studies on the evolution of the ptxP3 strains.
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Materials and methods
Strains and culturing
Strains were selected to form a geographically and temporally diverse collection. Strains were 
isolated in three European countries, Finland (n=7), the Netherlands (n=26) and Sweden 
(n=34) and in two African countries, Kenya (n=39) and Senegal (n=18). Strains were isolated 
in the period 1971 to 2005 (a table with strain information is available online from http://www.
plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0020340#s5). Strain 18323 
(B1121, ATCC number 9797) was isolated in the USA in 1947 and used to root the phylogenetic 
trees. All strains were grown on Bordet Gengou agar supplemented with 15% sheep blood and 
incubated for 3 days at 350C. 
Allele typing
The alleles for ptxP were determined by DNA sequencing as described before [16]. Briefly, 
bacterial cells were lysed in Tris EDTA buffer (Sigma-Aldrich, Zwijndrecht, Nl, 1.0M Tris-HCl, 
containing 0.1M EDTA) at 950C for 5 minutes, centrifuged for 1 min at 13000 rpm after which 
the supernatant was used for PCR. 
 
Single nucleotide polymorphism (SNP) typing
SNPs were identified using the complete genome sequences of the Tohama I strain and of 
six Dutch B. pertussis isolates [23,26]. Based on the seven genome sequences, a set of 120 
informative SNPs was selected. For SNP typing, chromosomal DNA was isolated using the 
GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich, Zwijndrecht, the Netherlands) following 
the manufacture’s instructions for Gram-negative bacteria. SNPs were determined using 
the iPLEX® Gold assay (Sequenom Inc, Hamburg, Germany). This assay is based on a 
multiplex PCR followed by a single primer extension reaction which results in allele-specific 
differences in mass between primer extension products. The primer extension products were 
analyzed using MALDI-TOF mass spectrometry. SNPs that were ambiguous in a large number 
of strains were removed which resulted in a final selection of 87 SNPs which were used in 
this study (a table with the 87 SNPs is available online from http://www.plosone.org/article/
info%3Adoi%2F10.1371%2Fjournal.pone.0020340#s5). For each strain, the 87 SNPs were 
concatenated to generate a contiguous DNA sequence which was used as character data for 
clustering. The Maximum Parsimony algorithm was applied for clustering using Bionumerics 
version 6.1 (Applied Maths, Sint-Martens-Latem, Belgium).
Pulsed-field gel electrophoresis (PFGE)
PFGE was performed as described before [18,27]. Most strains were typed by PFGE in previous 
studies [19,28] while the strains from Africa were analyzed in this study. Band matching was 
performed with an optimization of 1% and a position tolerance of 1%. The binary character 
data was used for clustering with the Maximum Parsimony algorithm in Bionumerics version 
6.1 (Applied Maths, Sint-Martens-Latem, Belgium).
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Multiple-locus variable-number tandem repeat analysis (MLVA) 
For MLVA, the number of repeats in 6 loci (VNTR1, VNTR3A, VNTR3B, VNTR4, VNTR5 and 
VNTR6) was determined as described previously [17,21]. MLVA profiles were clustered as 
character data using the Maximum Parsimony algorithm in Bionumerics version 6.1 (Applied 
Maths, Sint-Martens-Latem, Belgium).
Data analysis
To investigate genetic relationships based on SNPs, PFGE and MLVA, Maximum Parsimony 
trees were constructed in Bionumerics version 6.1 (Applied Maths, Sint-Martens-Latem, 
Belgium) and strain 18323 was used to root the trees. For all trees, a bootstrap analysis 
was performed with 1,000 iterations. Correspondence between the SNP, PFGE and MLVA 
typing with, respectively, the ptxP alleles and geographic origin of strains, was determined by 
calculating the Wallace coefficients using EpiCompare version 1.0 (Ridom GmbH, Wurzburg, 
Germany) [29]. A high Wallace coefficient, for e.g. SNP typing and ptxP alleles, implies that the 
SNP type accurately predicts the ptxP type. In addition, EpiCompare version 1.0 was used to 
calculate the Discriminatory Index (DI) for each typing method [30]. To explore the relationship 
between the genetic distances to the root and the isolation year of strains, a linear regression 
was performed and the R-squared value (R2) was determined.
Results
Genetic relationships between B. pertussis strains based on 87 SNPs
A Maximum Parsimony tree was constructed by concatenating all 87 SNPs of the analyzed 
strains (Fig. 1). B. pertussis strain 18323, which harbors the ptxP4 allele, was used to root 
the tree as we found that this strain was most closely related to B. bronchiseptica in this 
set of strains (data not shown), consistent with previous studies using multi-locus enzyme 
electrophoresis and comparative genomic hybridization [31-33]. In 125 strains, 14 different 
SNP types (STs) could be distinguished which resulted in a discriminatory index (DI) of 0.85 
(Table 1). Bootstrap values ranged from 63% to 100% (average 89%). Five STs (ST3, ST6, ST7, 
ST11 and ST12) predominated, representing 14%, 24%, 12%, 11% and 22% of the strains, 
respectively. Six STs were found only once. The predominance of certain STs may have been 
caused by phylogenetic discovery bias which leads to collapsing of branches [34,35].
Our collection contained strains from two African (Kenya and Senegal) and three European 
(Finland, the Netherlands and Sweden) countries. A high Wallace coefficient (0.95) (Table 
1) was found between ST and the continent of origin of strains. Three STs (ST2-ST4, 21%) 
were unique for African strains; eight STs (ST7-ST14, 50%) were found only in Europe, while 
two STs (ST5 and ST6, 28%) were found in both continents (Fig. 1). Of the five STs found in 
Africa, only one (24%) was found in both Kenya and Senegal, suggesting distinct populations. 
Alternatively, the lack of overlap in STs may be related to the different sampling years, as 
discussed below.
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Figure 1. Maximum Parsimony tree of 125 B. pertussis isolates based on 87 SNPs. The ptxP alleles, 
continent of origin and the year of isolation of the oldest isolate are indicated. The numbers refer the 
number of isolates for each ST. Bootstrap values are indicated in the tree. Abbreviation: ST; SNP type.
Table 1. Wallace coefficients and Discriminatory indices1.
Typing method Continent of origin ptxP allele Discriminatory index
SNP typing 0.95 1.00 0.85 [0.83-0.88]
PFGE 0.99 0.99 0.95 [0.93-0.96]
MLVA 0.92 0.82 0.83 [0.78-0.88]
1The Wallace coefficient of the typing method was calculated versus, respectively, continent of origin and ptxP 
allele. The confidence interval for the Discriminatory index has been indicated.
Since divergence increases over time due to the accumulation of SNPs, a relationship between 
isolation year and position in the tree is to be expected. Indeed, such a relationship was found, 
when the number of SNPs relative to the root was plotted against the isolation year of strains 
(R2=0.65, P < 0.005) (Fig. 2). A high Wallace coefficient (1.0) (Table 1) was found between ST 
and ptxP allele, as each ST was associated with a single ptxP allele. Further, the predominant 
ptxP alleles, ptxP1 and ptxP3, were separated into distinct clusters. The ptxP6 allele was 
identified in African strains only. The ptxP6 strains were placed close to the root suggesting 
they represent an ancient lineage. No evidence for homoplasy was found for ptxP alleles in 
the SNP-based tree. The tree indicated that the ptxP3 strains diverged from ptxP1 strains, 
as suggested previously [16]. Further, the relative large genetic distance between the ptxP3 
branch and the root suggested that this event occurred recently. Consistent with this, the 
earliest isolation year for a ptxP3 strain in the Netherlands was 1988.
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Figure 2. Relationship between year of isolation and the-root-to-tip distance in the SNP-based tree. The 
root-to-tip distance represents the number of SNP differences between a particular clinical isolate and 
strain 18323, used to root the tree. Linear regression was performed and the trend line and R-squared 
value (R2) are indicated. A significant increase of SNPs over time was found (R2=0.65, P < 0.005).
Genetic relationships between B. pertussis strains based on PFGE
PFGE analysis of 125 strains revealed 37 unique PFGE types which resulted in a DI of 0.95 
(Fig. 3, Table 1). Bootstrap values were lower compared to the SNP-based tree and ranged 
from 0% to 100% (average 14%). Nine PFGE types (SR3, SR10, SR11, SR5, SR23, SR127, 
AFR1, AFR5 and FINR9) predominated, representing 4%, 5%, 13%, 4%, 4%, 6%, 13%, 6% 
and 10% of all strains, respectively. Fourteen PFGE types were found only once.
A high Wallace coefficient (0.99) (Table 1) was found between PFGE typing and continent of 
origin of strains. Ten PFGE types (42%) were specific for Africa, 25 types (53%) were found 
only in Europe. One PFGE type (4%), SR23, was shared by the two continents but was found 
only once in Europe (Sweden) [36]. Of the ten African PFGE types, only one, FINR9, (10%) was 
found in both Kenya and in Senegal which suggested two distinct populations as mentioned 
above. In contrast to the SNP-based tree, a negative relationship between isolation year and 
tip-to-root distance was found (R2=0.29, P < 0.005) (Fig. S1).  
A high Wallace coefficient (0.99) (Table 1) was found between PFGE type and ptxP allele, as 
each PFGE type was associated with a single ptxP allele, except for SR10, which was shared 
by both ptxP1 and ptxP3 strains. The African ptxP6 lineage was represented by one unique 
PFGE type, AFR5. In contrast to the SNP-based tree, the ptxP1 and ptxP3 strains were not 
separated in distinct clusters as the ptxP3 strains were interrupted by ptxP1 strains, suggesting 
homoplasy. Further, the ptxP6 lineage was placed close to the tip and root in the PFGE- and 
SNP-based trees, respectively, suggesting that the ptxP6 lineage represented, respectively, a 
recent and an ancient branch.
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Figure 3. Maximum Parsimony tree of 125 B. pertussis isolates based on PFGE. See legends to Fig. 1 
for further details.
Genetic relationships between B. pertussis strains based on MLVA
MLVA analysis revealed 21 unique MLVA types which resulted in a DI of 0.83 (Fig. 4, Table 1). 
Bootstrap values were lower compared to the SNP-based tree and ranged from 5% to 100% 
(average 37%). Four MLVA types (MLVA29, MLVA10, MLVA149 and MLVA27) predominated, 
frequencies were 16%, 9%, 14% and 34% respectively. Eleven MLVA types were found only 
once. Although, a high Wallace coefficient (0.92) (Table 1) was found between MLVA type and 
continent of origin, separation of African strains and European strains was less pronounced 
compared to the trees based on SNPs. Seven MLVA types (36%) were specific for Africa, ten 
(42%) were unique for Europe and three MLVA types (21%) were shared by both continents. 
Of the seven African MLVA types, only one, MLVA96, (5%) was found in both Kenya and in 
Senegal which suggested two distinct populations similar to trees based on SNPs and PFGE. 
Similar to PFGE typing, a negative correlation was found between isolation year and distance 
to the root (R2=0.31, P < 0.005) (Fig. S2). 
Compared to the SNP- and PFGE-based trees, a lower Wallace coefficient (0.82) (Table 1) 
was found between MLVA type and ptxP allele. The ptxP6 lineage was represented by two 
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MLVA types, MLVA49 and MLVA169, which were clustered together. In contrast to the SNP-
based tree, but similar to the PFGE-based tree, the ptxP6 lineage showed a large distance to 
the root which suggested a recent origin.
Eleven MLVA types (38%) were specific for ptxP1 strains, five MLVA types (5%) were unique 
for ptxP3 strains and two MLVA types, MLVA27 and MLVA29, were shared by both ptxP1 and 
ptxP3 strains (frequencies, 34% and 16% respectively). MLVA27 and MLVA29 are currently 
the predominant types in Europe and Australia [13,17,21]. The two MLVA types were much 
better resolved by SNP and PFGE typing, resulting in a subdivision into, respectively, 13 and 
15 types for MLVA27 and 7 and 12 for MLVA29.
The ptxP1 and ptxP3 strains were well separated in two distinct clusters, except for the MLVA 
types, MLVA29 and MLVA27 which contained strains with both alleles. The presence of the 
ptxP3 allele in the MLVA29 branch, which was mainly comprised of ptxP1 strains and placed 
some distance from the main ptxP3 cluster, suggested homoplasy. Further, as observed for the 
SNP-based tree, the MLVA-based tree indicated that most ptxP3 strains represented a young 
branch in the tree which diverged from ptxP1 strains.  
Figure 4. Maximum Parsimony tree of 125 B. pertussis isolates based on MLVA. See legends to Fig. 1 
for further details.
Global distribution of the ptxP3 strain 
SNP typing was extended to include 179 ptxP3 strains from diverse geographic locations; 
Asia (1.1%), Australia (2.3%), Europe (86%), North America (8.9%) and South America (1.7%) 
(Fig. 5, a table with strain information is available online from http://www.plosone.org/article/
info%3Adoi%2F10.1371%2Fjournal.pone.0020340#s5). Bootstrap values ranged from 63% to 
97% (average 81%). Four new STs were identified (ST15-ST18). A Wallace coefficient of 0.77 
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was found between ST and continent of origin. Of the nine STs which were specific for the 
ptxP3 strains, four (ST13, ST14, ST17 and ST18) were found in only one continent (Europe). 
The remaining STs were found in strains from two to four continents. Two SNP types, ST11 and 
ST12, were found to be most prevalent.
Figure 5. Maximum Parsimony tree of 179 ptxP3 strains found worldwide based on 87 SNPs. See leg-
ends to Fig. 1 for further details.
Discussion
SNP typing has been used extensively to study the evolution, spread and phylogeography of 
bacterial pathogens and can be seen as the Gold Standard against which other methods can 
be compared [37]. B. pertussis populations have been mainly studied by PFGE and MLVA. 
Although these typing methods have been useful for strain discrimination, it is not clear to what 
extent they reflect genetic relationships. Here we compared the widely used typing systems 
based on PFGE and MLVA with the newly developed SNP typing. 
The strains were isolated in Europe and Africa and the SNP-based tree showed a striking 
consistency with geographic source. This may reflect geographic isolation. However, the 
congruence may also reflect the differences in isolation dates between the strains from Europe 
and Africa (average isolation dates, respectively, 1999 and 1980) or vaccination status of the 
populations. Most of the European strains (88%) were isolated from Finland, Sweden and the 
Netherlands in a period when the vaccination coverage was high (>96%) [38]. In Finland and 
the Netherlands mainly whole cell pertussis vaccines were used, while in Sweden acellular 
vaccines were used. The strains from Kenya were isolated in a period when only approximately 
20% of the children had a record of receiving three doses of a pertussis whole cell vaccine, 
while 10% received only two doses [39]. Strains from Senegal were isolated in 1990 to 1992, 
three to five years after the introduction of vaccination with a whole cell vaccine (i.e. in 1987) 
[40]. The differences in vaccination status between Europe and Africa may explain the distinct 
81
5
clustering of European and African strains in the SNP-based tree.
In the strain collection used in this study, one ptxP allele, ptxP6, was found only in the Kenyan 
strains (N=7), isolated in 1975 [41]. Analysis of ptxP alleles in a larger collection of strains 
also revealed the presence of ptxP6 in two Dutch strains, both isolated in 1977 (data not 
shown) and it is conceivable that these strains were imported from Africa. Further studies are 
required to determine if the ptxP6 allele is characteristic for African strains. No distinct African 
alleles were found for the virulence factors Ptx, pertactin, Fim2 and Fim3 (data not shown). In 
conclusion, at present we cannot conclude that the African strains form a distinct population. 
Lan and coworkers have used a DNA tiling microarray-based approach to detect SNPs and 
study the evolution of B. pertussis [25,42]. In contrast to our study, which covered the complete 
genome, Lan and coworkers targeted 34% (1.4 Mb) of the genome. Using 65 SNPs, 42 STs 
were identified in 316 isolates [42]. The DI obtained by Lan and coworkers was higher than the 
DI obtained by us (respectively, 0.94 and 0.85) and this may be due to the fact that their strain 
collection was more diverse with respect to geographic origin and year of isolation. Similar to 
our results with ptxP alleles, they found that surface protein alleles correlated with evolutionary 
lineages as revealed by SNP-typing. One branch (cluster I) identified by Lan and coworkers 
contained strains with a worldwide distribution, and we speculate that this branch contains 
ptxP3 strains. The results of Lan and coworkers are consistent with vaccine-drive evolution of 
B. pertussis as first proposed by us [2,6,14].
When we compared the resolving powers of SNP typing, PFGE and MLVA, the highest DI was 
found for PFGE (DI 0.95) followed by SNP typing (DI 0.85) and MLVA (DI 0.83). The limitations 
of MLVA were illustrated by the inability to resolve MLVA27 and MLVA29. These MLVA types 
represented 50% of all analyzed strains. Both types have a worldwide distribution [13,17,20,43] 
and in particular MLVA27 is associated with the ptxP3 allele [9,13,21]. The two MLVA types 
were resolved into, respectively, six and five types by SNP-typing and 15 and 12 types by 
PFGE. In contrast to the SNP-based tree, the PFGE- and MLVA-based trees revealed several 
examples of homoplasies with respect to ptxP alleles. Homoplasy with respect to ptxP3 was 
also suggested by a previous study using PFGE [43]. The SNP analysis indicated that these are 
false homoplasies, probably caused by convergence of PFGE and MLVA types. Recombination 
between insertion sequences and slipped strand mispairing, play an important role in generating 
diversity in PFGE and MLVA types, respectively. Both processes are reversible and may thus 
lead to convergence and false genetic relationships. A linear regression analysis of the root-to-
tip distance against the year of isolation showed a positive correlation for the SNP-based tree, 
reflecting the gradual accumulation of point mutations. Interestingly, a negative correlation was 
found for both PFGE and MLVA, implying that estimation of the relative age of strains is not 
possible with these methods. Overall, our comparison shows that in particular typing based on 
PFGE did not reflect true genetic relationships and is therefore less suitable for evolutionary 
studies of B. pertussis. However, in view of its high resolving power PFGE remains a useful 
tool for strain discrimination. Results obtained with MLVA are more consistent with SNP typing. 
However, the resolving power of MLVA is rather limited. It remains useful as a high throughput, 
highly portable, typing method, however. 
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We used SNP typing to study the genetic relationships between strains of the ptxP3 lineage 
which have been associated with the increase in pertussis in the Netherlands [16]. The SNP-
based tree suggested that ptxP3 strains, isolated in Asia, the Americas, Australia and Europe, 
formed a monophyletic group which evolved from ptxP1 strains. The tree is consistent with 
the assumption that a single clone spread globally and diversified. In particular two ptxP3 STs 
(ST11 and ST12) were found to predominate, suggesting fitness differences between ptxP3 
strains. It should be noted however that the predominance of STs may have been caused by 
phylogenetic discovery bias which leads to collapsing of branches [34,35]. The placement of 
the ptxP3 branch at the tip of the tree suggested that ptxP3 strains evolved relatively recently, 
possibly after the introduction of vaccination. Consistent with this assumption, ptxP3 strains 
were first detected in the Netherlands in 1988 and subsequently increased in prevalence 
to >90% in 2002. The absence of ptxP3 strains from populations in Africa with low vaccine 
coverage (Kenya), or where vaccination was introduced recently (Senegal), also suggests that 
ptxP3 strains evolved due to the introduction of vaccination.
In summary, the widespread use of SNP typing will enhance our understanding of the evolution 
and global epidemiology of B. pertussis.
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Figure S1. Relationship between year of isolation and root-to-tip distance in the PFGE-based tree. The 
root-to-tip distance between a particular isolate and strain 18323, used to root the tree, was based on 
the genetic distance. Linear regression was performed and the trend line and R-squared value (R2) are 
indicated. A negative correlation was found between isolation year and distance to the root (R2= 0.29, 
P < 0.005).
Figure S2. Relationship between year of isolation and root-to-tip distance in the MLVA-based tree. The 
root to tip distance between a particular isolate and strain 18323, used to root the tree, was based on 
the genetic distance. Linear regression was performed and the trend line and R-squared value (R2) are 
indicated. A negative correlation was found between isolation year and distance to the root (R2= 0.31, 
P < 0.005). 
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Abstract 
 
Before childhood vaccination was introduced in the 1940s, pertussis was a major cause of infant 
death worldwide. Widespread vaccination of children succeeded in reducing illness and death. 
In the 1990s, a resurgence of pertussis was observed in a number of countries with highly 
vaccinated populations, and pertussis has become the most prevalent vaccine-preventable 
disease in industrialized countries. We present evidence that in the Netherlands the dramatic 
increase in pertussis is temporally associated with the emergence of Bordetella pertussis strains 
carrying a novel allele for the pertussis toxin promoter, which confers increased pertussis toxin 
(Ptx) production. Epidemiologic data suggest that these strains are more virulent in humans. 
We discuss changes in the ecology of B. pertussis that may have driven this adaptation. Our 
results underline the importance of Ptx in transmission, suggest that vaccination may select for 
increased virulence, and indicate ways to control pertussis more effectively.                                        
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Introduction  
Bordetella pertussis causes whooping cough or pertussis, a respiratory disease that is most 
severe in infants. Before childhood vaccination was introduced in the 1940s, pertussis was 
a major cause of infant deaths worldwide. Widespread vaccination of children reduced the 
incidence of illness and deaths caused by pertussis [1]. However, globally pertussis remains 
1 of the top 10 causes of death in children [2]. Further, in the 1990s a resurgence of pertussis 
was observed in several countries with highly vaccinated populations [3,4], and pertussis has 
become the most prevalent vaccine-preventable disease in industrialized countries. In the 
Netherlands, the estimated incidence of infection was 6.6% per year for the 3–79-year age 
group from 1995 through 1996 [5]. Similar percentages have been found in the United States 
[6]. One of the hallmarks of the pertussis resurgence is a shift in disease prevalence toward 
older persons who have waning vaccine-induced immunity [7].
The reemergence of pertussis has been attributed to various factors, including increased 
awareness, improved diagnostics, decreased vaccination coverage, suboptimal vaccines, 
waning vaccine-induced immunity, and pathogen adaptation. The relative contribution of these 
factors may differ between countries and is the subject of ongoing debate. Pathogen adaptation 
is supported by several observations. We and others have shown that antigenic divergence 
has occurred between vaccine strains and clinical isolates with respect to surface proteins, 
which confer protective immunity: pertussis toxin (Ptx), pertactin (Prn), and fimbriae [8,9]. Strain 
variation was shown to affect vaccine efficacy in a mouse model [10–13]. Because adaptation 
may involve the structure of virulence factors (by antigenic variation) and their regulation, we 
extended our studies on the evolution of B. pertussis by investigating polymorphism in the 
promoter of Ptx (ptxP), a major virulence factor and component of all pertussis vaccines [1]. 
We provide evidence that expansion of strains with increased Ptx production has contributed 
to the resurgence of pertussis in the Netherlands.
Materials and methods
Pertussis notifications 
Pertussis became a notifiable disease in the Netherlands in 1976. Notifications are submitted 
online by local health authorities. Other notifiable diseases are also monitored through this 
system, which falls under the responsibility of the Dutch National Institute of Health and 
Environment [3].
Bacterial strains
B. pertussis strains examined were obtained from 1935 through 2004. A total of 1,566 isolates, 
879 from the Netherlands and 687 from other countries, were analyzed for polymorphism 
in ptxP (a table with strain information is available online from http://wwwnc.cdc.gov/eid/
article/15/8/08-1511-techapp1.pdf). Eight strains isolated from patients in the Netherlands 
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from 1999 through 2001 were selected to study Ptx and Prn production: B1834 (ptxP1), B1868 
(ptxP1), B1878 (ptxP1), B1920 (ptxP1), B1836 (ptxP3), B1865 (ptxP3), B1917 (ptxP3), and 
B2030 (ptxP3) (Table 1). 
Table 1. Characteristics of strains used for Ptx and Prn production experiments1.
Strain Year of isolation Patient age, mo ptxP allele prn allele ptxA allele
B1834 1999 28 PtxP1 Prn2 PtxA1
B1836 1999 3 PtxP3 Prn2 PtxA1
B1865 2000 2 PtxP3 Prn2 PtxA1
B1868 2000 35 PtxP1 Prn2 PtxA1
B1878 2000 45 PtxP1 Prn2 PtxA1
B1917 2000 44 PtxP3 Prn2 PtxA1
B1920 2000 9 PtxP1 Prn2 PtxA1
B2030 2001 3 PtxP3 Prn2 PtxA1
1Ptx, pertussis toxin: Prn, pertactin; ptxP, pertussis toxin promoter; prn, gene for pertactin; ptxA, gene for A 
subunit of pertussis toxin. 
Sequencing
The primers 5′-AATCGTCCTGCTCAACCGCC-3′ and 5′-GGTATACGGTGGCGGGAGGA-3′ 
were used for amplification and sequencing of ptxP and correspond, respectively, to bases 
60–79 and 633–614 of the ptx sequence with GenBank accession no. M14378. The ptx gene 
cluster from the strains B1834 (ptxP1), B1920 (ptxP1), B1917 (ptxP3), and B1831 (ptxP3) 
was sequenced completely. The sequences of the ptx gene clusters from strains B1834, 
B1920, B1917, and B1831 can be found under the following accession numbers, respectively: 
FN252334, FN252335, FN252336, and FN252333. The ptxP1-ptxP11 sequences have been 
assigned accession nos. FN252323, FN252322, FN252324, FN252325, FN252326, FN252327, 
FN252328, FN252329, FN252330, FN252331, and FN252332.
Pertussis toxin and pertactin production
B. pertussis strains were grown on Bordet-Gengou agar plates supplemented with 15% sheep 
blood and incubated for 3 days at 35°C. Cells were harvested and suspended in 2 mL Verwey 
medium [14] per plate. Cells from 1 mL were collected by centrifugation and resuspended 
in Verwey medium to a concentration of 5 × 106 bacteria/mL. Subsequently, 100 μL of this 
suspension (5 × 105 CFU) was plated on Bordet-Gengou agar plates. After an incubation of 
48 to 60 hours at 35°C, cells were harvested in 2.5 mL Verwey medium. The cell suspension 
was heat-inactivated for 30 min at 56°C and stored at 4°C. An ELISA was used to quantify 
Ptx and Prn. For Ptx, Maxisorp 96-well plates (Nunc International, Rochester, NY, USA) 
were coated with 100 μL of 0.04 mg/mL fetuin (Sigma-Aldrich, St. Louis, MO, USA) in 0.04 M 
carbonate buffer, pH 9.6, overnight at 4°C. For Prn, polystyrene 96-well plates (Immunolon II; 
Dynatech, Chantilly, VA, USA) were coated with 100 μL of a 2,000-fold dilution of polyclonal 
rabbit anti-Prn immunoglobulin (Ig)G [15] in 0.04 M carbonate buffer, pH 9.6, overnight at 20°C. 
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Plates were blocked by incubation with 130 μL 1% bovine serum albumin (Sigma- Aldrich) in 
phosphate-buffered saline (PBS) for 1 hour at 37°C, after which plates were washed twice 
with PBS supplemented with 0.05% Tween. A 3-fold serial dilution of the heat-inactivated cell 
suspensions was made in 100 μL PBS supplemented with 0.1% Tween (PBST); 1 μg/ mL 
of Prn and Ptx were used as reference. The suspensions were incubated for 1 hour at 37°C 
followed by 2 washings. The Prn monoclonal antibody (MAb) (PeM85) that was used binds 
to the linear epitope GGFGPGGFGP present in the repeat region 1 of all known Prn variants, 
except Prn13 (15). The Ptx MAb (3F10) binds to a conformational epitope in the PtxA subunit 
[16]. All strains selected for the ELISA experiments produced Prn2 and PtxA1 (Table 1). The 
MAbs were diluted in PBST, added to the wells, and incubated for 1 hour at 37°C, followed 
by 2 washings. To detect bound MAbs, plates were incubated with horseradish peroxidase–
conjugated polyclonal rabbit anti- mouse IgG (DakoCytmation, Glostrup, Denmark), diluted 
in PBST, for 1 hour at 37°C, and followed by 2 washings. The optical density at 450 nm was 
measured with a plate reader (PowerWave HT 340; Biotek, Winooski, VT, USA) and the amount 
of produced Ptx and Prn were calculated using the KC4 program (Biotek).The ratio of Ptx and 
Prn production by ptxP1 and ptxP3 strains was calculated as follows: Ptx (or Prn) production 
ptxP3 strains divided by Ptx (or Prn) production ptxP1 strains.
Statistical analysis
The significance of the increases in illness and death were calculated with the Fisher exact 
test. Ptx and Prn production was analyzed on the basis of the following considerations: 1) that 
there are random variations among experiments that influence Ptx and Prn production; 2) that 
there is a correlation between Ptx and Prn production; and 3) that the distribution Ptx and Prn 
measurements were skewed. To take into account these considerations regarding sources 
of random variation, a random intercept model was used and a logarithmic transformation 
was used before further analysis. Logarithmically transformed Ptx and Prn values were first 
analyzed with a random intercept model by using SAS PROC MIXED (SAS, Cary, NC, USA) 
and by using experiment as a random effect. We first tested whether there were differences 
between ptxP1 and ptxP3 strains in the production of Ptx and Prn by analyzing the logarithm 
of Ptx production and Prn production, respectively, as a dependent variable, and by using 
experiment as random effect and incubation time (in classes) and type (ptxP1 or ptxP3) as 
fixed effects. To determine whether the ratio of production in ptxP3 versus ptxP1 strains differ 
significantly for Prn and Ptx, we further fitted a multivariate model with both factors (Ptx and Prn) 
as dependent variables, again using experiment as random effect, and allowing all variance 
parameters to be factor (Ptx or Prn) specific. In this model the interaction between type (ptxP1 
or ptxP3) with factor (Ptx or Prn) then gives the required P value.
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Results
Polymorphism of the pertussis toxin promoter
The synthesis and export of Ptx requires 14 genes, which are co-transcribed from ptxP [17]. 
ptxP comprises a region of ≈170 bases upstream of the Ptx subunit gene ptxA and contains 
the RNA polymerase binding site and 6 binding sites for the BvgA dimer (18). BvgA is a global 
regulator of B. pertussis virulence genes, and cooperative binding of BvgA to ptxP is required 
for efficient transcription of ptx [18]. We investigated polymorphism in ptxP by sequencing a 
DNA region of ≈380 bases upstream of ptxA by using a collection of 1.566 B. pertussis strains 
from 12 countries isolated during 1935–2004. Polymorphism was found to be restricted to 
the DNA region implicated in binding of RNA polymerase and BvgA. Eleven ptxP alleles were 
identified (Fig. 1).
Figure 1. Alleles of pertussis toxin promoter (ptxP) observed worldwide. Bases are numbered –173 to 
+27 relative to the start of transcription (+1). The region to which 6 dimers of BvgA, the global regula-
tor of B. pertussis virulence genes, bind is shaded. The –10 sequence motif and initiation codon are 
underlined. The DNA region –370 to –174, not shown here, was devoid of polymorphism. Locations of 
transcriptional signals and BvgA bindings sites are based on Bartoloni et al. [16].
Geographic and temporal differences in ptxP frequencies
Next we investigated geographic and temporal differences in ptxP frequencies. The following 
geographic regions were distinguished: the Netherlands, the continents of Africa, Asia, Europe 
(excluding the Netherlands), North America, and South America. Two periods, chosen on the 
basis of the appearance of ptxP3 strains in the Netherlands, were compared: 1935 through 
1990 and 1991 through 2004 (Table 2). Only strains from the later period were available from 
South America. Two ptxP alleles were found to predominate worldwide, ptxP1 and ptxP3, and 
. 
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the remaining 9 alleles were pooled. Strains with ptxP1 predominated in the first period and 
were found in lower frequencies in the second period (global frequencies were 88% and 47%, 
respectively). A reverse trend was observed for the ptxP3 strains (global frequencies, 3% and 
52%, respectively). In the first period, ptxP3 strains were only detected in the Netherlands 
and the United States (frequencies were 3% and 13%, respectively). The only region in which 
ptxP3 strains were not detected was Africa, where only ptxP1 strains were found. The minor 
ptxP alleles were observed in higher frequencies during 1935–1990 compared with 1991–2004 
(global frequencies were 9% and 1%, respectively). The differences in ptxP allele frequencies 
may be due to sampling bias, geographic factors, or differences in vaccines, vaccination history, 
and vaccination coverage. Nevertheless, these data provide strong evidence that, in most 
parts of the world, ptxP3 strains emerged recently and replaced the resident ptxP1 strains. The 
ptxP3 allele was first detected in a strain isolated in the United States in 1984.
To investigate if ptxP1 and ptxP3 alleles were linked to other polymorphisms in ptx genes, the 
gene clusters from 2 ptxP1 and 2 ptxP3 strains were sequenced. The ptx sequences were 
identical, except for a single point mutation in ptxC. The single nucleotide polymorphism (SNP) 
in ptxC has been described previously, does not result in a change in amino acid sequence, 
and is therefore most likely selectively neutral [19]. To study the linkage, ptxC was sequenced 
in 249 ptxP1 and 142 ptxP3 strains. Linkage between ptxP1-ptxC1 and ptxP3-ptxC2 was 100% 
and 98%, respectively. Only 3 strains harbored the combination ptxP3-ptxC1.
Table 2. Worldwide frequencies of ptxP1 and ptxP3 during 1935-1990 en 1991-20041.
1935-1990 1991-2004
Region2 ptxP1 ptxP3 Other3 N ptxP1 ptxP3 Other3 N
the Netherlands 89 3 8 265 47 53 0 614
Africa 100 0 0 11 100 0 0 7
Asia 100 0 0 12 83 13 3 30
Europe4 73 0 27 22 46 53 0 577
North America 50 13 38 8 20 80 0 10
South America - - - 0 10 80 10 10
Total 88 3 9 318 47 52 1 1.248
1ptxP, pertussis toxin promoter. Allele frequencies are given in percentages. 
2The following countries represented the continents: Africa: Senegal; Asia: Japan and Australia; Europe: Denmark, 
Finland, France, Germany, Italy, Sweden; North America: USA; South America: Argentina.                          
3Nine ptxP alleles were found in low frequencies: ptxP2, ptxP4, ptxP5, ptxP6, ptxP7, ptxP8, ptxP9, ptxP10 and 
ptxP11.
4Dutch strains were excluded.
Association of the ptxP3 allele with the resurgence of pertussis in the Netherlands
The availability of a large strain collection allowed us to analyze temporal trends in the 
Netherlands in more detail. From 1989 through 2004, a total of 99% of the strains harbored 
ptxP1 or ptxP3. In this period, ptxP1 was gradually replaced by ptxP3, which increased in 
frequency from 0% in 1989 to 100% in 2004. A close temporal relationship was shown between 
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the increase in ptxP3 frequency and mandatory pertussis notifications (Fig. 2A). Increased 
notifications were found in all age groups, however, the largest increase was among persons 
>5 years of age (Fig. 2B). The shift toward older age categories coincided with emergence 
of ptxP3 strains. There was no change in age distribution from 1989 through 1992, which 
preceded the emergence of the ptxP3 allele.
Figure 2. Relationship between the emergence of pertussis toxin promoter 3 (ptxP3) strains and the 
epidemiology of pertussis in the Netherlands, 1989–2004. A) Temporal trends in the frequencies of 
ptxP3 strains and notifications. In this period 99% of the strains harbored either ptxP1 or ptxP3. B) Shift 
in age-specific distribution of notifications (this figure is available in color in the appendix).
Ptx and Prn production by ptxP1 and ptxP3 strains 
The effect of polymorphism in ptxP was assessed by determining the ratio of Ptx produced 
by ptxP1 and ptxP3 strains (Ptx produced by ptxP3 strain / Ptx produced by ptxP1 strain) 
after 48, 54, and 60 h growth on plates. In addition, we assessed the production of a second 
virulence factor, Prn, which is also regulated by bvg. No polymorphism was observed in the 
Prn promoter of the 8 strains analyzed. Data from 4 ptxP1 and 4 ptxP3 strains were pooled 
(Fig. 3). The Prn ratios were slightly lower than 1, indicating that ptxP3 strains produce slightly 
less Prn than ptxP1 strains (average over all time points 0.94; p = 0.03). In contrast, the Ptx 
ratio was significantly larger than 1 (average over all time points 1.62; p<0.0001), indicating 
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that ptxP3 strains produce more Ptx than ptxP1 strains under the growth conditions tested. The 
Ptx and Prn ratios were significantly different (p<0.0001).
Figure 3. Production of pertussis toxin (Ptx) and pertactin (Prn) by pertussis toxin promoter 1 (ptxP1) 
and ptxP3 strains. Strains were incubated for the 48, 54, and 60 h, after which the amount of Ptx and 
Prn was determined by ELISA. The production ratio was calculated as follows: ptxP3 strain values/ptxP1 
strain values; 8 strains, 4 ptxP1 strains and 4 ptxP3 strains, were used. The experiment was performed 
3 times. Error bars indicate 95% confidence intervals. The Ptx and Prn ratios were significantly different 
from 1 (p<0.0001 and 0.03, respectively).
Evidence for increased virulence of ptxP3 strains in humans
Ptx is assumed to contribute to the severity of infection. Therefore, we investigated whether 
ptxP3 strains were more virulent in humans than ptxP1 strains by comparing the incidence of 
hospitalizations, deaths, and lethality (ratio of deaths to hospitalizations) in the Netherlands 
during 2 periods, 1981 through 1992 and 1993 through 2004, with low (1.6%) and high (54.5%) 
ptxP3 frequencies, respectively (Table 3). All 3 parameters showed a statistically significant 
increase (1.41, 10.21, and 7.23 times respectively; p values <0.0001, 0.0058, and 0.03, 
respectively), suggesting that ptxP3 strains are more virulent in humans.
Table 3. Increases in illness and death caused by pertussis in 2 periods with low and high frequencies 
of ptxP3 strains in the Netherlands1.
Parameter ptxP3 frequency,% Hospitalizations/100,000 Deaths/100,000 Lethality2
1981-1992 1.6 1.38 0.00057 0.00041
1993-2004 54.5 1.95 0.00582 0.00299
Increase 33.1 1.41 (1.34-1.49) 10.21 (1.31-79.11) 7.23 (0.93-56.07)
p value <0.0001 0.0058 0.03
1ptxP, pertussis toxin promoter. Numbers in parentheses are 95% confidence intervals. 
2Lethality=no. of deaths/no. of hospitalizations.
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Discussion  
The persistence of pertussis in the face of intense vaccination is unexpected because B. 
pertussis is extremely homogeneous [19-21], implying a limited ability to adapt. However, the 
Ptx promoter showed a relative high degree of polymorphism, suggesting that fine tuning of 
Ptx production has adaptive value. Globally, 11 ptxP alleles were found in 1,566 strains, 8 of 
which occurred in the B. pertussis population in the Netherlands. Polymorphism was restricted 
to a region required for transcription of ptx. Silent ptx genes are found in the closely related 
species B. parapertussis and B. bronchiseptica [17]. The silencing of ptx genes indicates that 
production of Ptx involves both benefits and costs. Thus, production of Ptx is beneficial for the 
pathogen by suppressing host defenses but also involves metabolic costs and increases the 
number of immunologic targets. Ptx is a major antigen of B. pertussis, and Ptx antibodies are 
used in diagnosing pertussis cases.
Globally, ptxP1 and ptxP3 were the most prevalent ptxP alleles. In the Netherlands, during 1989-
2004, ptxP1 was completely replaced by ptxP3. The replacement of ptxP1 strains by ptxP3 
strains in recent times is a global phenomenon because it has been observed in 11 countries 
representing 4 continents; Asia, Europe, and North and South America. Notably, ptxP3 strains 
were not observed in Africa. A broad current distribution of ptxP3 strains was also suggested 
by a recent study in which strains from 8 different European countries were compared by 
pulsed-field gel electrophoresis (PFGE). One PFGE profile, BpSR11, predominated in 5 of the 
8 European countries [22]. We have found that, in the Dutch population, all BpSR11 strains 
carry the ptxP3 allele (N = 18).
In the Netherlands, emergence of ptxP3 strains was associated with increased notifications and 
a shift in disease prevalence towards older age categories. Changes in diagnostic procedures 
may have contributed to the latter 2 phenomena [3]. However, hospitalizations, which are 
less sensitive to surveillance artifacts, also increased concurrently with the emergence of 
ptxP3 strains (Fig. S1). Furthermore, an extensive analysis of surveillance data confirmed a 
true increase in the pertussis incidence after 1995 in the Netherlands [3]. The expansion of 
ptxP3 strains was also associated with the resurgence of pertussis in Finland, where a large 
nationwide epidemic was observed in 2003 [23].
The SNP distinguishing the ptxP1 and ptxP3 alleles is located in a region involved in binding 
of BvgA, the global regulator of virulence gene expression in B. pertussis. We hypothesize that 
the ptxP3 allele confers increased binding of BvgA compared to ptxP1, resulting in increased 
toxin production. When compared with ptxP1 strains, ptxP3 strains produced 1.62 times more 
Ptx. In contrast, the production of another bvg-regulated virulence factor, Prn, was slightly 
suppressed in ptxP3 strains compared with ptxP1 strains (factor 0.94), indicating that increased 
Ptx production cannot be explained by a global up-regulation of virulence genes.
The expansion of ptxP3 strains is remarkable and suggests that ptxP3 increases strain fitness 
or is linked to other genetic loci that do so. Although we cannot exclude that other loci are 
involved in the expansion of ptxP3 strains, several arguments underline the role of ptxP3. First, 
the high degree of polymorphism in the ptxP promoter indicates positive selection. Second, the 
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increased Ptx production observed by ptxP3 strains provides a rationale for its emergence. It 
has been well established that Ptx plays a central role in immune suppression. Ptx enhances 
colonization of both naive and immune mice by targeting macrophages and neutrophils [24,25]. 
Ptx also suppresses antibody responses [26]. The ptxP3 allele was found associated with 2 
ptxC alleles, ptxC1 and ptxC2, which are distinguished by a silent SNP. This finding suggests 
that the ptxP3 allele is found in different genetic backgrounds which may be explained by 
homoplasy or horizontal gene transfer. Both possibilities suggest that ptxP3 confers increased 
fitness. In most strains (98%), ptxP3 was linked to ptxC2. Further, genomic profiling of Dutch 
B. pertussis strains indicated that ptxP3 strains are closely related, and are characterized by a 
chromosomal deletion [27]. Thus it is seems likely that, in the Netherlands, ptxP3 strains arose 
mainly by clonal expansion. We are analyzing a geographically more diverse strain collection 
to investigate this issue further. 
Ptx has been suggested to increase severity of B. pertussis infections because the closely 
related B. parapertussis, which does not produce Ptx, generally causes less severe infections 
[28]. Furthermore, Ptx causes leukocytosis in humans by inhibiting egression of leukocytes 
from the vasculature, and high levels of leukocytosis are associated with an increased mortality 
rate in infants due to pulmonary hypertension [29]. Thus the invasion of ptxP3 strains may 
result in increased illness and deaths. Consistent with this assumption, we found that the 
emergence of ptxP3 strains in the Netherlands was associated with increased incidence of 
hospitalizations and deaths and increased lethality. A recent Swedish study also suggested 
that B. pertussis strains differ in virulence. Infection with strains with PFGE profile BpSR11 was 
associated with a longer duration of hospital stay [30]. As noted above, BpSR11 strains carry 
the ptxP3 allele. An association between Fim2 and increased disease severity was found in 
a study in the UK [31]. In contrast, the Swedish study found no association between serotype 
and virulence. Nevertheless, it is conceivable that other polymorphic loci in B. pertussis may 
also affect virulence.
An important issue is, whether vaccination has selected for the ptxP3 strains. Several lines of 
evidence support this contention. First, ptxP3 strains were not found in the prevaccination era. 
Furthermore, although ptxP3 strains were found in high frequencies in vaccinated populations 
in the 1990s, they were not detected in Senegal, where vaccination was introduced in 1987 [32]. 
Several studies have provided evidence that increased host immunity may select for higher 
virulence. Vaccination against 2 avian viruses, the Marek disease virus, and the infectious 
bursal disease virus, were associated with the emergence of more virulent strains [33]. An 
important role of host immunity in selecting for virulence is also suggested by the co-evolution 
of the myxomatosis virus and rabbits [34]. Furthermore, immune pressure was shown to 
select for more virulent Plasmodium chabaudi parasites in mice [35]. Based on mathematical 
modeling, vaccines designed to reduce pathogen growth rate and/or toxicity may result in the 
evolution of pathogens with higher levels of virulence [36].
We propose that the crucial event, which shifted the competitive balance between ptxP1 
and ptxP3, strains was the removal by vaccination of naive infants as the major source for 
transmission, selecting for strains, which are more efficiently transmitted by primed hosts. 
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Recent studies and historical data indicate an important role of naïve infants in transmission in 
unvaccinated populations. In a previously unvaccinated population, infant vaccination resulted 
in a reduction in pertussis in the vaccinated and unvaccinated part of the population [37]. 
Furthermore, in unvaccinated populations, 60%-80% of the pertussis cases were found in 
children 0-5 years of age, most of whom were probably immunologically naïve [32,38]. In 
most countries infants receive their first vaccination at the age of 2 or 3 months, essentially 
eliminating transmission by naïve hosts. In primed hosts, increased Ptx production may delay 
an effective immune response [24-26] enhancing transmission, and hence pathogen fitness. 
Increased Ptx production may also be beneficial for the pathogen as the host requires higher 
levels of antibodies against Ptx for toxin neutralization. The antigenic divergence observed 
between vaccine strains and circulating strains [8,9] may act synergistically with the ptxP3 
polymorphism by enhancing transmission by hosts primed by vaccination. Pertussis among 
recently vaccinated children is rare, indicating that pathogen adaptation does not play a role 
unless immunity has waned. Thus, we propose that waning immunity and pathogen adaptation 
have contributed to the resurgence of pertussis, although other factors such as increased 
awareness and improved diagnostics have also played a role.
The effect of pathogen adaptation on disease impact may depend on factors such as vaccine 
coverage and the quality of the vaccine used, which may differ between countries. A relatively 
weak vaccine used in the Netherlands may have exacerbated the effect of the emergence 
of ptxP3 strains on disease impact [3]. Our results underline the important role of Ptx in the 
transmission of B. pertussis and suggest that an effective way to control pertussis is the 
improvement of current vaccines to induce Ptx-neutralizing antibodies which persist longer. 
An important question is whether other childhood vaccines also select for pathogens that are 
more efficiently transmitted by primed hosts and whether this results in increased virulence.
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Figure S1. Temporal trends in the frequencies of pertussis toxin promoter 3 (ptxP3) strains, notifica-
tions, and hospitalizations. In this period, 99% of the strains harbored either ptxP1 or ptxP3. In Novem-
ber 2001, a preschool booster immunization was introduced, which may have reduced hospitalizations.
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Abstract 
Bordetella pertussis is the causative agent of pertussis, a highly contagious disease of the 
human respiratory tract. Despite high vaccination coverage, pertussis has resurged and has 
become one of the most prevalent vaccine-preventable diseases in developed countries. 
We have proposed that both waning immunity and pathogen adaptation have contributed to 
the persistence and resurgence of pertussis. Allelic variation has been found in virulence-
associated genes coding for the pertussis toxin A subunit (ptxA), pertactin (prn), serotype 
2 fimbriae (fim2), serotype 3 fimbriae (fim3) and the promoter for pertussis toxin (ptxP). In 
this study, we investigated how more than 60 years of vaccination has affected the Dutch 
B. pertussis population by combining data from phylogeny, genomics and temporal trends in 
strain frequencies. Our main focus was on the ptxA, prn, fim3 and ptxP genes. However, we 
also compared the genomes of 11 Dutch strains belonging to successful lineages. Our results 
showed that, between 1949 and 2010, the Dutch B. pertussis population has undergone as 
least four selective sweeps that were associated with small mutations in ptxA, prn, fim3 and 
ptxP. Phylogenetic analysis revealed a stepwise adaptation in which mutations accumulated 
clonally. Genomic analysis revealed a number of additional mutations which may have a 
contributed to the selective sweeps. Five large deletions were identified which were fixed in 
the pathogen population. However, only one was linked to a selective sweep. No evidence 
was found for a role of gene acquisition in pathogen adaptation. Our results suggest that the 
B. pertussis gene repertoire is already well adapted to its current niche and required only fine 
tuning to persist in the face of vaccination. Further, this work shows that small mutations, even 
single SNPs, can drive large changes in the populations of bacterial pathogens within a time 
span of six to 19 years. 
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Introduction
Compared to theoretical studies on the effect of vaccination on pathogen evolution [1-4], 
there is a paucity of data from field studies, especially with respect to bacterial and protozoan 
pathogens. There are practical reasons for this, such as the lack of historical strain collections, 
the relatively complexity bacterial and protozoan genomes and their relative slow evolution 
rate. The early introduction of vaccination (in the 1940s and 1950s), the presence of extensive 
strain collections and its clonal and monomorphic nature has made Bordetella pertussis an 
attractive model to study the effect of vaccination on pathogen evolution [1,3,5-7].
The Gram-negative bacterium B. pertussis is the main causative agent of whooping cough 
or pertussis, a highly contagious disease of the human upper respiratory tract (for recent 
reviews see [6,8-10]). Typical symptoms of the disease are paroxysmal coughs which are 
often followed by vomiting and whooping, due to forced inhalation through restricted airways. 
Less severe forms of whooping cough are caused by two species which are closely related 
to B. pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Before childhood 
vaccination was introduced, pertussis was one of the major causes of infant death worldwide. 
In the Netherlands, vaccination was introduced in 1953 resulting in a dramatic reduction in 
pertussis morbidity and mortality [6,9]. However, despite high vaccine coverage, pertussis 
resurged in the 1990s in the Netherlands and also in many other countries [6,10-15]. Indeed, 
pertussis has become one of the most prevalent vaccine-preventable diseases in developed 
countries with estimated infection frequencies of 1-6% [16-19]. In the Netherlands, the infection 
frequency was estimated to be 9.3% for the age category > 9 years in 2006-2007 [20].  Due 
to the high circulation rate of B. pertussis, adolescents and adults are often the source of 
infection for newly born who are too young to be (fully) vaccinated and for whom pertussis is 
life threatening [21,22].  
We have provided evidence that the persistence and resurgence of pertussis in the Netherlands 
are the compound effect of waning immunity and pathogen adaptation [6,7,23]. However, 
increased awareness and improved detection, may also have contributed to the higher numbers 
of notified cases. B. pertussis is extremely monomorphic [5,24,25] and allelic variation was 
mostly studied in virulence-associated genes, in particular in the genes for the pertussis toxin 
promoter (ptxP), for the pertussis toxin A subunit (ptxA), for pertactin (prn) and for the serotype 
2 and 3 fimbrial subunits (fim2 and fim3, respectively). For ptxP, ptxA, prn, fim2 and fim3, 
respectively, 18, 8, 13, 2 and 4 alleles have been identified worldwide [6,26]. In most cases, 
the differences between the alleles are caused by single nucleotide polymorphisms (SNPs). In 
the case of prn, however, variation is mainly generated by insertions or deletions in a region 
with repeats, although SNPs have also been identified [6,23].
Previous work, by us and others, has provided evidence that variation in these genes may 
have played an important role in adaptation of B. pertussis to vaccination [6,8]. Further, it 
has been proposed that gene loss may also have contributed to pathogen adaptation, as 
comparative genomic hybridization using microarrays showed that B. pertussis clinical isolates 
differ in gene content and, over time, a reduction in genome size of B. pertussis clinical isolates 
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was observed [27-32].
Variation in ptxP, ptxA, prn, fim2 and fim3 may have an adaptive value as studies in humans 
and animals have shown that vaccination with these proteins confers protection [6]. Indeed the 
five proteins are incorporated in different combinations in current acellular pertussis vaccines 
(ACVs) [9,10]. Thus variation in these proteins may affect immune recognition and hence strain 
fitness. Significantly, antigenic divergence has been observed between circulating strains and 
vaccine strains with respect to these five proteins and several studies in mouse models have 
provided evidence this affects vaccine efficacy [33-37]. Besides antigenic divergence between 
circulating strains and vaccine strains, another adaptive phenomenon may be the recent 
emergence of strains with increased Ptx production [5,26,38,39]. These strains carry a novel 
allele for the Ptx promoter, ptxP3. The ptxP3 strains have gradually replaced the resident ptxP1 
strains in the 1990s. Of interest is the close relationship between the emergence of the ptxP3 
strains and increased pertussis notifications in the Netherlands, Finland and Australia [39,40]. 
The ptxP3 strains have probably recently expanded globally [26,38,40,41]. Lately, strains 
have emerged which do not express genes coding for proteins used in pertussis vaccines, in 
particular Prn [42,43, our unpublished data].
The Netherlands offers a number of unique features for the study of the evolution of B. pertussis. It 
comprises a relatively small country, in which vaccination coverage has been consistently high. 
Further, the vaccines and vaccine strains used have been well characterized, and changes in 
vaccines and vaccination schedules were implemented nationwide. Mass vaccination against 
pertussis with a whole cell vaccine (WCV) was introduced in the Netherlands in 1953. The 
vaccination schedule was initially 3, 4, 5 and 48 months. In 1962, the schedule was changed 
to 3, 4, 5 and 11 months. Other changes in the vaccination program involved a temporary 
lowering of the WCV dose between 1975 and 1984, acceleration of the first 3 doses to 2, 3 and 
4 months in 1999 instead of 3, 4 and 5 months, the introduction of an ACV booster for 4 year 
olds in 2001 and, finally, the replacement of the WCV by an ACV in 2005. Two ACVs have been 
used in the Netherlands, a three component vaccine from GlaxoSmithKline (GSK), containing 
FHA, Prn and Ptx, and a five component vaccine from Sanofi Pasteur-MSD which contains two 
additional antigens, Fim2 and Fim3 [9].
Here, we explore how more than sixty years of intensive vaccination has affected the B. 
pertussis population in the Netherlands by integrating data from phylogeny, genomics, and 
temporal trends in strain frequencies. Our aims were to establish the origin of novel clones, their 
genetic relationships and to identify novel polymorphic loci potentially involved in adaptation. 
Our results show that the Dutch B. pertussis population has undergone at least four selective 
sweeps. These sweeps were associated with small mutations, mostly SNPs, in ptxA, ptxP, prn 
and fim3. A number of large deletions were found to be fixed in the B. pertussis population, 
one of which was associated with a selective sweep. Using comparative genomics, additional 
polymorphism were identified which may have contributed to adaptation of B. pertussis. No 
evidence for a role of gene acquisition in adaptation was found. Our results suggest that small 
mutations, even single SNPs, can drive large changes in the populations of bacterial pathogens 
within a time span of six to 19 years.
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Materials and methods 
Strains
Strains were isolated from Dutch patients that were suspected for pertussis in the period 1949 
to 2010. In total 704 strains were used in this study (a table with strain information is vailable 
from the authors). Strains were selected randomly, where possible.
Sequencing of virulence-associated genes
Polymorphisms in the following DNA regions were analyzed: the pertussis toxin promoter 
(ptxP), the gene for the pertussis toxin subunit A (ptxA), region 1 of the pertactin gene (prn), 
the genes for serotype 2 (fim2) and serotype 3 fimbriae (fim3). Amplification and sequencing 
was performed as described in previous work [23,39,44]. A part of the sequence data was 
derived from previous studies [23,39,44]. For DNA isolation, strains were grown on Bordet 
Gengou (BG) agar plates supplemented with 15% sheep blood and incubated for at 3 to 4 days 
at 350C. Bacterial cells were lysed in Tris EDTA buffer (Sigma-Aldrich, Zwijndrecht, Nl, 1.0M 
Tris-HCl, containing 0.1M EDTA) at 950C for 5 minutes, centrifuged briefly and used in a PCR. 
Alternatively, chromosomal DNA was isolated using the GenElute Bacterial Genomic DNA Kit 
(Sigma-Aldrich, Zwijndrecht, NL) following the manufacturer’s instructions for Gram-negative 
bacteria.
Single nucleotide polymorphism typing and phylogenetic analysis
The phylogenetic relationship between 198 B. pertussis strains, isolated from the period 
1949 to 2008, was determined using 85 single nucleotide polymorphisms (SNPs) essentially 
as described before using the Sequenom technology [41]. Briefly, DNA was amplified by a 
multiplex PCR followed by single base primer extension reactions. Primer extension products 
were analyzed using MALDI-TOF mass spectrometry (a table with the SNPs is available 
from the authors). The choice of the SNPs was based on the complete genome sequences 
of the Tohama I strain and six Dutch strains, as described previously [24]. The SNPs were 
concatenated for each strain resulting in 31 unique sequence types (STs). The concatenated 
sequences were used to construct a tree with the Maximum Parsimony (MP) algorithm using 
Bionumerics v6.1 (Applied Maths, Sint-Martens-Latem, Belgium). Bootstrap analysis was 
performed with 1,000 replicates. 
Diversity index
The diversity index (DI) and 95% confidence interval (CI) of the STs were calculated using the 
Hunter and Gaston’s modification of the Simpson’s diversity index [45]. Results were generated 
using an online tool (V-DICE) provided by the Health Protection Agency’s Bioinformatics Unit 
(available via http://www.hpa.org.uk/).
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Gene loss
Gene loss based on comparative genomic hybridization and genome sequencing was available 
from previous publications for 65 strains [24,28]. For this work the genome sequence of an 
additional five strains was determined to assess gene loss.
Whole genome sequencing
Five novel genome sequences were derived from Dutch B. pertussis isolates, B0296, B0400, 
B0496, B0738 and B3405, using the Illumina Genome Analyzer system resulting in paired-end 
reads of 50 base pairs. The sequence data of these strains were submitted to the Sequence 
Read Archive (SRA) (accession number: SRA051375). 
SNP detection from sequence data
SNPs in 454 data were identified previously [24]. To identify SNPs in Illumina data, reads 
were mapped to the reference genome B. pertussis Tohama I [46] using Maq v0.6.6 [47]. 
SNPs detected in illumina data were filtered according to the following quality criteria: base call 
quality > 30, mapping quality > 30, fraction of reads with SNP > 0.90 and read depth > 4. The 
filtered SNP calls from illumina data and 454 data were combined into a single list of SNP loci 
and the allele of each locus in B. pertussis isolate was determined. This allowed recovery of 
some SNPs that were initially rejected in one isolate because of low confidence but with high 
confidence in a second isolate. Unmapped reads were mapped to the reference genome B. 
parapertussis 12822 and B. bronchiseptica RB50 [46] to identify regions that were not present 
in B. pertussis Tohama I.   Information on genes and protein sequences were retrieved from the 
sequenced genome B. pertussis Tohama I. Domain information and conserved positions were 
recovered from SMART (http://smart.embl-heidelberg.de) and Conserved Domain Database 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml). Subcellular localization was predicted 
by PSORTb version 3.0 (http://www.psort.org/psortb/). Information on uncharacterized proteins 
was found by BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Furthermore, a literature search 
in Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/) was performed to retrieve information on 
characterized genes. 
Statistical analysis
A Chi-square test was performed to compare the distribution of the three serotypes Fim2+, 
Fim3+, Fim2+, Fim3- and Fim2-, Fim3+ in the fim3-1 population and fim3-2 population. 
Results
Genetic relationship between Dutch strains isolated between 1949 and 2008
The genetic relationship between 198 Dutch strains, isolated between 1949 and 2008, was 
inferred using the 85 concatenated SNPs and the Maximum Parsimony (MP) algorithm (Fig. 1). 
Ninety eight Dutch strains were included in a previous study in which various typing methods, 
including SNP typing, were compared [41]. The tree was rooted with an 18323-like strain 
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(B0442) which is closely related to B. bronchiseptica, a species from which B. pertussis has 
evolved [48]. Thirty one sequence types (STs) were identified of which 15 were novel compared 
to our previous work [41]. Bootstrap values ranged from 52% - 100% (average 76%). 
The MP tree allowed us to investigate the genetic relationship between strains containing allelic 
variants of genes implicated in the adaptation of B. pertussis [10,23,39,44,49-51]: ptxP, ptxA, 
prn, fim2 and fim3 (Figure S1). The fim2 gene was omitted from this analysis, however, as 
very little allelic variation was observed in the Dutch population. Further, alleles for ptxP, ptxA, 
prn and fim3, which were found in low frequencies (≤ 2%), were included for the calculation of 
frequencies but are not shown in Fig. 1. Finally, prn2 and prn3 were combined, as switching 
between these alleles may occur with relative high frequency due to slipped strand mispairing 
in a repeated region.
Figure 1: Relationship between phylogeny and the accumulation of mutations in virulence genes. The 
Maximum Parsimony tree was based on 85 SNPs and 198 Dutch strains isolated between 1949 and 
2008. The 85 SNPs resolved the 198 strains in 31 sequence types (STs). Alleles for the pertussis toxin 
promoter (ptxP), the pertussis toxin A subunit (ptxA), pertactin (prn) and the serotype 3 fimbrial subunit 
(fim3) are indicated. The alleles prn2 and prn3 were combined as they are both non-vaccine types. 
Based on the ptxP, ptxA, fim3 and prn alleles, seven allele types (ATs), I – VII, could be distinguished. 
Coloured dots represent distinct ATs and arrows indicate changes between ATs. ATs used for the produc-
tion of the whole cell and acellular vaccines are blocked. Bootstrap values are indicated in the tree (this 
figure is available in color in the appendix).
The genetic relationship between the strains containing allelic variants revealed that the B. 
pertussis population evolved by a successive accumulation of mutations in the four genes. These 
mutations were found in the trunk of the tree, i.e. were fixed in the population and persisted until 
replaced by subsequent mutations. Further, there was a notable linkage between particular 
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alleles allowing us to define seven allele types (AT-I to AT-VII), comprised of different allelic 
combinations of the four genes which were observed in the Dutch B. pertussis population (Fig. 
1). The seven ATs can also be seen as seven clusters of closely related strains, as defined by 
the MP tree. Most differences between subsequent ATs were due to a single mutational event, 
either a point mutation, as in case for ptxP, ptxA and fim3, or the insertion or deletion of a 15 
base repeat, as in the case for prn. However, the differences between AT-I, AT-II on the one 
hand and AT-III on the other, involved more than two mutational events. These ATs lie close 
to the root of the tree, and we presume that our collection did not contain the (hypothetical) 
intermediates. The two strains used to produce the Dutch WCV belonged to AT-II and AT-III, 
both of which are found close to the root. The WCV was later replaced by ACVs derived from 
the 10536 and Tohama I strains, which belonged to, respectively, AT-II and AT-III [52,53], this 
work]. When travelling from the root to the tip of the tree, a gradual divergence between the 
two Dutch WCV strains and the B. pertussis population was observed with respect to the four 
genes. Except for prn, which contains three silent SNPs at positions 390, 828 and 831, all 
mutations in ORFs resulted in amino acid changes (Figure S1). 
Looking within particular ATs, it was clear that certain STs predominated. Of particular note are 
ST-7, ST-11 and ST12, which represent 76%, 76% and 92% of the strains within, respectively, 
AT-V, AT-VI and AT-VII (Fig. 1). Assuming this was not due to a sampling artefact, this suggests 
that other, as yet unidentified, mutations are responsible for fitness differences within ATs.
Temporal trends in AT frequencies in the Netherlands in the period 1949-2010
Next, we explored the temporal trends in AT frequencies in The Netherlands in the period 
1949-2010 (Fig. 2). For this, we determined the ATs for an additional 506 Dutch strains isolated 
between 1949 and 2010, resulting in a total of 704 strains for which the AT was known. This is 
an extension and update of previous work [23,39,44,54].
Before the introduction of vaccination in 1953, AT-II and AT-III predominated. As mentioned 
before, the strains used for production of the Dutch WCV and ACVs, belong to these ATs. 
Approximately ten years after the introduction of vaccination, AT-IV emerged which differed 
from AT-III by a non-silent point mutation in the ptxA gene (allele designation, ptxA1). This 
mutation resulted in a mismatch with the vaccine strains. AT-IV nearly completely replaced 
AT-II and AT-III, representing 60% to 90% of all isolates in the period 1962 to 1988. AT-IV 
was subsequently gradually replaced by AT-V. AT-IV and AT-V differ with respect to the prn 
alleles. While AT-IV contained the vaccine type allele prn1, AT-V harboured either prn2 or prn3. 
The three prn alleles code for three different protein variants. AT-V was first detected in the 
period 1973-1980 (frequency 11%), and reached high frequencies in the period 1991 to 1998 
(frequency 47%-70%). AT-V was replaced by AT-VI and AT-VII. While AT-V contained ptxP1, 
AT-VI and AT-VII contained a novel promoter allele, designated ptxP3. Strains with the ptxP3 
allele were first detected in 1988 and since 2001 more than 90% of the B. pertussis population 
was comprised of ptxP3 strains. Strains with the ptxP3 allele were associated with two fim3 
alleles, fim3-1 (the vaccine type) and fim3-2, designated as AT-VI and AT-VII, respectively. AT-
VII was first detected in 1996, increased in frequency to 62% in 2002 and then decreased in 
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frequency. Presently, 100% of the B. pertussis populations consist of AT-VI.
The rise and fall in AT-VII (and hence fim3-2) frequencies, suggested frequency-dependent 
selection. If this assumption is true, it implies that one amino acid change can cause a significant 
shift in the B. pertussis population in a few years. We explored this issue further by determining 
the frequency with which the fim3-2 allele was expressed. The fim2 and fim3 genes are subject 
to phase variation and switched on and off by insertions and deletions in a homopolymeric 
C-stretch in the promoter region [55]. Thus strains may express both fimbrial genes (i.e. carry 
the phenotype Fim2+, Fim3+), or more generally, express either fim2 or fim3 (resulting in the 
phenotypes Fim2+, Fim3- and Fim2-, Fim3+, respectively). If the switch from fim3-1 to fim3-
2 has driven the expansion of AT-VII, one would expect fim3-2 to be mainly associated with 
strains expressing fim3. This is indeed what we found. In the period 1995-2008, when fim3-2 
was detected in the Dutch B. pertussis population, 99% of the fim3-2 strains expressed fim3 (N 
74) (P < 0.0001). Only 1% of the Fim2+ Fim3- strains (N=81) contained a (silent) fim3-2 allele. 
Figure 2: Temporal trends in strain frequencies and notifications in the Netherlands in the period 1949-
2010. Strain frequencies are indicated by coloured lines. Strains were aggregated into allele types (ATs) 
defined by the combination of alleles for ptxP, ptxA, prn and fim3 as shown in the top of the graph. No 
distinction was made between strains with the prn2 and prn3 alleles. ATs are indicated by blocked Ro-
man numbers and allele changes resulting in differences between ATs are indicated. Non-vaccine type 
alleles are underlined. ATs found in one or two periods only, with a frequency lower than 15%, are not 
shown. If necessary, years were combined to increase the number of analyzed strains to at least 6. Note 
that due to this, the X-axis is not proportional. Changes in the vaccination program are indicated below 
the X-axis. From 1962 to 1999, four doses of WCV were given at the ages 3, 4, 5 and 11 months. In 
1999, the schedule was changed to 2, 3, 4 and 11 months. In 2001, a booster with an ACV was intro-
duced for 4 year olds and in 2005 the WCV was replaced by an ACV for all age categories. Between 
1975 and 1984, the WCV dose was temporarily reduced. Abbreviations: N, number of strains analysed; 
WCV, whole cell vaccine; ACV, acellular vaccine (this figure is available in color in the appendix).
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Genetic diversity
Decreases and increases in genetic diversity may reflect clonal expansion and strain 
diversification, respectively. Using the frequency of STs, we explored the relationship between 
variations in genetic diversity and AT frequencies (Fig. 3). For this, the diversity index (DI) based 
on the 31 STs was calculated for periods of approximately 10 years. Between the periods 1949-
1960 and 1961-1970, AT-IV expanded, largely replacing AT-II and AT-III. AT-IV differs from AT-II 
and AT-III in all four alleles and ptxA only, respectively. The expansion of AT-IV coincided with 
a decrease in DI from 0.48 to 0.25. The following two periods, 1961-1970 and 1971-1980, 
revealed only a slight increase in AT-IV frequency, while the DI was slightly reduced from 0.25 
to 0.24. Between 1971-1980 and 1981-1990 AT-IV decreased slightly in frequency while AT-V 
emerged. Between these periods an increase in DI was observed from 0.24 to 0.59. This may 
reflect diversification of AT-IV, which predominated for 27 years from 1962-1988. In the period 
1991-2000, AT-IV was reduced in frequency and mainly replaced by AT-V, although AT-VI and 
AT-VII also increased in frequency compared to the previous period. AT-IV and AT-V differ in 
prn alleles only, containing respectively prn1 and prn2 or prn3. Differences between these 
three alleles occur by deletions and insertion of 15 base repeats. Such mutations occur with 
higher frequencies than point mutations, possibly allowing a more polyclonal expansion and 
explaining why DI did not decrease between 1981-1990 and 1991-2000, but actually increased 
from 0.59 to 0.66. In the last two periods, 1991-2000 and 2001-2010 a significant expansion 
was observed of AT-VI and to a lesser extent of AT-VII. These expansions coincided with a 
decrease in DI from 0.66 to 0.35. The difference between AT-V and AT-VI is a single point 
mutation in ptxP, while AT-VII contains an additional mutation in fim3.
Figure 3: Frequency of allele types and genetic diversity of the Dutch B. pertussis population in the 
period 1949-2010. The diversity index (DI) and 95% confidence interval (CI) for each period, based 
on the sequence types (STs), were calculated using the Hunter and Gaston’s modification [45] of the 
Simpson’s diversity index and are indicated. Frequencies of allele types are calculated for each period 
and coloured as in Fig. 1. Significant differences in DI between periods are indicated with asterisks. Ab-
breviations: AT, allele type; N, number of strains; DI, diversity index; CI, 95% confidence interval (this 
figure is available in color in the appendix).
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In summary, changes in alleles due to SNPs were associated with decreases in genetic diversity 
in the bacterial population, suggesting clonal expansions. In contrast, changes in alleles due to 
variation in repeats were associated with a (slight) increase in genetic diversity, suggesting a 
polyclonal expansion.  These observations are consistent with the relative frequency in which 
point mutations and mutations in repeated regions occur.
The role of gene loss in adaptation of B. pertussis
The genomic content of B. pertussis strains is variable due to deletions which arise by 
homologous recombination between insertion sequence (IS) elements [27-32]. We investigated 
whether gene loss could explain the observed shifts in the B. pertussis populations. Comparative 
genomic hybridization (CGH) using microarrays [28,29] and whole genome sequencing [24, 
this work] has identified approximately 35 DNA loci which are deleted in one or more of the 65 
Dutch strains included in this study (Fig. 4). Thirty deletions were found in one to ten strains, 
while ten of these were observed in one strain only. Evidence for homoplasy was seen for 
eight deletions. As none of these thirty deletions were fixed in the population, they are probably 
neutral or deleterious.
Five deletions (BP0910-BP0934, BP1135-BP1141, BP1948-BP1966, BPP0511-BPP0512 and 
BPP2338-BPP2347) were fixed in the population, suggesting that these deletions are neutral 
or confer a selective advantage. Four out of five deletions (BP0910-BP0934, BP1135-BP1141, 
BPP0511-BPP0512 and BPP2338-BPP2347) were first found in AT-III, an AT which was found 
relatively close to the root and predominated in the pre-vaccination era (Fig. 1). The four 
deletions were absent in one vaccine strain (B0005), but present in the second vaccine strain 
(B0006). Thus if deletion of these loci reduces the antigenic profile of strains, they may increase 
fitness in vaccinated populations. Deletions encompassing BPP0511-12 or BPP2338-47 were 
already fixed in AT-III strains, while deletions encompassing BP0910-34 and BP1135-41 were 
observed in respectively 43% and 86% of strains belonging to AT-III. 
With a single exception, the fifth fixed locus (BP1948-BP1966) was found only in AT-VI and 
AT-VII. As noted before, this deletion is associated with ptxP3 strains [29]. The single exception 
concerns B0295, an atypical B. pertussis strain isolated in 1978 which harbours the ptxP1 
allele and contains one of the smallest B. pertussis genomes known [28]. 
In summary, of the deletions fixed in the bacterial population, four (BP0910-34, BP1135-41, 
BPP0511-12, BPP2338-47) were already present before large shifts were observed, excluding 
a role in driving these changes. A role for the fifth deletion (BP1948-66) in driving expansion of 
AT-VI and AT-VII cannot be excluded. 
114
Figure 4: Relationship between phylogeny and gene loss. Strains with their corresponding allele type 
(AT) and sequence type (ST) are shown in the left columns. Strains were clustered according to their 
position in the phylogenetic tree as shown in Fig 1. Colouring of ATs is as in Fig. 1. DNA loci with cor-
responding gene designations [46] are shown in the top row. The two strains used for the Dutch whole 
cell vaccine, B0005 and B0006, are indicated in the two bottom rows. Absence and presence of DNA 
loci are indicated by + and -, respectively and deletions showing homoplasy are indicated with asterisks 
in the top row. Abbreviations: AT, allele type; ST, sequence type; VS, vaccine strain used for the Dutch 
WCV (this figure is available in color in the appendix).
Comparative genomics
Our results showed that the alleles ptxA1, prn2/3, ptxP3 and fim3-2 were associated with 
clonal expansions, suggesting that they significantly affect strain fitness. However, we could 
not exclude the possibility that these alleles were hitchhiking with other, as yet unidentified, 
alleles which (also) increased fitness and which may be primarily responsible for the selective 
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sweeps. To address this issue, we analyzed the genomes of 11 Dutch clinical isolates, six 
of which were determined previously [24], and the Tohama I strain [46], representing all ATs 
except AT-I which was found only once in the Dutch B. pertussis populations. We identified 48 
SNPs that were linked to the alleles ptxA1, prn2/3, ptxP3 and fim3-2 in these 11 strains (Table 
S1). Using a larger number of strains (N=45) the degree of linkage was further assessed by 
DNA sequencing (Table S1). This revealed that the linkage percentage varied from 89% to 
100%. Of these 48 SNPs, 24 were assumed not to affect fitness as they were silent, located 
in pseudo-genes, in transposons or in intergenic regions downstream from ORFs. The latter 
SNPs were assumed not to affect expression of ORFs. The seven pseudogenes were initially 
defined on the basis of the Tohama I sequence [46], but we found that these genes were also 
inactivated in the two modern isolates B1917 and B1920. A possible role for the remaining 24 
SNPs was further explored (Table 1).
Eight of the 24 SNPs were uniquely associated with ptxA1. Affected ORFs coded for proteins 
located in the cytoplasm or periplasm (N=4 and 1, respectively). The subcellular localization 
of two proteins could not be predicted. One of the affected ORFs was known to be Bvg-
repressed. One SNP was located in an intergenic region between ORFs coding for an integral 
membrane protein and a GntR-family transcriptional regulator. As the SNP was located in a 
putative promoter region, it could affect expression of one or both ORFs. 
Ten SNPs were uniquely associated with the prn2/3 alleles. Affected ORFs coded for proteins 
located in the cytoplasm or inner membrane (N=2 and 4, respectively). The subcellular 
localization of one protein could not be predicted. One SNP was located in an ORF coding for a 
two component histidine kinase which was known to be Bvg-activated [56].  Three SNPs were 
located in putative promoter regions. One of these SNPs could affect transcription of the type 
III secretion system (TTSS) chaperone and effector genes, btcA and bteA and was described 
previously [24,57]. As the SNP was located in the putative TATA box of btcA it might primarily 
affect transcription of this gene. A second intergenic SNP was located in between two ORFs 
coding for an exported protein and a 30S ribosomal protein. The third SNP was located in the 
putative promoter region of a gene encoding 16S ribosomal DNA. 
Six SNPs were uniquely associated with the ptxP3 allele. Affected ORFs coded for proteins 
located in the inner membrane (N=2). The subcellular localization of three proteins could not 
be predicted. Two SNPs were located in putative promoter regions. One of these SNPs could 
affect transcription of an integral membrane transport protein. A second intergenic SNP was 
located proximal to the genes for glycyl tRNA synthetase alpha chain (glyQ) and a transporter. 
One SNP was located in an ORF coding for the Bvg-activated type three secretion system 
protein, BscI.
None of the 24 SNPs were uniquely associated with the fim3-2 allele.
In summary, the alleles ptxA1, prn2/3, ptxP3 were associated with SNPs which could affect 
both structure and regulation. The SNPs associated with ORFs which are Bvg-activated may 
be particularly interesting, since many Bvg-activated ORFs have been implicated in host-
pathogen interactions [58]. Further functional studies are required to determine if and how 
these polymorphisms affect strain fitness.
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Discussion
Phylogenetic analyses of Dutch strains isolated between 1949 and 2008 revealed a tree, the 
topology of which was very similar to that of trees derived for the human influenza A virus 
haemagglutinin genes [60], exhibiting a ladder-like structure with a long trunk and short side 
branches (Fig. 1). As remarked for the human influenza A virus haemagglutinin tree [60], the 
trunk corresponds to the progenitor lineage. Mutations that occur along the trunk are eventually 
fixed, persisting until replaced by subsequent mutations. In contrast, mutations that appear 
on side branches are eventually lost from the population. The mutations in four virulence-
associated genes ptxP, ptxA, prn and fim3 were found in the trunk of the tree and were fixed 
until they were replaced by novel mutations in the same gene. When travelling from the root 
to the tip of the tree, a gradual divergence between the two Dutch whole cell vaccine strains 
and the B. pertussis populations was observed with respect to the four genes. The distribution 
of ATs in the tree indicated that new genotypes emerged “de novo” rather than being selected 
from ancient reservoirs, implying a recent change in the B. pertussis niche, most likely caused 
by the introduction of vaccination. These results confirm and substantially extend our previous 
study in which we showed that ptxP3 strains arose recently from ptxP1 strains and spread 
worldwide [26,38,39,41].
Lan and co-workers used SNP typing to analyze a worldwide collection of 316 B. pertussis 
strains [40,61]. These authors found a similar relationship between the distribution of mutations 
in virulence genes and phylogeny and concluded that the observed changes in the B. pertussis 
population were consistent with selection by vaccine-induced immunity. Further, based on SNP 
typing, six B. pertussis clusters were identified of which the most recently evolved showed a 
worldwide distribution [61]. The latter cluster contained the ptxP3 strains, in accordance with 
our previous studies (see above). In line with our observations for Finland and the Netherlands 
[39], this group provided evidence that ptxP3 strains were associated with the resurgence of 
pertussis in Australia [40].
There was a notable linkage between the alleles of the four virulence-associated genes 
allowing us to define seven allele types (AT-I to AT-VII) which were observed in the Dutch B. 
pertussis population (Fig. 1). A plot of the frequency of these ATs revealed four large shifts in 
Dutch B. pertussis population in the period 1949-2010 (Fig. 2). Each shift was associated with 
an allele change and resulted largely in the replacement of the extant population by the novel 
AT (i.e. a clonal sweep). The time which elapsed between the first isolation of a particular 
AT and when it reached its highest frequency was found to be 19, 16, 12 and 6 years for AT-
IV, AT-V, AT-VI and AT-VII, respectively. Comparison of temporal trends in genetic diversity 
(based on STs) and AT frequencies suggested that point mutations in the four virulence 
genes were associated with clonal expansions, while mutations in a repeated region of prn 
resulted in a more polyclonal expansion, consistent with the relative frequencies in which these 
mutations arise. An effect of vaccination on the genetic diversity of B. pertussis populations 
was noted before [38,52,54,62]. These studies were, however, based on IS1002 fingerprinting 
and multiple-locus variable-number tandem repeat analysis (MLVA), methods which are less 
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discriminatory than SNP typing. The first shift, in which AT-II and AT-III were replaced by AT-
IV, was observed approximately 12 years after introduction of vaccination in 1953. No other 
obvious relationship between changes in the vaccination programme and later shifts in ATs 
were observed. However, the most important change, the replacement of the WCV by ACVs 
was implemented relatively recently in 2005 and it may be too early to expect an effect on the 
pathogen population structure.
Within ATs, we observed large differences in the frequencies of STs. Assuming this was not 
due to a sampling artefact, this suggests that other, as yet unidentified, polymorphisms may 
be responsible for fitness differences between ATs and contributed to the clonal sweeps. Such 
polymorphisms may include horizontally acquired genes, insertions or deletions, chromosomal 
rearrangements and as yet unidentified SNPs. The sequencing of 12 B. pertussis genomes did 
not provide evidence for recent horizontal acquisition of genes. The technology we used for 
genome sequencing did not allow the accurate determination of small (~50 bases) insertions 
and deletions or large rearrangements. However, large deletions have been identified with 
CGH [27-32] and genome sequencing [24, this work]. Gene loss has been suggested to play 
a role in adaptation of B. pertussis. Our phylogenic analysis revealed that of the 35 deletions 
identified in Dutch strains in previous and this work, five (14%) were fixed in the pathogen 
population (Fig. 4). Their fixation suggests that these five deletions may have a positive effect 
on strain fitness. As four of the deletions were already predominantly present in the pre-
vaccination era, it seems unlikely that they were the cause for the clonal expansions observed 
after the introduction of vaccination. The fifth deletion, comprising 18 ORFS (BP1948-66), was 
linked to the ptxP3 allele as noted before [29] and may have contributed to the expansion of 
ptxP3 strains. The analyses of the deleted ORFs did not provide clues as to how their loss may 
increase strain fitness. 
We used comparative genomics and targeted sequencing to determine if additional SNPs 
were linked to clonal sweeps. Forty eight SNPs were found with a linkage percentage of ≥ 
89% to the ptxA1, prn2/3 and ptxP3 or fim3-2 alleles. After filtering out silent SNPs, SNPs 
in pseudogenes and SNPs in intergenic regions located downstream of ORFs (hence not 
involved in transcription initiation), 24 SNPs remained. Of these 24 SNPs, eight, ten and six 
were associated with, respectively, ptxA1, prn2/3 and ptxP3 (Table 1). None of the 24 SNPs 
were linked to fim3-2. Only the three SNPs, possibly affecting regulation or structure of Bvg-
activated genes will be discussed, as many Bvg-activated proteins have been shown to be 
involved in host-pathogen interactions [58]. One SNP, associated with prn2/3 could affect 
transcription of the type III secretion system (TTSS) chaperone and effector genes, btcA and 
bteA. For B.bronchiseptica it has been shown that BteA is translocated into the host cell and is 
cytotoxic for a wide range of mammalian cells [63,64]. This SNP, identified previously [24,57], 
was also observed in five prn2 strains, but not in five prn1 strains, isolated in Japan [57]. 
Interestingly, in the Japanese study it was found that bteA was expressed at a higher level in 
the prn2 strains compared to the prn1 strains. The lower level of expression in prn1 strains was 
associated with an IS insertion upstream of bteA. It was suggested that the higher expression of 
bteA in prn2 strains may have contributed to its emergence in Japan. An IS element upstream 
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of bteA has not been found in the sequenced genome of other prn1 strains [24,46,65]. We 
are currently investigating the effect of the TTSS-SNP on expression. The second SNP was 
linked to ptxP3, located in bscI and resulted in an amino acid change. The bscI gene is part 
of a large TTSS cluster, bsc, which is Bvg activated and is involved in secretion of proteins 
directly into host cells [66,67]. The homolog of bscI in Yersinia is essential for secretion of 
proteins [66]. The allele was designated bscI2. The linkage between bscI2 and ptxP3 was not 
absolute and found in nine out of the 14 ptxP3 strains investigated. Therefore this SNP cannot 
be responsible for the early phase of the clonal expansion of ptxP3 strains. However if this 
SNP has a positive effect on the strain fitness it may contribute to a further expansion of strains 
with the ptxP3 allele. 
The third SNP was located in a histidine kinase of a two component sensory transduction 
system and is partially linked to prn2/3. Of the investigated strains 3 out of 12 prn1 strains 
and all prn2/3 strains have this SNP. This SNP may have contributed to the expansion of 
prn2/3 strains as two component sensory transduction systems are important in adapting to 
environmental stimuli. Indeed, the major regulator of virulence genes in B. pertussis, BvgAS, 
belongs to this category of regulatory systems [68]. Although the remaining SNPs are not 
located in (known) virulence associated genes, this does not exclude a role in adaptation. 
Further studies of the identified loci may elucidate the role of these polymorphisms in the 
ecology of B. pertussis. 
Several lines of evidence support a role for the ptxA, prn2/3, ptxP3 and fim3-2 alleles in 
driving the observed clonal sweeps, although the above described, or as yet to be identified 
polymorphisms, may also have played a role. All mutations in ORFs that caused transitions 
between alleles resulted in amino acid changes. Further, the polymorphic region which 
distinguishes Prn1, Prn2 and Prn3 has been shown to be part of a B-cell epitope [37,69], and 
variation in this region was shown to affect vaccine efficacy in a mouse model and antibody 
binding [37,70]. The variable amino acid which distinguishes Fim3-1 and Fim3-2 is part of a 
seven residue long peptide recognized by human sera [71]. Significantly, the corresponding 
codon is also polymorphic in B. bronchiseptica (Fig. S1). B. pertussis fimbrial genes are subject 
to phase variation and strains may contain silent fim3 genes [55]. If the switch from fim3-1 to 
fim3-2 has driven a clonal sweep, one would expect fim3-2 to be mainly associated with strains 
expressing fim3. This is indeed what we found, as 99% of the fim3-2 strains produced Fim3 
fimbriae. It is plausible that increased Ptx production, associated with the ptxP3 allele has also 
driven a clonal sweep. Ptx has been shown to suppress both innate and acquired immunity in 
mice [72-76] and increased production may be particularly important in a population primed 
by vaccination [39]. We have found that polymorphism in ptxP affects colonization of mice 
[77]. It is likely that the mutations have a cumulative effect. In a series of elegant experiments 
with isogenic strains differing only in ptxA or prn, Komatsu and co-workers [33] showed that 
mismatches with vaccine strains in these genes reduced vaccine efficacy in a mouse model. 
Interestingly, a mismatch in both genes was required to have a measurable effect in vivo.
In conclusion, our work provides evidence that B. pertussis has adapted by the accumulation 
of small mutations. It seems that, even in the context of complex bacterial genomes, small 
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mutations in single genes can have a significant effect on strain fitness, resulting in clonal 
sweeps within a period of six to 19 years. As illustrated by the emergence of ptxP3 strains, 
the effect may be large enough to be of relevance for public health [39,40]. We have identified 
several novel SNPs which may have contributed to the adaptation of B. pertussis. Clarification 
of the role of these SNPs may elucidate further how B. pertussis has persisted and resurged 
in the phase of intensive vaccination, and ultimately allow us to improve pertussis vaccines on 
a rational basis [9,39].
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Figure S1: Variation in the Dutch B. pertussis population in the genes for the pertussis toxin promoter 
(ptxP), the pertussis toxin A subunit (ptxA), fimbrial subunit 2 (fim2), fimbrial subunit 3 (fim3) and pert-
actin (prn). Dots and dashes indicate identity and gaps, respectively. Positions with silent mutations in 
prn are shaded. The initiation codon for ptxA has been underlined in the ptxP sequence. Numbering 
of the nucleotides in ptxA, fim3, fim2 and prn is relative to the start of the open reading frame. In the 
prn sequences, the three types of repeated sequences and the RGD sequence, involved in attachment 
to mammalian cells, are underlined [6,23,44]. Allele fim3-5, which is found in B. bronchiseptica is also 
indicated. 
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Gene loss has been suggested to play an important role in the adaptation of B. pertussis 
and in chapter 2 of this thesis, we analyzed clinical isolates that to not express the tracheal 
colonization factor A gene (TcfA), which codes for an autotransporter involved in colonization of 
the trachea [1,2]. Strains not expressing tcfA were found in three different European countries 
(Belgium, the Netherlands and the United Kingdom) and belonged to different lineages based 
on multiple-locus variable-number tandem repeat analysis (MLVA). We noted two different 
mechanisms by which B. pertussis lost its ability to produce tcfA, recombination between direct 
repeats and small mutations in a homopolymeric G-track. These mechanisms, respectively, 
irreversibly and reversibly inactivate tcfA. It is conceivable that inactivation or loss of tcfA 
reflects the ongoing reduction of the B. pertussis genome as found in previous studies based 
on microarray experiments and whole genome sequencing [3-11]. But we found no evidence 
that the tcfA mutants spread through the population and hence that the mutation was fixed. 
Our results suggest that this mutation does not significantly contribute to the fitness of B. 
pertussis and may be deleterious in the long term. However, temporary loss of tcfA expression 
may confer an advantage during particular stages in the transmission cycle of B. pertussis, i.e. 
confer a transient increase in fitness. Adhesins such as TcfA are involved in attachment to the 
human epithelium while spread through the host and transmission require detachment. Thus 
transient loss of expression of adhesins may facilitate these processes. Further, vaccination 
with a WCV was introduced in the Netherlands in the 1950s and the presence of TcfA in 
the WCV may have resulted in immune selection of TcfA-deficient strains. Indeed, TcfA is 
highly polymorphic [12] suggesting that an immune response targeting TcfA has a significant 
effect on strain fitness. WCVs have now been largely replaced by ACVs in western countries 
which do not contain TcfA, but Ptx in combination with one or more of the following proteins; 
FHA, Fim2, Fim3 and Prn. The introduction of ACVs may result in new adaptations in the B. 
pertussis population especially as ACVs induce high antibody levels against a few B. pertussis 
proteins only. Indeed, in France, Japan and the Netherlands, strains have been found that 
do not express Prn due to IS481 insertion or deletion of a part of Prn [13,14, our unpublished 
results]. These observations underline the importance of a continued monitoring of changes 
in the B. pertussis population, not only by gene typing, but also by assessing whether genes 
are expressed. Further, studying the genetic relationships between the strains harbouring 
mutations is also important to establish whether mutations are disseminated and fixed in the 
population.
In chapter 3 of this thesis, we re-investigated the cause of the first whooping cough epidemic 
in the Netherlands after the introduction of vaccination in 1953. The epidemic occurred in the 
period 1983-1987 and followed a reduction of the vaccine dose from 16 IOU/ml to 10 IOU/
ml which was implemented in 1975. At the time it was suggested that the epidemic was a 
surveillance artifact caused by changes in diagnostic procedures and increased surveillance 
and the reduction of the vaccine dose was downplayed as possible cause [15]. In previous 
studies, we have shown that vaccination may significantly affect the B. pertussis population 
[16,17]. An effect of vaccination of the B. pertussis populations has since then been observed 
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worldwide [18-22]. Therefore, we reasoned that if lowering of the vaccine dose in the period 
1975-1984 had reduced host population immunity (and consequently resulted in increased 
notifications), this may be reflected in changes in the B. pertussis population. Indeed, our data 
showed significant changes in the B. pertussis population in the period 1983-1987 following the 
lowering of the vaccine dose. In particular, shifts in serotypes and MLVA types were associated 
with the increased notifications. Shifts in serotypes have been associated with changes in 
population immunity in several studies [23-25]. Our results provide evidence that the change 
in the vaccine dose affected host immunity and, consequently, contributed to an increase in 
pertussis morbidity. Further, we showed that fimbrial serotyping and MLVA typing of strains 
can be used as early warning for pertussis epidemics. Importantly, our work illustrates that 
strain surveillance is essential to interpret changes in the disease burden caused by infectious 
agents [26,27]. It is therefore unfortunate that in many studies on pertussis outbreaks, typing 
of strains is neglected [28-30].
In chapter 4 of this thesis, costs and benefits of variation in the virulence factor Prn were 
investigated. Several functions for Prn have been suggested such as adhesion and immune 
suppression which may be beneficial for B. pertussis [1]. However, antibodies against Prn 
contribute to protective immunity [31,32] and therefore production of Prn also involves costs in 
the sense that it decreases bacterial fitness. After introduction of the WCV in 1953, antigenic 
divergence was observed between vaccine strains and circulating strains. Strains harbouring 
the vaccine type Prn1 were replaced by strains with the non-vaccine types Prn2 and Prn3 
[33,34]. The strains with the non-vaccine types of Prn were first isolated in the 1980s. Nowadays, 
Prn2 strains dominate worldwide [35]. We suggested that the introduction of vaccination 
has changed the competitive balance between strains carrying Prn variants, resulting in the 
observed shifts. To investigate this hypothesis, we compared the colonizing ability of Prn 
variants in the mouse model. As several studies suggested that Prn is not required for infection 
of mice [36,37], we first reinvestigated whether Prn played a role in the colonization of mice. 
We found that inactivation of Prn significantly reduced colonization of the lungs and the trachea 
of mice by B. pertussis. Moreover, we showed that Prn1 strains were better colonizers of the 
mouse lung compared to Prn2 and Prn3 strains. No significant difference in colonizing ability 
was observed between Prn2 and Prn3 strains, however. These observations suggest that, if 
B. pertussis is mainly transmitted by naïve populations as was probably the case before the 
introduction of vaccination, Prn1 strains are fitter than Prn2 or Prn3 strains. The higher fitness 
of Prn1 strains may be due to a better fit with host receptors. Introduction of vaccination shifted 
the competitive balance towards the non-vaccine type Prn variants, Prn2 and Prn3. We further 
speculate that the predominance of Prn2 over Prn3 is caused by a higher degree of cross-
immunity induced by Prn1 against Prn3 strains compared to Prn2 strains [38]. However, it is 
also possible that Prn2 shows a better fit to the host receptor than Prn3. This work suggests 
that inclusion of Prn2 in ACVs may improve their efficacy. Recently, strains have been found in 
France, Japan and the Netherlands that do not express Prn [13,14, our unpublished data]. We 
suggest that this is due to the replacement of WCVs by ACVs, which contain Prn. ACVs induce 
132
high titers against a few antigens, whereas WCV induce lower titers against a very broad range 
of antigens. Thus this switch has again changed the fitness landscape, possibly in favour of 
Prn deficient strains. The first Prn deficient strains were observed in the Netherlands in 2010. 
As yet the prevalence of these strains is relatively low (6%). If the prevalence of Prn strains 
increases, this may significantly affect vaccine efficacy. 
Typing of bacterial pathogens is important for contact tracing, to identify successful clones 
during epidemics, to establish genetic relationships and to study pathogen evolution. Further, 
as shown in chapter 3, typing can be used as an early warning system for pertussis epidemics. 
single nucleotide polymorphism (SNP) typing has been used extensively to study the evolution, 
spread and phylogeography of bacterial pathogens and can be seen as the Gold Standard 
against which other methods can be compared [39]. The two typing techniques currently used 
to study B. pertussis populations are pulsed-field gel electrophoresis (PFGE) and  MLVA which 
both have drawbacks. PFGE is a laborious technique and difficult to standardize. The latter 
makes inter-laboratory comparisons of PFGE patterns problematic. The disadvantage of MLVA 
is that it has a low discriminatory power. In chapter 5 of this thesis, we describe a SNP typing 
method using 87 SNPs which were derived from six Dutch B. pertussis genomes and the 
Tohama I sequence [5,11]. The SNP typing method was compared to PFGE and MLVA. We 
showed that SNP typing was phylogenetically more informative compared to PFGE and MLVA. 
Further, in contrast to PFGE, SNP typing is readily standardized, allowing inter-laboratory 
comparisons. We have used the SNP typing method to study the evolution of the ptxP3 strain, 
which contains a novel allele for the pertussis toxin promoter (chapter 6). Our study showed that 
ptxP3 strains isolated from different continents formed a monophyletic lineage which evolved 
recently from the ptxP1 strains, as was later confirmed by other studies [40]. Two predominant 
ptxP3 subtypes were identified which spread worldwide. This work illustrated how the use of 
SNP typing may enhance our understanding of the evolution of B. pertussis, in particular the 
evolution and global epidemiology of the ptxP3 strain. The SNP typing method we developed 
is now being used to study the effect of different vaccination programs on the emergence of 
vaccine-adapted strains in Europe. 
Pertussis toxin (Ptx) is a major virulence factor of B. pertussis and is known to cause leukocytosis 
and suppression of the host immune response [41-44]. Ptx is included in all currently used ACVs 
as antibodies against Ptx are associated with protective immunity [31,32]. After introduction 
of vaccination in 1953, antigenic divergence was observed between vaccine strains and 
circulating strains with respect to Ptx [12,34]. We hypothesized that adaptation may involve 
both the (antigenic) structure of surface proteins and their regulation. Therefore we investigated 
polymorphisms in the promoter for Ptx (ptxP) in chapter 6. Our work revealed a high degree of 
polymorphism in ptxP. Further we observed a selective sweep in which the predominant ptxP1 
allele was replaced by the ptxP3 allele. Interestingly, the increase in frequency of ptxP3 strains 
was closely associated with the resurgence of pertussis in the Netherlands observed since 
1996. This suggests a large impact of the ptxP3 strain on public health. In vitro studies showed 
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that ptxP3 strains produced more Ptx than ptxP1 strains. Consistent with this, epidemiological 
data suggested that ptxP3 strains are more virulent compared to ptxP1 strains. Our data 
suggest that the ptxP3 strain emerged in the 1970s or 1980s. Nowadays, this strain is found 
worldwide and predominates in many European countries, Asia, the Americas and Oceania 
[4,40,45, chapter 5]. The ptxP3 strains have recently been associated with pertussis outbreaks 
in Australia [46]. Our work underlines the importance of Ptx in transmission of B. pertussis and 
points to ways to improve pertussis vaccines: to control pertussis in an effective way, a longer 
persistence of Ptx neutralizing antibodies after vaccination is needed. This may be achieved 
by replacing the chemically detoxified Ptx by a genetically detoxified Ptx, as the latter has been 
shown to be more immunogenic [35,47,48]. Our work also suggests that the amount of Ptx in 
pertussis vaccines is an important criterion for selection of the of pertussis vaccines [35,47]. 
In chapter 7, we investigated how more than 60 years of vaccination has affected the Dutch B. 
pertussis population by combining data from phylogeny, comparative genomics and temporal 
trends in strain frequencies. The focus of this chapter was on the ptxA, prn, fim3 and ptxP genes, 
genes that code for antigens that are included in the currently used ACVs. Small mutations in 
these genes resulted in antigenic divergence between vaccine strains and circulating strains 
and these mutations were associated with clonal sweeps which suggests increased strain 
fitness. Phylogenetic analysis based on SNPs revealed a stepwise adaptation in which these 
mutations accumulated. Large deletions due to gene loss have been suggested to play a 
role in adaptation of B. pertussis [10,11] and in chapter 7 we showed that only five out of 35 
deletions were fixed in the population. Only one of these deletions may have contributed to a 
clonal sweep after the introduction of vaccination. As previously noted [7], this deletion was 
associated with the ptxP3 allele. To identify additional polymorphisms which could increase 
fitness, complete genomes of Dutch clinical isolates, representing successful lineages, were 
compared. No evidence was found for the acquisition of novel genes. However, several novel 
SNPs were identified which may have contributed to adaptation. Further functional studies are 
required to determine if and how these polymorphisms affect strain fitness. In this chapter, we 
provided evidence that small mutations, even SNPs, can drive large changes in the populations 
of bacterial pathogens. We suggest that the combination of antigenic divergence between 
vaccine strains and clinical isolates and increased Ptx production can delay an effective 
immune response in vaccinated hosts. 
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Implications for vaccine policy 
The B. pertussis adaptation with the largest impact on public health is probably the shift from 
ptxP1 to ptxP3 strains in the 1990s (chapter 6). The ptxP3 strains represent a highly successful 
lineage which has spread worldwide in a short period of time and has been implicated in 
increased pertussis notifications in several countries. The ptxP3 allele is associated with 
an increased production of Ptx, a toxin known to suppress host defenses. Therefore, the 
persistence of Ptx antibodies after vaccination is of crucial importance in controlling pertussis. 
This implies that lowering the Ptx dose, as in adult pertussis vaccines to reduce side effects, 
should be balanced against a possible loss in long term efficacy. Further, current ACVs can be 
improved by replacing chemically detoxified Ptx by genetically detoxified Ptx [48]. Genetically 
detoxified Ptx is more immunogenic compared to chemically detoxified Ptx [49,50]. In addition 
to the mutation which resulted in ptxP3, we identified several other mutations, in particular in 
the genes for ptxA, prn and fim3, which were associated with clonal expansions of B. pertussis, 
providing further targets for vaccine-improvement. Thus, ACVs may be improved by including 
protein variants which circulate in current populations; PtxA1, Prn2 and Fim3-2. Together, these 
changes may significantly lengthen the duration of protection afforded by ACVs. Another way 
to improve pertussis vaccination in the long term is the use of a live attenuated B. pertussis 
strain as a single-dose nasal vaccination [51]. Importantly, in contrast to ACVs, this attenuated 
live vaccine also protects against B. parapertussis [52]. Finally, our work shows that strain 
surveillance is an important public health tool, as it identifies successful clones, vaccine 
escape mutants and can serve as an early warning system for epidemics. Therefore, strain 
surveillance should be an integral part of the evaluation of the National Immunization Program, 
even more so when changes in the program are implemented. 
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Kinkhoest wordt veroorzaakt door de bacterie Bordetella pertussis en is een ernstige, zeer 
besmettelijke infectie aan de bovenste luchtwegen. Minder ernstige en minder frequente 
infecties kunnen worden veroorzaakt door andere Bordetella species, Bordetella parapertussis, 
Bordetella bronchiseptica en Bordetella holmesii. Kinkhoest was in het begin van de 20e eeuw 
een van de meest voorkomende kinderziekten totdat er in het begin van de jaren 50 is gestart 
met vaccineren. Kinkhoest verloopt het meest ernstig bij pasgeborenen die nog niet, of nog 
niet volledig, zijn gevaccineerd. Bij kinkhoest wordt een aantal fasen onderscheiden. De eerste 
fase van de ziekte wordt gekenmerkt door weinig specifieke symptomen zoals verkoudheid en 
milde koorts. Deze fase wordt gevolgd door de kenmerkende “kinkende” hoest, een periode 
die weken tot maanden kan duren waarbij taai slijm wordt opgehoest. Pasgeborenen en kleine 
kinderen kunnen dit taaie slijm niet ophoesten als gevolg van ademhalingsproblemen, soms 
met de dood tot gevolg. 
Behandeling van kinkhoest met antibiotica is alleen zinvol wanneer er gestart wordt met de 
behandeling binnen 2 of 3 weken na de eerste symptomen. Na 3 weken zijn de nasopharynx 
en de longen weer schoon van bacteriën en worden de typische symptomen veroorzaakt door 
toxines die inmiddels al door de bacterie zijn uitgescheiden. 
In de jaren 50 is er gestart met vaccineren tegen kinkhoest met zogenaamde whole cell vaccins 
(WCVs). Deze vaccins bestaan uit hele, gedode kinkhoestbacteriën en hebben geleid tot een 
drastische afname van het aantal kinkhoestgevallen in de jaren daarna. Destijds werd er gestart 
met het vaccineren op de leeftijd van 3, 4 en 5 maanden en werd er een booster gegeven op 
12 maanden. Tegenwoordig wordt er gevaccineerd op de leeftijd van 2, 3 en 4 maanden om 
de periode waarin de zuigeling niet of onvolledig beschermd is te verkorten. Tevens wordt er 
een booster gegeven op 11 maanden. Als gevolg van de negatieve publiciteit over de WCVs 
en de bijwerkingen zijn er in de jaren 90 acellulaire vaccins (ACVs) ingevoerd, bestaande uit 
gezuiverde eiwitten van B. pertussis. In eerste instantie werd in Nederland in 2001 alleen een 
acellulaire booster op 4 jaar ingevoerd maar sinds 2005 worden alle zuigelingen op 2, 3, 4 en 
11 maanden gevaccineerd met ACVs. Het aantal geregistreerde bijwerkingen is als gevolg van 
de invoering van het ACV aanzienlijk verlaagd. 
Al voor de invoering van vaccinatie vertoonden kinkhoestaangiften een cyclus, waarbij 3-5 
jaarlijkse pieken in aangiften werden afgewisseld met perioden waarin kinkhoest veel minder 
voorkwam. De kinkhoestpieken zijn na de invoering van vaccinatie veel kleiner geworden. 
Echter, in 1996 nam in Nederland het aantal geregistreerde kinkhoestgevallen plotseling enorm 
toe. Een toename in kinkhoestaangiften is ook gevonden in andere landen met een hoge 
vaccinatiegraad zoals Australië, de Verenigde Staten, Noorwegen en Israël. Uit serologisch 
onderzoek blijkt bovendien dat er, ondanks vaccinatie, sprake is van een hoge circulatie 
van de kinkhoestbacterie in Nederland en andere landen. Een Nederlandse studie laat een 
infectiefrequentie zien van meer dan 9% in 2006-2007 voor de populatie ouder dan 9 jaar. 
Omdat adolescenten en volwassenen die geïnfecteerd raken met de kinkhoestbacterie vaak 
een asymptomatische of mildere infectie doormaken wordt de infectie vaak niet herkend als 
kinkhoest. Adolescenten en vooral volwassenen zijn een belangrijke bron van infectie voor 
zuigelingen voor wie kinkhoest levensbedreigend kan zijn.
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Er worden verschillende oorzaken genoemd voor de aanhoudende toename van het aantal 
kinkhoestaangiften. De diagnostiek van kinkhoest is sterk verbeterd en huisartsen zijn alerter 
op het voorkomen van de infectie waardoor er vaker op kinkhoest wordt getest. Verder is de 
duur van bescherming na vaccinatie niet levenslang, immuniteit na vaccinatie verdwijnt na 
5-10 jaar. Uit RIVM onderzoek is gebleken dat aanpassing van de bacterie aan vaccinatie 
ook een oorzaak is van de toename van kinkhoest. Zowel in Nederland als in andere landen 
zijn grote verschuivingen gevonden in de B. pertussis populatie na invoering van vaccinatie. 
Deze verschuivingen zijn vooral te zien in de virulentie factoren van B. pertussis, de eiwitten 
die belangrijk zijn voor infectie en transmissie; fimbriae (Fim2 en/of Fim3), pertussis toxine 
(Ptx) en pertactine (Prn). Antilichamen opgewekt met deze eiwitten bieden bescherming tegen 
kinkhoest en deze eiwitten zijn daarom onderdeel van de ACVs die wereldwijd worden gebruikt. 
Er zijn kleine verschillen tussen de eiwitten die in het vaccin worden gebruikt en de eiwitten 
die gevonden worden in circulerende stammen. Het is waarschijnlijk dat deze mismatches de 
effectiviteit van de vaccins verminderen. Experimenten in muizen wijzen daar inderdaad op.
Het doel van het onderzoek dat beschreven wordt in dit proefschrift was om meer inzicht te 
krijgen in de evolutie van de Nederlandse B. pertussis populatie in de afgelopen jaren. We 
hopen hierdoor meer te weten te komen over de verschillende strategieën die de bacterie 
gebruikt heeft om zich te kunnen handhaven in een populatie met een hoge vaccinatiegraad. 
Op basis van deze kennis kunnen dan gerichte tegenmaatregelen worden genomen. 
In hoofdstuk 2 worden stammen geanalyseerd die een virulentie eiwit van B. pertussis, de 
tracheale kolonisatie factor A (TcfA), niet meer maken. In een muismodel model is aangetoond 
dat dit eiwit belangrijk is om de ademhalingswegen te koloniseren. Het voorkomen van 
stammen zonder TcfA wijst er echter op dat de bacterie onder sommige omstandigheden 
zich ook zonder dit eiwit kan handhaven. Ons onderzoek toonde aan dat B. pertussis twee 
verschillende mechanismen gebruikt om TcfA te inactiveren. Het TcfA gen kan in zijn geheel 
verwijderd worden uit het genoom van de bacterie doordat er een deletie ontstaat tussen twee 
identieke DNA sequenties. Daarnaast kunnen ook kleine veranderingen in de DNA sequentie, 
puntmutaties, ontstaan waardoor het TcfA niet meer wordt gemaakt. De stammen die geen TcfA 
produceren zijn afkomstig uit Nederland, België en Engeland en bleken niet epidemiologisch 
gerelateerd. Dit betekent dat de mutaties in het TcfA gen meerdere keren, in verschillende 
stammen, is ontstaan. De mutatie werd maar in een klein aantal stammen gevonden wat 
suggereert dat deze deletie geen significante bijdrage heeft geleverd aan de aanpassing van 
B. pertussis aan vaccinatie.
In hoofdstuk 3 zijn de oorzaken van de kinkhoestepidemie uit de jaren 80 onderzocht. In 
de periode 1983-1987 werd een verhoogd aantal kinkhoestgevallen geregistreerd. Tevens 
was het aantal ziekenhuisopnames in diezelfde periode verhoogd. Gedurende de periode 
1975-1984 was de vaccindosis verlaagd om de bijwerkingen van het vaccin te verminderen. 
Op het moment dat de vaccindosis weer verhoogd werd tot oorspronkelijk niveau, verdween 
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de epidemie. Destijds werd er gesuggereerd dat de waargenomen toename van het aantal 
kinkhoestgevallen een artefact was ten gevolge van de verbeterde diagnostiek die in de jaren 
80 werd ingevoerd. De verlaging van de vaccindosis als oorzaak werd gerelativeerd. Aan de 
hand van de verschuivingen in de B. pertussis populatie gedurende de epidemische periode 
hebben wij aannemelijk kunnen maken dat het hier om een echte epidemie ging. Sommige 
verschuivingen in de B. pertussis populatie die wij waarnamen zijn gevonden in andere landen 
toen de populatieimmuniteit afnam. Verschuivingen in de populatie waren al zichtbaar voordat 
het aantal kinkhoestgevallen toenam, dus deze studie heeft laten zien dat kiemsurveillance 
gebruikt kan worden om vroegtijdig te waarschuwen tegen kinkhoestepidemieën.
In hoofdstuk 4 hebben we onderzocht waarom een bepaald pertactine type domineert in 
gevaccineerde populaties. Pertactine is een belangrijk virulentie eiwit van B. pertussis en een 
van de componenten van het ACV. Het vaccin bevat pertactine type 1, Prn1, terwijl in de 
populatie pertactine type 2 (Prn2) en type 3 (Prn3) circuleren. In muis experimenten is de 
functie van pertactine bestudeerd door het pertactine gen te inactiveren. Vervolgens werd naar 
het effect van deze mutatie gekeken in de muislong. Hierbij bleek dat de pertactine mutant 
minder goed in staat was de long te koloniseren ten opzichte van een niet gemuteerde stam. 
Het muismodel werd ook gebruikt om de kolonisatie van de longen met Prn1, Prn2 en Prn3 
stammen met elkaar te vergelijken. Hieruit bleek Prn1 stammen beter in staat zijn dan Prn2 
en Prn3 stammen de muislong te koloniseren. Wij speculeren dat het gebruik van vaccins met 
Prn1 dit voordeel teniet heeft gedaan, waardoor Prn2 stammen, die minder goed bestreden 
worden door het vaccin, zijn opgekomen. Deze studie suggereert dat opname van Prn2 in het 
vaccins, de vaccineffectiviteit zal verbeteren.
In hoofdstuk 5 wordt een nieuwe typeringsmethode beschreven om B. pertussis populaties 
te kunnen bestuderen. Bij deze techniek wordt gebruik gemaakt van kleine verschillen 
tussen genomen, single nucleotide polymorphisms (SNPs). De nieuwe SNP methode werd 
vergeleken met de bestaande typeringsmethoden, namelijk pulsed-field gel electrophorese 
(PFGE) en multiple-locus variable-number tandem analysis (MLVA). Uit dit onderzoek bleek 
dat de SNP methode informatiever en betrouwbaarder was dan PFGE en MLVA. Verder werd 
de SNP methode gebruikt om de evolutie van de ptxP3 stam te onderzoeken. De ptxP3 stam 
is geassocieerd met kinkhoestuitbraken in een aantal landen, waaronder Nederland. Uit dit 
onderzoek bleek dat de ptxP3 stammen die geïsoleerd zijn uit verschillende landen wereldwijd 
onderling nauw verwant zijn en recent zijn ontstaan uit de ptxP1 stam. 
In hoofdstuk 6 is de oorzaak van de 1996 epidemie verder onderzocht aan de hand van de 
invloed van de mutatie in de ptxP3 stam op de productie van pertussis toxine (Ptx). Ptx is een van 
de belangrijkste virulentie factoren van B. pertussis, het veroorzaakt leukocytose en onderdrukt 
het immuunsysteem. Uit dit onderzoek bleek dat de ptxP3 stam meer Ptx produceert dan de 
ptxP1 stam. Tevens is de ptxP3 stam geassocieerd met een hoger aantal ziekenhuisopnames 
en sterftegevallen vergeleken met de ptxP1 stam wat suggereert dat de ptxP3 stam virulenter 
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is. De ptxP3 stam wordt hedendaags niet alleen meer in Nederland gevonden maar heeft 
zich in de afgelopen jaren verspreid over Europa, Azië, Amerika en Australië. De hogere Ptx 
productie door de ptxP3 stam benadrukt het belang van Ptx bij transmissie. Dit onderzoek 
geeft wegen aan om het kinkhoest probleem aan te pakken: het gebruik van vaccins die Ptx 
neutraliserende antilichamen tegen Ptx induceren die langer persisteren. Verder kan uit dit 
onderzoek afgeleid worden dat de hoeveelheid Ptx in ACVs een belangrijk criterium is om te 
kiezen tussen ACVs. 
De effecten van 60 jaar vaccinatie op de Nederlandse B. pertussis populatie worden in 
hoofdstuk 7 beschreven. De focus ligt hierbij op de genen die geassocieerd zijn met eiwitten 
die geincludeerd zijn in de ACVs; ptxA, prn, ptxP en fim3. Kleine mutaties in deze genen 
hebben geresulteerd in mismatches tussen vaccinstammen en circulerende stammen en deze 
mutaties bleken geassocieerd met een toename in stam frequenties. Naast deze mutaties 
is ook gekeken naar het verlies van genen omdat dit ook bijgedragen zou kunnen hebben 
aan adaptatie aan vaccinatie. Hoewel B. pertussis stammen met grote regelmaat genen 
verliezen, bleek maar één deletie ontstaan en gefixeerd te zijn na de invoering van vaccinatie. 
Dit gebied is geassocieerd met de ptxP3 stam. Om een vollediger beeld te krijgen van mutaties 
die geassocieerd zijn met succesvolle stammen, zijn hele B. pertussis genomen met elkaar 
vergeleken. Dit resulteerde in de identificatie van een aantal nieuwe SNPs die mogelijk een 
positieve invloed hebben gehad op adaptatie aan vaccinatie. Het belang van deze mutaties 
moet blijken uit verder onderzoek. Uit ons onderzoek bleek niet dat B. pertussis na de introductie 
van vaccinatie nieuwe genen heeft opgenomen. 
Dit proefschrift laat zien dat de B. pertussis adaptatie met de grootste impact op public health 
de verschuiving van ptxP1 naar ptxP3 stammen is. De ptxP3 stam heeft zich in een korte 
periode wereldwijd verspreid, is waarschijnlijk virulenter dan de ptxP1 stam en is geassocieerd 
met een hogere Ptx productie. Dit onderzoek toont de cruciale rol aan die Ptx speelt bij infectie 
met en verspreiding van de bacterie en geeft wegen aan om het kinkhoest probleem aan te 
pakken: het gebruik van vaccins die Ptx neutraliserende antilichamen tegen Ptx induceren die 
langer persisteren. Dit kan (ten dele) bereikt worden door gebruik te maken van ACVs met een 
hoog gehalte aan Ptx. De huidige ACVs zouden verder kunnen worden aangepast door Ptx niet 
chemisch te inactiveren maar genetisch, omdat genetisch geïnactiveerd Ptx immunogener is. 
Verder kan de beschermingsduur van ACVs waarschijnlijk verlengd worden door eiwitvarianten 
te includeren in vaccins die voorkomen in de huidige B. pertussis populaties. Tenslotte heeft 
het werk in dit proefschrift het belang van kiemsurveillance aangetoond: kiemsurveillance 
geeft inzicht in het effect van vaccinatie op de pathogeenpopulatie, maar ook in de oorzaken 
van epidemieën en geeft daarbij wegen aan om epidemieën te bestrijden. Routinematige 
kiemsurveillance kan bovendien vroegtijdig waarschuwen voor het ontstaan van epidemieën. 
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Dankwoord
Het dankwoord…Ik schat zo in het meest gelezen onderdeel van een proefschrift. Misschien 
wel het leukste om te schrijven, omdat het persoonlijk is maar ook het moeilijkste. Juist omdat 
het zo persoonlijk is. Eindelijk is het zover! Het boekje is af, de promotiedatum staat en nu 
mag ik iedereen bedanken die op zijn of haar manier de afgelopen jaren hun bijdrage hebben 
geleverd aan het tot stand komen van dit boekwerk. Ik weet het, het klinkt cliché maar zonder 
deze mensen waren de afgelopen jaren een stuk minder leuk geweest.
Allereerst de belangrijkste persoon, een van mijn 2 promotoren, Frits Mooi. Best Frits, ik weet 
het nog heel goed. Zo’n 11 jaar geleden kwam ik, als net afgestudeerde 20-jarige bij jullie 
solliciteren. Het schrijven van een proefschrift lag toen nog helemaal niet in de planning maar 
na een jaar of 5 heb je me deze kans gegeven. Daar wil ik je hartelijk voor bedanken. Bedankt 
voor al het vertrouwen, voor de begeleiding en voor alle tijd die je in me hebt gestoken. Zelfs 
bereikbaar in het weekend of tijdens je vakantie. Maar vooral bedankt voor je deur die altijd 
voor me openstond, en zo lang ik nog onderdeel ben van de kinkhoest groep, nog steeds staat.
Peter Hermans, mijn andere promotor. Beste Peter, bedankt dat je mijn promotor wilt zijn. We 
hebben elkaar in de afgelopen jaren niet heel veel gesproken maar het contact dat we hadden 
was prettig en bedankt voor je enthousiasme.
 
Zonder onze internationale samenwerkingen was een aantal hoofdstukken uit dit proefschrift 
vast en zeker nooit van de grond gekomen. I want to thank the following people for their fruitful 
collaboration and their help: Dénis Pierard, Sabine Lauwers, Teemu Kallonen, Qiushui He, 
Jussi Mertsola, Abdolreza Advani, Hans Hallander and Koen Janssens. I hope to see some of 
you in Poland next year for the EUpert strain meeting! 
Hierbij wil ik alle leden van de promotiecommissie bedanken voor hun tijd en het plaatsnemen 
in de commissie. 
Dan 2 onmisbare personen op de promotie, mijn paranimfen Corrie en Richarda. Lieve 
Corrie, het is zover, eindelijk heb ik een datum. En wat voor eentje, een hele mooie! Ik zal ons 
sollicitatiegesprek zo’n 11 jaar geleden nooit vergeten en nog steeds bedankt daarvoor. Maar 
vooral bedankt voor de afgelopen jaren. Samen met Henny heb je heel veel voor me gedaan. 
Jullie zijn heel erg waardevol voor me geworden en ik ben erg blij dat je mijn paranimf wilt zijn 
op deze bijzondere dag. 
Mijn andere paranimf, Richarda. Lieve Richarda, het gaat nu toch ook bij mij echt gebeuren. Als 
stagiaire ben je een aantal jaar geleden bij ons begonnen en gelijk hadden we een ontzettende 
klik. Jouw tijd in Utrecht was super! Veel etentjes, biertjes en vooral veel gesprekken. Ik heb 
heel veel aan je gehad en dat heb ik nog steeds. Ondanks dat je weer terug bent gegaan naar 
je Brabantse roots ben je nog altijd even belangrijk voor me. Bedankt dat je mijn paranimf wilt 
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zijn, ik kan uit ervaring zeggen dat het heel erg leuk is!
De andere kinkhoesters. Allereerst de mannen, Han en Kees, bedankt voor alles! Wat prettig 
om bij jullie in de groep te zitten. En wat heb ik veel van jullie geleerd. Han, onze database-
pc-script expert en Kees, wat zit het organisatorisch bij jou toch altijd goed in elkaar. Bedankt 
voor de fijne samenwerking, jullie bijdrage aan een aantal publicaties maar vooral bedankt 
voor alle gezelligheid. Anne, nog niet zo heel lang deel van de kinkhoestgroep maar nu al 
een aanwinst, ook voor S2.26. Onze paar dagen Oslo waren super. Zelfs zonder een avondje 
dronken worden…Marieke, ook jij bedankt voor al je wetenschappelijke input. Heel veel 
succes met je boekje en het gaat je lukken! Sabine, ook een flinke bijdrage aan een van mijn 
publicaties. Bedankt voor de fijne samenwerking en ons tripje naar Amerika was erg leuk. 
Saskia, inmiddels geen kinkhoest meer voor jou maar bedankt voor alle gezelligheid, vooral 
ook buiten het lab. En Audrey en Tamara, ook ex-kinkhoest, jullie ook bedankt. Greetje, mijn 
stagiaire, wat heb ik veel aan je gehad en wat werkte je hard. Top!
De andere S2-gangers. Pneumokokken, haemophilus, het maakt niet uit. Leo, Sandra, Corrie, 
Ingrid en Karin, we delen misschien niet direct elkaars onderwerp maar wel een ander heel 
belangrijk onderdeel van het werk, namelijk de koffiepauzes en de lunch. En die zouden zonder 
jullie een stuk minder gezellig zijn geweest! Een praatje, even lekker zeuren of gewoon lachen, 
gieren, brullen…geen probleem. Bedankt! Verder alle mensen bedankt voor de gezelligheid in 
de koffiekamer en daar buiten. Nel en Carola, bedankt voor alle dropjes…
Dan de mensen dichterbij huis…Vriendjes, vriendinnetjes, ze waren er niet zozeer om me 
wetenschappelijk bij te staan maar op sociaal gebied waren ze de afgelopen jaren onmisbaar. 
Lieve Liane, van nichtjes tot hele goede vriendinnetjes. Ja Li, nog steeds kinkhoest en 
waarschijnlijk voor jou nog altijd abra cadabra…Maar wat maakt het uit?? We hebben heel 
veel gedeeld samen en dat we elkaars getuige waren op onze huwelijken (o nee, geregistreerd 
partnerschap) zegt volgens mij genoeg. Ik kan me nu al verheugen op onze kampeer avonturen 
die gaan komen…Lieve Esther, onze eerste kennismaking was op het RIVM zo’n 10 jaar 
geleden. We hadden vanaf het eerste moment een enorme klik en hieruit ontstond een hele 
hechte vriendschap. De afwisseling Breda/Oosterhout en Utrecht gaat al jaren perfect en ik 
zou het voor geen goud willen missen. We kunnen alles met elkaar delen en overal over 
praten. Je bent een vriendin uit duizenden en dat zal je altijd blijven!! Lieve Karen, wat ben ik 
trots op ons! We hebben een te gekke tijd gehad samen en uiteindelijk hebben we een weg 
gevonden om “zonder” elkaar verder te gaan. Ik heb veel van je geleerd, wat belangrijk is in 
het leven en wat niet. We hebben veel van de wereld gezien, waar ik je nog altijd erg dankbaar 
voor ben. Inmiddels hebben we beide ons geluk weer gevonden en dat we dat elkaar van 
harte gunnen en toch nog deel uitmaken van elkaars leven zegt wat mij betreft genoeg...Lieve 
Karin, al eerder genoemd als S2-ganger. Al een paar jaar delen we S2.26. Maar we delen veel 
meer, leuke dingen maar zeker ook de minder leuke. We weten zo ongeveer alles van elkaar, 
kunnen het overal over hebben. We zijn samen bezig geweest aan ons proefschrift en zelfs 7 
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maanden tegelijk zwanger geweest. Je bent erg belangrijk voor me geworden...op naar ons 
moederschap!
En verder de volgende mensen die op wat voor manier dan ook belangrijk voor me zijn. 
Christiaan, op verschillende vlakken ben ik je erg dankbaar. En dan weet je wel welke ik 
bedoel toch? Over een tijdje gaan we weer eens naar een dansfeestje ok? Ancel en Diederick, 
ons jaartje Gouda was super. En zullen we dat boek nog eens gaan schrijven? Edith, we waren 
elkaar uit het oog verloren maar we hebben elkaar na 15 jaar weer gevonden. Ik ben erg blij 
met onze vriendschap en zullen we elkaar nu niet meer kwijtraken? En last but not least, 
Andrej, without you, our life wouldn’t have been the same…Thanks!
Lieve familie Slijkhuis, helaas wonen we niet bij elkaar om de hoek en zien we elkaar niet zo 
vaak. Maar bedankt dat jullie me zo liefdevol hebben opgenomen in jullie gezin.
Lief zusje, wat hebben we het goed gedaan hè! Ik ben trots op je, hoe je uiteindelijk je master 
hebt gehaald, hoe je in het leven staat en gewoon op hoe je bent. Maar ik ben vooral trots op je 
als fantastische moeder van Mels. We zijn de afgelopen jaren enorm naar elkaar toe gegroeid, 
3 maanden samen zwanger geweest en straks zijn we allebei moeder. Ik kijk ernaar uit! En 
Dennis, al 13 jaar hoor je bij Simone. Je bent een onwijze goedzak en een soort broer voor me 
geworden. Jullie zijn een super stel samen, je bent erg goed voor m’n zus en ook jij bent een 
geweldige vader voor Mels. Tot slot, lieve Mels, je bent nu pas een paar maanden oud dus je 
snapt er niks van maar wat heb jij mijn leven verrijkt. 
Liefste pap en mam, eindelijk is het af! En toch best indrukwekkend hè zo’n proefschrift? 
Zonder jullie was dit nooit gelukt. Jullie zijn fantastische ouders, mijn basis. Bedankt voor jullie 
onvoorwaardelijke liefde en voor alles wat jullie voor me hebben gedaan en nog steeds doen. 
En wat een feest, 2 kleinzonen in 2012. Het is jullie gegund, ik hou van jullie!
Allerliefste Jorien, daar was je ineens…Op het goede moment op de goede plek zeggen ze 
weleens. Op papier zijn we alles behalve een match maar het past, en hoe?? Ik ben nog elke 
dag blij dat we per ongeluk een dubbele date waren. Ons eerste avontuur samen in Australië 
was geweldig! Inmiddels ga je als een “van Gent” door het leven en kan ik niet wachten om 
samen met jou en onze kleine man een gezinnetje te worden. Nog eventjes geduld…Bedankt 
voor alles, voor je onvoorwaardelijke liefde en steun maar vooral gewoon bedankt voor wie je 
bent. Love u!!!
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Marjolein van Gent was born on Augustus 23, 1980 in Tiel. She attended high school at the 
GSG Lingecollege in Tiel and completed her HAVO exam in 1997. In 2001, she graduated from 
the Hogeschool Utrecht at the faculty Nature and Technique, studying Biology and Medical 
Laboratory Research. During this study, she completed her first internship at the National 
Institute for Public Health and the Environment (RIVM) in Bilthoven where she developed a 
reversed line blot for the detection of atypical Mycobacteria. This research was done under 
the supervision of Dr. K. Kremer. Her second internship was at the diagnostic laboratory of the 
Groot Ziekengasthuis in ‘s Hertogenbosch.
In 2001, she started as a research technician at the laboratory for vaccine preventable diseases 
(LTR) of the RIVM under the supervision of Prof. Dr. F.R. Mooi where she first studied whooping 
cough. In 2006, she started her PhD project in the same group. This research resulted in 
several international publications and are described in this thesis. She currently works as a 
researcher at the RIVM. She has a relationship with Jorien van Gent-Slijkhuis and she lives in 
Utrecht. 
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Chapter 1
Figure 4. The 13 Prn variants found in B. pertussis populations. Prn variants are shown on the left and 
dots and dashes indicate identical and absent amino acids respectively. Silent mutations are shaded 
and numbering is relative to the start of the protein. The two regions (region 1 and 2) with five and three 
amino acid repeats have been blocked. Small differences are observed between the five amino acid 
repeats and the three subtypes have been given different colors. The RGD motif, involved in adherence, 
is underlined [13].
Chapter 3
Figure 4. Minimum spanning tree based on MLVA of 252 Dutch B. pertussis clinical isolates. MLVA types 
are indicated in the circles, the size of which is related to the number of isolates with that particular MLVA 
type. The colored segments indicate the frequencies of serotypes: Fim2 (green), Fim3 (red), Fim2,3 
(blue) and not detectable or autoagglutinable (yellow). Thick set, thin set and dotted lines indicate differ-
ences of one locus, two loci and more than two loci respectively.
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Chapter 3
Figure S1: Notifications and frequencies of tcfA2, tcfA3, tcfA4, tcfA7, tcfA8, tcfA9 and ∆tcfA alleles in the 
period 1965 to 1992. The distribution of the tcfA alleles over the three periods was significantly different 
(P<0.0001). See legend to Fig. 2 for further details. 
Figure S2: Notifcations and frequencies of ptxA1, ptxA2 and ptxA4 alleles in the period 1965 to 1992. 
The distribution of the ptxA alleles over the three periods was significantly different (P=0.0018). See 
legend to Fig. 2 for further details. 
Figure S3: Notifications and frequencies of prn1, prn2 and prn3 alleles in the period 1965 to 1992. The 
distribution of the prn alleles over the three periods was significantly different (P<0.0001). See legend 
to Fig. 2 for further fetails. 
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Chapter 6 
Figure 2. Relationship between the emergence of pertussis toxin promoter 3 (ptxP3) strains and the 
epidemiology of pertussis in the Netherlands, 1989–2004. A) Temporal trends in the frequencies of 
ptxP3 strains and notifications. In this period 99% of the strains harbored either ptxP1 or ptxP3. B) Shift 
in age-specific distribution of notifications.
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Figure 1: Relationship between phylogeny and the accumulation of mutations in virulence genes. The 
Maximum Parsimony tree was based on 85 SNPs and 198 Dutch strains isolated between 1949 and 
2008. The 85 SNPs resolved the 198 strains in 31 sequence types (STs). Alleles for the pertussis toxin 
promoter (ptxP), the pertussis toxin A subunit (ptxA), pertactin (prn) and the serotype 3 fimbrial subunit 
(fim3) are indicated. The alleles prn2 and prn3 were combined as they are both non-vaccine types. 
Based on the ptxP, ptxA, fim3 and prn alleles, seven allele types (ATs), I – VII, could be distinguished. 
Coloured dots represent distinct ATs and arrows indicate changes between ATs. ATs used for the pro-
duction of the whole cell and acellular vaccines are blocked. Bootstrap values are indicated in the tree.
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Figure 2. Temporal trends in strain frequencies and notifications in the Netherlands in the period 1949-
2010. Strain frequencies are indicated by coloured lines. Strains were aggregated into allele types (ATs) 
defined by the combination of alleles for ptxP, ptxA, prn and fim3 as shown in the top of the graph. No 
distinction was made between strains with the prn2 and prn3 alleles. ATs are indicated by blocked Ro-
man numbers and allele changes resulting in differences between ATs are indicated. Non-vaccine type 
alleles are underlined. ATs found in one or two periods only, with a frequency lower than 15%, are not 
shown. If necessary, years were combined to increase the number of analyzed strains to at least 6. Note 
that due to this, the X-axis is not proportional. Changes in the vaccination program are indicated below 
the X-axis. From 1962 to 1999, four doses of WCV were given at the ages 3, 4, 5 and 11 months. In 
1999, the schedule was changed to 2, 3, 4 and 11 months. In 2001, a booster with an ACV was intro-
duced for 4 year olds and in 2005 the WCV was replaced by an ACV for all age categories. Between 
1975 and 1984, the WCV dose was temporarily reduced. Abbreviations: N, number of strains analysed; 
WCV, whole cell vaccine; ACV, acellular vaccine.
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Figure 3. Frequency of allele types and genetic diversity of the Dutch B. pertussis population in the 
period 1949-2010. The diversity index (DI) and 95% confidence interval (CI) for each period, based 
on the sequence types (STs), were calculated using the Hunter and Gaston’s modification [45] of the 
Simpson’s diversity index and are indicated.  Frequencies of allele types are calculated for each period 
and coloured as in Fig. 1. Significant differences in DI between periods are indicated with asterisks. Ab-
breviations: AT, allele type; N, number of strains; DI, diversity index; CI, 95% confidence interval.
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Figure 4: Relationship between phylogeny and gene loss. Strains with their corresponding allele type 
(AT) and sequence type (ST) are shown in the left columns. Strains were clustered according to their 
position in the phylogenetic tree as shown in Fig 1. Colouring of ATs is as in Fig. 1. DNA loci with corre-
sponding gene designations [46] are shown in the top row. The two strains used for the Dutch whole cell 
vaccine, B0005 and B0006, are indicated in the two bottom rows. Absence and presence of DNA loci are 
indicated by + and -, respectively and deletions showing homoplasy are indicated with asterisks in the 
top row. Abbreviations: AT, allele type; ST, sequence type; VS, vaccine strain used for the Dutch WCV.
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